👪

Inheritance

1

Autosomal Recessive HP:0000007

Classic Bernard-Soulier syndrome is autosomal recessive, with 85% of probands homozygous and consanguinity the dominant risk multiplier. Obligate carriers are generally indistinguishable from controls, though carriers of some GP9 variants show reduced complex expression and defective aggregation, so heterozygosity is not always silent. A separate autosomal dominant form exists, caused by monoallelic GP1BA or GP1BB variants.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:17109744 SUPPORT Human Clinical

"The syndrome is transmitted as an autosomal recessive trait."

States the inheritance pattern of the classic form.

PMID:21173099 SUPPORT Human Clinical

"Except for obligate carriers of a GP9 mutation with a reduced GPIb/IX/V expression and defective aggregation, all the other carriers had no obvious anomalies."

Documents that carriers are usually unremarkable but not invariably so.

◆

Subtypes

4

BSS type A1 (GP1BA-related, biallelic) MONDO:1060238

GP1BA hgnc:4439

Biallelic GP1BA variants, accounting for 28% of genotyped families in the international consortium. GP1BA encodes GPIbalpha, the ligand-binding subunit.

BSS type B (GP1BB-related, biallelic) MONDO:1060239

GP1BB hgnc:4440

Biallelic GP1BB variants, 28% of genotyped families. GP1BB sits inside the commonly deleted 22q11.2 interval, so every patient with 22q11.2 deletion syndrome is an obligate carrier and a second hit on the retained allele produces full disease.

BSS type C (GP9-related, biallelic) MONDO:1060237

GP9 hgnc:4444

Biallelic GP9 variants, the commonest genotype at 44% of genotyped families.

BSS type A2 (monoallelic, autosomal dominant) MONDO:0007930

GP1BA hgnc:4439

The dominant monoallelic form, caused by heterozygous GP1BA or GP1BB variants. Milder, later-presenting, and frequently mistaken for immune thrombocytopenic purpura. The best-characterized allele is the southern Italian Bolzano founder variant GP1BA c.515C>T, which accounted for 20% of inherited thrombocytopenia patients at two Italian referral centers over a decade. Platelet aggregation is often normal here, so genetic testing rather than aggregometry is what makes the diagnosis.

Show evidence (1 reference)

PMID:21933849 SUPPORT Human Clinical

"Although the clinical expression was variable, patients with this mutation typically had a mild form of Bernard-Soulier syndrome with mild thrombocytopenia and bleeding tendency."

Characterizes the monoallelic Bolzano form as a mild variant of the syndrome.

◈

Mechanistic Hypotheses

1

GPIbalpha Mechanosensory Domain Unfolding as a Platelet-Clearance Timer

shear_mechanosensor_platelet_clearance EMERGING

Evidence balance 1 support

A third, newer contributor to the thrombocytopenia that is not part of the canonical two-branch model. GPIbalpha contains a relatively unstable mechanosensory domain; von Willebrand factor binding under physiological shear unfolds it, and the unfolded domain triggers intracellular signaling and rapid platelet clearance. If a BSS-causing missense variant destabilized that domain, it could in principle shorten platelet survival independently of production, adding a clearance mechanism alongside the production defect. The direct link from BSS-causing variants to accelerated clearance in patients has not been demonstrated, which is why this is EMERGING and is deliberately not modeled as a pathophysiology node.

Show evidence (1 reference)

PMID:27670775 SUPPORT In Vitro

"The unfolded MSD, particularly the juxtamembrane 'Trigger' sequence therein, leads to intracellular signalling and rapid platelet clearance."

Establishes the mechanosensory-unfolding to clearance link in the receptor, which is the basis for the hypothesis.

?

Discussions and Knowledge Gaps

4

What determines bleeding severity in Bernard-Soulier syndrome, given that it does not track genotype, platelet count, or receptor expression level?

KNOWLEDGE GAP bss_no_genotype_phenotype_correlation

Attached to

pathophysiology#Failure of Primary Hemostatic Plug Formation

In the largest systematically evaluated single-center series, bleeding severity varied widely between individuals while thrombocytopenia was uniformly moderate and GPIbalpha expression uniformly under 10% of control. The authors were explicit that they could define no correlations. That combination, a variable output with the measured inputs pinned, is the shape you would expect if unidentified modifiers were doing the work. No modifier allele has been established. This is a genuine gap in the literature rather than a gap in searching, and it has direct clinical consequence because there is currently no way to predict which patient will bleed badly.

Show evidence (2 references)

PMID:21173099 SUPPORT Human Clinical

"Regardless of mutations identified, the patients' bleeding diathesis did not correlate with thrombocytopenia, which was always moderate, and platelet GPIbalpha expression, which was always severely impaired."

Establishes the absence of correlation with the two obvious candidate predictors.

PMID:21173099 SUPPORT Human Clinical

"Aware of the limitations of our cohort, we cannot define any correlations."

The authors' own statement of the negative result, with its cohort-size caveat.

Why has no Bernard-Soulier-causing variant ever been found in GP5, the fourth subunit of the complex?

OPEN QUESTION bss_gp5_never_implicated

Attached to

pathophysiology#Biallelic Loss of Function in GP1BA, GP1BB, or GP9

GP5 encodes GPV, the fourth subunit, and it maps to a known locus like the other three, yet across 211 genotyped families and two decades of review no disease-causing GP5 variant has been reported. The straightforward reading is that GPV is dispensable for complex assembly and surface expression, so losing it does not produce the phenotype. This is a real curatable negative rather than an artifact of ascertainment, and it constrains any model of how the complex assembles.

Show evidence (2 references)

PMID:17109744 SUPPORT Human Clinical

"Genes coding for the four subunits of the receptor, GPIBA, GPIBB, GP5 and GP9, map to chromosomes 17p12, 22q11.2, 3q29, and 3q21, respectively. Defects have been identified in GPIBA, GPIBB, and GP9 but not in GP5."

States the negative finding alongside the three positive genes.

PMID:39191409 SUPPORT Human Clinical

"To date, no BSS mutations in the GP5 gene have been reported."

Confirms the negative finding still stands in the current definitive review, nearly twenty years later.

Lentiviral gene therapy corrects the phenotype across all three causal genes and now works in patient-derived cells, so why has no clinical trial been conducted?

KNOWLEDGE GAP bss_gene_therapy_no_clinical_trial

Attached to

pathophysiology#Failure of GPIb-IX-V Complex Assembly and Surface Expression

The preclinical package is unusually complete for a disease this rare: correction in GPIbalpha-null and GPIbbeta-null mice with sustained expression through serial transplant, and ex vivo correction of hematopoietic stem cells from two unrelated type C patients. What is missing is any clinical trial. The plausible obstacles are the conditioning regimen required for stem cell gene therapy against a disease whose prognosis is generally good with supportive care, the very small and geographically scattered patient population, and the absence of an agreed clinical endpoint given that bleeding score correlates only weakly with lived burden. None of these has been formally addressed in the literature, so the gap between a solved preclinical problem and an untried clinical one is recorded here rather than explained.

Show evidence (1 reference)

PMID:37416759 SUPPORT In Vitro

"These results demonstrate the potential of lentiviral-based gene therapy to rescue BSS type C."

States the preclinical conclusion, which is as far as the evidence currently goes.

Why is quality of life only weakly related to bleeding-assessment score in inherited platelet function disorders, and what should be measured instead?

OPEN QUESTION bss_qol_decoupled_from_bleeding_score

Attached to

phenotypes#Iron Deficiency Anemia

A recent multi-instrument study using EQ-5D, SF-36, and FACIT alongside annual bleed rate and the ISTH bleeding assessment tool found the relationship between quality-of-life scores and bleeding score was weak. If event count does not predict lived burden, then trials and clinical follow-up anchored on bleed rate are measuring the wrong thing. The plausible drivers are chronic anemia and fatigue, treatment access, and disruption to schooling and work, none of which a bleeding score captures, but this has not been formally decomposed.

Show evidence (1 reference)

PMID:41100648 SUPPORT Human Clinical

"The relationship between quality of life (QoL) scores and ISTH-BAT score was weak."

The finding that motivates the question.

⚙

Pathophysiology

7

Biallelic Loss of Function in GP1BA, GP1BB, or GP9

Pathogenic variants in any one of the three genes encoding the GPIbalpha, GPIbbeta, or GPIX subunits cause the disease. Across 211 genotyped families the burden splits GP9 44%, GP1BA 28%, GP1BB 28%, spanning 112 distinct variants of every class, and 85% of probands are homozygous with founder effects in several regions. The fourth subunit gene, GP5, has never been implicated, which is a genuine negative finding rather than an absence of looking.

GP1BA hgnc:4439 GP1BB hgnc:4440 GP9 hgnc:4444

Downstream

Failure of GPIb-IX-V Complex Assembly and Surface Expression Loss of any one subunit prevents the complex reaching the platelet membrane, because assembly is obligately stoichiometric.

Show evidence (3 references)

PMID:24934643 SUPPORT Human Clinical

"With 79 additional families for which molecular data were gleaned from the literature, the 211 families characterized so far have mutations in the GP1BA (28%), GP1BB (28%), or GP9 (44%) genes."

Gives the genotype distribution across the largest assembled cohort.

PMID:17109744 SUPPORT Human Clinical

"Genes coding for the four subunits of the receptor, GPIBA, GPIBB, GP5 and GP9, map to chromosomes 17p12, 22q11.2, 3q29, and 3q21, respectively. Defects have been identified in GPIBA, GPIBB, and GP9 but not in GP5."

Establishes the three causal genes and the negative finding for GP5.

PMID:39191409 SUPPORT Human Clinical

"To date, no BSS mutations in the GP5 gene have been reported."

Independently restates the GP5-negative finding in the current definitive review.

Failure of GPIb-IX-V Complex Assembly and Surface Expression

The dominant molecular consequence is failure of the complex to reach the platelet surface at all, because assembly is obligately stoichiometric and a single null subunit sinks the whole receptor. A minority of variants instead permit surface expression but abolish von Willebrand factor binding, a genuinely separate mechanism with the same clinical result. Surface GPIbalpha in biallelic disease is consistently under 10% of control values.

platelet CL:0000233 megakaryocyte CL:0000556

glycoprotein Ib-IX-V complex GO:1990779

Animal models

Cocker Spaniel GP9 large-deletion natural model Dog recapitulates A spontaneous GP9 null produces absent functional GPIb-IX-V with macrothrombocytopenia and a bleeding phenotype, arrived at naturally rather than by engineering.

Downstream

Loss of von Willebrand Factor Capture Under Shear Without surface receptor there is no von Willebrand factor A1 domain capture, so platelet tethering under arterial shear never begins.

Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton Loss of the complex removes the cytoplasmic-tail linkage to filamin A and 14-3-3 zeta that anchors the membrane skeleton during proplatelet extrusion.

Loss of Platelet-Surface Coagulation Factor Binding GPIbalpha also binds thrombin, factor XI, factor XII, and high-molecular-weight kininogen, so its absence degrades platelet-supported coagulation as well as adhesion.

Show evidence (2 references)

PMID:24934643 SUPPORT Human Clinical

"Most of the mutations identified in the genes encoding for the GP1BA (GPIbα), GP1BB (GPIbβ), and GP9 (GPIX) subunits prevent expression of the complex at the platelet membrane or more rarely its interaction with VWF."

Establishes the two molecular consequence classes, failed surface expression and, more rarely, failed ligand interaction.

PMID:21173099 SUPPORT Human Clinical

"Consistent with expression levels of GPIbα always lower than 10% of control values, platelet aggregation was absent or severely reduced."

Quantifies the residual surface expression in biallelic disease and links it to the functional readout.

Loss of von Willebrand Factor Capture Under Shear

Under arterial shear, von Willebrand factor unfurls on exposed subendothelium and its A1 domain is the only thing fast enough to catch a platelet moving at that velocity. GPIbalpha is the catcher's mitt. Without it there is no capture step, so nothing downstream ever starts: no rolling, no outside-in signaling, no inside-out activation of the integrin alphaIIb-beta3, no firm adhesion. The laboratory expression of this node is the absent ristocetin-induced agglutination that is not corrected by adding normal plasma, which is the entire diagnostic logic of the disease in one sentence.

platelet CL:0000233

primary hemostasis GO:0007599 ↓ DECREASED

Downstream

Failure of Primary Hemostatic Plug Formation Without the capture step no platelet aggregate forms at the site of vessel injury.

Impaired Ristocetin-Induced Platelet Aggregation Ristocetin artificially promotes von Willebrand factor to GPIbalpha engagement, so a platelet lacking the receptor cannot agglutinate however much normal plasma is supplied.

Show evidence (2 references)

PMID:24934643 SUPPORT Human Clinical

"As a consequence, platelets are unable to adhere to the vascular subendothelium and agglutinate in response to ristocetin."

States both the adhesion failure and its diagnostic laboratory correlate.

PMID:23336709 SUPPORT In Vitro

"The glycoprotein (GP)Ib-IX-V complex is the platelet receptor for von Willebrand factor and many other molecules that are critically involved in hemostasis and thrombosis."

Establishes the receptor identity and its role as a multi-ligand hemostatic hub.

Loss of Platelet-Surface Coagulation Factor Binding

GPIbalpha is not only a von Willebrand factor receptor. It also binds thrombin, factor XI, factor XII, high-molecular-weight kininogen, P-selectin, and the leukocyte integrin Mac-1. Losing this hub degrades platelet-supported coagulation and platelet-leukocyte crosstalk on top of the adhesion defect, and the clinical fingerprint of that second loss is the markedly reduced prothrombin consumption seen in these patients. This is the arm that gets dropped from modern write-ups, and it is part of why bleeding is worse than a pure adhesion defect would predict.

blood coagulation GO:0007596 ↓ DECREASED

glycoprotein Ib-IX-V complex GO:1990779

Downstream

Failure of Primary Hemostatic Plug Formation Loss of platelet-supported coagulation compounds the adhesion failure at the site of injury.

Show evidence (2 references)

PMID:17109744 SUPPORT Human Clinical

"Prothrombin consumption is markedly reduced."

The laboratory fingerprint of impaired platelet-supported coagulation, distinct from the adhesion defect.

PMID:23336709 SUPPORT In Vitro

"The glycoprotein (GP)Ib-IX-V complex is the platelet receptor for von Willebrand factor and many other molecules that are critically involved in hemostasis and thrombosis."

Supports the multi-ligand character of the receptor beyond von Willebrand factor.

Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton

The second job. The GPIbalpha cytoplasmic tail binds filamin A and 14-3-3 zeta, anchoring the membrane skeleton to the underlying cytoskeleton while a megakaryocyte extrudes proplatelets. Without it, megakaryocyte progenitor numbers, differentiation, and endoreplication are all normal, but the mature cells have a thickened peripheral zone and a poorly developed demarcation membrane system, proplatelet extension falls by about 41%, and the marginal microtubular ring contains twice as many tubulin fibers. The same defect is demonstrable in cultured human megakaryocytes from patients, with proplatelet formation reduced about 50%, enlarged proplatelet tips, and severely deranged alpha-tubulin distribution. Human and mouse converge here unusually well for a rare disease.

megakaryocyte CL:0000556

platelet formation GO:0030220 ↓ DECREASED

Experimental models

Patient-derived megakaryocyte culture (Bolzano heterozygotes) PRIMARY CELL CULTURE Reproduces the proplatelet-formation defect and the microtubule derangement in human patient cells, converging with the mouse knockouts.

Animal models

GPIbbeta-null mouse Mouse recapitulates Proplatelet extension is reduced by 41% in cultured knockout megakaryocytes with normal upstream differentiation, localizing the lesion precisely to proplatelet formation.

Downstream

Release of Fewer, Abnormally Large Platelets Deranged proplatelet formation yields fewer platelets, each larger than normal.

Show evidence (3 references)

PMID:19377075 SUPPORT Model Organism

"The number of megakaryocyte progenitors, their differentiation and progressive maturation into distinct classes and their level of endoreplication were normal in GPIbbeta(-/-) bone marrow. However, the more mature cells exhibited ultrastructural anomalies with a thicker peripheral zone and a..."

Localizes the defect to late megakaryocyte maturation rather than to progenitor number or differentiation.

PMID:19377075 SUPPORT Model Organism

"The marginal microtubular ring contained twice as many tubulin fibers in GPIbbeta(-/-) proplatelet buds in cultured and circulating platelets."

Provides the cytoskeletal abnormality that accompanies the proplatelet defect.

PMID:19067792 SUPPORT In Vitro

"Morphological evaluation of proplatelet formation revealed an increased size of proplatelet tips, which was consistent with the increased diameters of patients' blood platelets. Moreover, alpha-tubulin distribution within proplatelets was severely deranged."

Demonstrates the same proplatelet and microtubule abnormality in cultured human patient megakaryocytes, not only in mouse.

Release of Fewer, Abnormally Large Platelets

The output of the thrombopoietic branch: a moderate thrombocytopenia, typically not severe, with platelets that can approach lymphocyte size. The two arms of the disease are cleanly dissociable at the domain level. A chimeric receptor swapping the GPIbalpha ectodomain for an unrelated one doubles the circulating platelet count and halves platelet size while leaving the bleeding phenotype severe, so the cytoplasmic tail drives size and count and the ectodomain drives hemostasis.

platelet CL:0000233

Animal models

GPIbalpha-null mouse Mouse recapitulates The knockout reproduces mild thrombocytopenia with giant platelets and a bleeding phenotype, and rescue by transgenic human GPIbalpha demonstrates the dependency directly.

Downstream

Macrothrombocytopenia Fewer and larger circulating platelets.

Giant Platelets Released platelets are abnormally large.

Increased Mean Platelet Volume The size shift raises measured mean platelet volume.

Show evidence (3 references)

PMID:10706630 SUPPORT Model Organism

"The results demonstrate a direct link between expression of a GP Ib-IX-V complex and normal megakaryocytopoiesis and platelet morphogenesis."

Establishes the causal link between the receptor and platelet production, which had been assumed but unproven for decades.

PMID:12200373 SUPPORT Model Organism

"The characterization of these mice revealed a 2-fold increase in circulating platelet count and a 50% reduction in platelet size when compared with platelets from the mouse model of the Bernard-Soulier syndrome."

The chimeric-receptor rescue quantifying how much of the size and count phenotype is attributable to the cytoplasmic tail rather than the ectodomain.

PMID:12200373 SUPPORT Model Organism

"Mice expressing the chimeric receptor retain a severe bleeding phenotype, confirming a critical role for the GP Ibalpha extracytoplasmic domain in hemostasis."

The other half of the dissociation: rescuing size and count does not rescue bleeding, so the two branches are separable.

Failure of Primary Hemostatic Plug Formation

The convergence of both hemostatic losses, adhesion and platelet-supported coagulation. The clinical signature is bleeding disproportionate to the platelet count, which is the observation that separates this from a simple thrombocytopenia and which drove the search for a receptor defect in the first place.

platelet aggregation GO:0070527 ↓ DECREASED

Downstream

Epistaxis Mucocutaneous bleeding from the nasal mucosa.

Menorrhagia Heavy menstrual bleeding, consistently reported in all post-menarchal females in case series.

Gingival Bleeding Mucosal bleeding from the gums.

Bruising Susceptibility Easy bruising and ecchymoses from minor trauma.

Petechiae Cutaneous petechial hemorrhage.

Gastrointestinal Hemorrhage Mucosal bleeding from the gastrointestinal tract.

Prolonged Bleeding After Surgery Surgical, dental, and obstetric procedures provoke prolonged bleeding.

Post-Partum Hemorrhage Delivery is a high-risk bleeding event.

Intracranial Hemorrhage The rare but principal life-threatening bleeding site.

Prolonged Bleeding Time Failure of primary hemostasis prolongs the skin bleeding time.

Iron Deficiency Anemia Chronic mucosal blood loss depletes iron stores, particularly in menstruating women.

Show evidence (3 references)

PMID:17109744 SUPPORT Human Clinical

"The underlying defect is a deficiency or dysfunction of the glycoprotein GPIb-V-IX complex, a platelet-restricted multisubunit receptor required for normal primary hemostasis."

Human clinical source establishing that the receptor is required for normal primary hemostasis, which is what fails at this node.

PMID:10706630 SUPPORT Model Organism

"The bleeding in patients with the Bernard-Soulier syndrome is disproportionately more severe than suggested by the reduced platelet count and is explained by a defect in primary hemostasis owing to the absence of the platelet glycoprotein (GP) Ib-IX-V membrane receptor."

States the defining clinical observation that bleeding is disproportionate to the platelet count. Tagged MODEL_ORGANISM because the study this sentence introduces is a mouse knockout paper, and evidence_source classifies the publication's study type rather than the topic of the quoted sentence.

PMID:17109744 SUPPORT Human Clinical

"Clinical manifestations usually include purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding."

Enumerates the mucocutaneous bleeding phenotypes downstream of this node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

15

Blood 7

Epistaxis VERY_FREQUENT HP:0000421

Show evidence (2 references)

PMID:41100648 SUPPORT Human Clinical

"Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."

Epistaxis is named first among the commonest manifestations in a 76-patient natural history study.

PMID:17109744 SUPPORT Human Clinical

"Clinical manifestations usually include purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding."

Lists epistaxis among the usual clinical manifestations.

Menorrhagia VERY_FREQUENT HP:0000132

Show evidence (1 reference)

PMID:41100648 SUPPORT Human Clinical

"Menorrhagia was seen in all females in the reproductive age group."

Universal among reproductive-age females in this cohort, supporting a VERY_FREQUENT band.

Gingival Bleeding FREQUENT HP:0000225

Show evidence (1 reference)

PMID:41100648 SUPPORT Human Clinical

"Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."

Gingival bleeding is among the commonest manifestations reported.

Bruising Susceptibility FREQUENT HP:0000978

Show evidence (1 reference)

PMID:41100648 SUPPORT Human Clinical

"Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."

Ecchymosis is listed among the commonest manifestations.

Petechiae HP:0000967

Show evidence (1 reference)

PMID:17109744 SUPPORT Human Clinical

"Clinical manifestations usually include purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding."

Purpura is named among the usual manifestations. PARTIAL because petechiae specifically are not separately enumerated in this source.

Gastrointestinal Hemorrhage FREQUENT HP:0002239

Show evidence (1 reference)

PMID:41100648 SUPPORT Human Clinical

"Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."

Gastrointestinal bleeding is among the commonest manifestations reported.

Iron Deficiency Anemia HP:0001891

Temporal: CHRONIC

Show evidence (1 reference)

PMID:41100648 SUPPORT Human Clinical

"Menorrhagia was seen in all females in the reproductive age group."

Establishes the dominant chronic blood-loss route. PARTIAL because iron deficiency anemia itself is not quantified in this snippet.

Other 8

Macrothrombocytopenia OBLIGATE HP:0040185

Show evidence (2 references)

PMID:17109744 SUPPORT Human Clinical

"Diagnosis is based on a prolonged skin bleeding time, the presence of a small number of very large platelets (macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent expression of the GPIb-V-IX complex."

Establishes macrothrombocytopenia as part of the diagnostic definition, supporting an OBLIGATE band.

PMID:21173099 SUPPORT Human Clinical

"Patients all had a moderate thrombocytopenia with giant platelets and a bleeding tendency whose severity varied among individuals."

All 13 patients in the largest single-center series had moderate thrombocytopenia with giant platelets.

Giant Platelets OBLIGATE HP:0001902

Show evidence (1 reference)

PMID:17109744 SUPPORT Human Clinical

"Bernard-Soulier syndrome (BSS), also known as Hemorrhagiparous thrombocytic dystrophy, is a hereditary bleeding disorder affecting the megakaryocyte/platelet lineage and characterized by bleeding tendency, giant blood platelets and low platelet counts."

Giant platelets are part of the defining description of the disease.

Increased Mean Platelet Volume HP:0011877

Show evidence (1 reference)

PMID:19067792 SUPPORT In Vitro

"Morphological evaluation of proplatelet formation revealed an increased size of proplatelet tips, which was consistent with the increased diameters of patients' blood platelets."

Documents increased platelet diameter in patients and ties it to the proplatelet defect.

Impaired Ristocetin-Induced Platelet Aggregation OBLIGATE HP:0011871

Show evidence (1 reference)

PMID:39191409 SUPPORT Human Clinical

"In biallelic BSS, giant platelets in the peripheral blood smear, absence of ristocetin-induced platelet aggregation (RIPA) using light transmission aggregometry (LTA), and complete loss of GPIbIX complex in flow cytometry are observed, whereas in monoallelic forms, genetic diagnosis is..."

Distinguishes the obligate absent response in biallelic disease from the variable response in monoallelic disease.

Prolonged Bleeding Time HP:0003010

Show evidence (1 reference)

PMID:17109744 SUPPORT Human Clinical

"Diagnosis is based on a prolonged skin bleeding time, the presence of a small number of very large platelets (macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent expression of the GPIb-V-IX complex."

Lists prolonged skin bleeding time among the diagnostic findings.

Prolonged Bleeding After Surgery HP:0004846

Show evidence (1 reference)

PMID:17109744 SUPPORT Human Clinical

"The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."

Identifies surgical procedures as a trigger for severe bleeding episodes.

Post-Partum Hemorrhage FREQUENT HP:0011891

Show evidence (1 reference)

PMID:36889343 SUPPORT Human Clinical

"In the literature review, postpartum hemorrhage (PPH) was found in 52.9% (27/51) of deliveries. Late PPH occurred more frequently than early PPH (35.3 and 31.4%, respectively)."

52.9% of 51 reported deliveries, within the FREQUENT band of 30 to 79%. The denominator is published deliveries rather than all pregnancies in this disease, so the figure is ascertainment-biased upward and the band should be read as applying to reported pregnancies.

Intracranial Hemorrhage HP:0002170

Show evidence (1 reference)

PMID:17109744 SUPPORT Human Clinical

"The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."

Establishes that severe bleeding episodes occur despite a generally good prognosis. PARTIAL because intracranial hemorrhage is not separately named in this source, so no frequency band is assigned.

🧬

Genetic Associations

3

GP1BA, GP1BB, and GP9 Biallelic Loss of Function

Gene: GP1BA hgnc:4439 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (3 references)

PMID:24934643 SUPPORT Human Clinical

"There is a wide spectrum of mutations with 112 different variants, including 22 novel alterations."

Quantifies the allelic heterogeneity across the international consortium.

PMID:24934643 SUPPORT Human Clinical

"Consistent with the rarity of the disease, 85% of the probands carry homozygous mutations with evidence of founder effects in some geographical areas."

Documents the predominance of homozygosity and the founder effects that follow from consanguinity.

PMID:39191409 SUPPORT Human Clinical

"Patients with autosomal recessively inherited biallelic BSS have a homozygous or compound heterozygous expression in the GPIbalpha, GPIbbeta, and GPIX subunits of the GPIbIX complex. Patients with autosomal dominantly inherited monoallelic BSS have a heterozygous expression in only the GPIbalpha..."

Establishes the two inheritance modes and which subunits each involves.

GP1BA Bolzano Founder Variant (c.515C>T)

Gene: GP1BA hgnc:4439 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:21933849 SUPPORT Human Clinical

"Our study indicates that monoallelic Bolzano mutation is the most frequent cause of inherited thrombocytopenia in Italy, affecting 20% of patients recruited at our institutions during the last 10 years."

Quantifies the contribution of this single allele to the inherited thrombocytopenia caseload in Italy.

PMID:21933849 SUPPORT Human Clinical

"Because many people from southern Italy have emigrated during the last century, this mutation may have spread to other countries."

Notes the likely geographic spread of the founder allele beyond Italy.

22q11.2 Deletion Conferring GP1BB Hemizygosity

Gene: GP1BB hgnc:4440 relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (2 references)

PMID:38625506 SUPPORT Human Clinical

"Patients with 22q11.2 deletion syndrome (22q11.2DS) are obligate carriers of BSS because GP1BB resides on chromosome 22q11.2."

States the structural basis for obligate carrier status in 22q11.2 deletion syndrome.

PMID:38625506 SUPPORT Human Clinical

"Gene panel testing revealed a novel variant in GP1BB, p.(Val169_Leu172del)."

Documents the second-hit variant on the retained allele that converts carrier status into disease.

💊

Medical Actions

7

Antifibrinolytic Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: tranexamic acid CHEBI:48669

Tranexamic acid, oral, topical as a mouthwash, or intravenous, is first-line for mucocutaneous bleeding and menorrhagia and is used peripartum alongside platelet transfusion. It is contraindicated in upper urinary tract bleeding because of the risk of clot obstruction, and generally avoided in pulmonary hemorrhage.

Mechanism Target:

MODULATES Failure of Primary Hemostatic Plug Formation — Antifibrinolytics do not restore platelet adhesion. They stabilize the clot that does form by blocking its breakdown, which is why they help mucocutaneous bleeding without touching the receptor defect. MODULATES rather than RESTORES for exactly that reason.

Show evidence (2 references)

PMID:39191409 SUPPORT Human Clinical

"Antifibrinolytics and oral contraceptives are utilized as supplementary treatments."

Establishes antifibrinolytics as supplementary therapy in the current definitive review.

PMID:36889343 SUPPORT Human Clinical

"Single donor platelet transfusions and oral tranexamic acid were administered as prophylaxis at the peripartum period."

Documents peripartum use of tranexamic acid alongside platelet transfusion.

Platelet Transfusion

Action: platelet transfusion Ontology label: Platelet Transfusion NCIT:C15366

The mainstay of treatment for significant bleeding and for procedural prophylaxis, preferably HLA-matched, leukoreduced, single-donor apheresis product. Its central hazard is what makes the whole treatment algorithm escalate: repeated exposure drives HLA and anti-GPIb alloimmunization, producing refractoriness, and in mothers transplacental antibody can cause fetal or neonatal alloimmune thrombocytopenia.

Mechanism Target:

RESTORES Failure of Primary Hemostatic Plug Formation — Transfused donor platelets carry a functional GPIb-IX-V complex and can execute the capture and plug-formation steps the patient's own platelets cannot.

Show evidence (2 references)

PMID:39191409 SUPPORT Human Clinical

"Platelet transfusion is the main therapy but recombinant factor VIIa is advised in alloimmunized patients, and allogeneic stem cell transplantation is suggested in refractory cases."

Establishes platelet transfusion as the main therapy and sets out the escalation path when alloimmunization occurs.

PMID:17109744 SUPPORT Human Clinical

"Treatment of bleeding or prophylaxis during surgical procedures usually requires platelet transfusion."

Confirms platelet transfusion as the standard for both treatment and procedural prophylaxis.

Recombinant Activated Factor VIIa

Action: Pharmacotherapy NCIT:C15986

Licensed for Glanzmann thrombasthenia rather than for this disease, so its use here is off-label but guideline-endorsed, and it is specifically advised where alloimmunization has made platelet transfusion ineffective. It works by bypassing the GPIb-dependent adhesion step entirely and driving thrombin generation on the platelet surface. Recent case-report evidence suggests a prophylactic weekly schedule can reduce bleeding frequency, but that is two patients, and access is a real constraint: none of the patients in a 76-participant Indian natural-history cohort were receiving it.

Mechanism Target:

BYPASSES Failure of Primary Hemostatic Plug Formation — Drives thrombin generation on the platelet surface without requiring the GPIb-dependent capture step, which is why it works in a receptor-deficient platelet.

Show evidence (3 references)

PMID:39191409 SUPPORT Human Clinical

"Platelet transfusion is the main therapy but recombinant factor VIIa is advised in alloimmunized patients, and allogeneic stem cell transplantation is suggested in refractory cases."

Establishes the indication for recombinant factor VIIa in alloimmunized patients.

PMID:41259294 SUPPORT Human Clinical

"Following initiation of prophylaxis, both patients experienced a marked reduction in the frequency and severity of bleeding episodes."

Supports a prophylactic schedule. PARTIAL because this is a case report of two siblings, with the authors themselves calling for studies to establish standardized protocols.

PMID:41100648 SUPPORT Human Clinical

"Platelet transfusion was the main mode of treatment; none of the patients in the present series were on activated recombinant factor VII (rFVIIa) therapy."

Documents the real-world access gap for this therapy outside well-resourced settings.

Hormonal Control of Menorrhagia

Action: Pharmacotherapy NCIT:C15986

Agent: levonorgestrel CHEBI:6443

Combined oral contraceptives, levonorgestrel-releasing intrauterine systems, progestins, and gonadotropin-releasing hormone agonists. Given that menorrhagia is close to universal in reproductive-age women with this disease and is the dominant route to iron deficiency, this is arguably the highest-yield routine intervention available.

Mechanism Target:

MODULATES Menorrhagia — Hormonal suppression reduces endometrial bleeding volume. It acts on the bleeding substrate rather than on the platelet, which is why it is effective for the single highest-burden manifestation while leaving the receptor defect untouched.

Show evidence (1 reference)

PMID:39191409 SUPPORT Human Clinical

"Antifibrinolytics and oral contraceptives are utilized as supplementary treatments."

Names oral contraceptives among the supplementary treatments.

Allogeneic Hematopoietic Stem Cell Transplantation

Action: hematopoietic cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Curative in principle, because the defect is intrinsic to the megakaryocyte lineage, and the only curative option currently available in the clinic; lentiviral gene therapy addresses the same origin but remains preclinical. Suggested for refractory disease. Reserved for severe transfusion-dependent or alloimmunized patients given the transplant-related morbidity and mortality.

Mechanism Target:

BYPASSES Biallelic Loss of Function in GP1BA, GP1BB, or GP9 — Replaces the patient's megakaryocyte lineage with donor cells carrying functional alleles, addressing both branches of the disease at once.

Show evidence (1 reference)

PMID:39191409 SUPPORT Human Clinical

"Platelet transfusion is the main therapy but recombinant factor VIIa is advised in alloimmunized patients, and allogeneic stem cell transplantation is suggested in refractory cases."

Places allogeneic transplantation at the top of the escalation ladder for refractory disease.

Eltrombopag

Action: Pharmacotherapy NCIT:C15986

Agent: eltrombopag CHEBI:85010

A thrombopoietin-receptor agonist trialed in a mixed cohort of inherited thrombocytopenias that included monoallelic Bernard-Soulier syndrome. Response rates were substantial, but two caveats govern how far this generalizes. The trial included only monoallelic disease and only as part of a mixed cohort, so it is not evidence for biallelic disease. And mechanistically, raising the count of platelets that still cannot bind von Willebrand factor addresses only the thrombopoietic branch, leaving the adhesion defect untouched.

Mechanism Target:

MODULATES Release of Fewer, Abnormally Large Platelets — Thrombopoietin-receptor agonism raises platelet count. It does not act on the adhesion branch, so it addresses half the disease at most.

Show evidence (2 references)

PMID:31273088 SUPPORT Human Clinical

"Of 23 patients evaluable for response, 11 (47.8%) achieved a major response (platelet count >100 ×109/L), ten (43.5%) had a minor response (platelet count at least twice the baseline value), and two patients (8.7%) did not respond."

Reports the response rates. PARTIAL because the cohort was mixed and included only monoallelic Bernard-Soulier syndrome, so the result does not transfer to biallelic disease.

PMID:31273088 SUPPORT Human Clinical

"We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia."

Documents the mixed cohort and the restriction to monoallelic disease, which is the basis for the PARTIAL grading above.

Lentiviral Gene Therapy (Investigational)

Action: Gene Therapy NCIT:C15238

The most active research front, and the reason the transplantation entry above should not be read as the only conceivable cure. Lentiviral delivery of the missing subunit under a platelet-specific promoter has corrected the phenotype across all three genes: in GPIbalpha-null mice it corrected the tail bleeding time and improved the macrothrombocytopenia with sustained expression through serial transplant; in GPIbbeta-null mice it restored GPIb-IX in 97% of circulating platelets with normal bleeding times; and for type C it has reached patient material, correcting GPIX expression and platelet size in hematopoietic stem cells from two unrelated patients. No clinical trial of gene therapy in this disease has been conducted, so this is preclinical throughout and is curated as investigational.

Mechanism Target:

RESTORES Failure of GPIb-IX-V Complex Assembly and Surface Expression — Delivering a functional copy of the missing subunit to hematopoietic stem cells restores assembly and surface expression of the complex on the platelets those cells go on to produce, which addresses both branches of the disease at their shared origin.

Show evidence (3 references)

PMID:22044935 SUPPORT Model Organism

"Therapeutic levels of hGPIbα expression were achieved that corrected the tail bleeding time and improved the macrothrombocytopenia."

Demonstrates correction of both the hemostatic and the thrombopoietic arm in the GPIbalpha-null mouse.

PMID:27148783 SUPPORT Model Organism

"hGPIbβ transplanted into the bone marrow of GPIbβ(null) mice rescued GPIb-IX expression in 97% of circulating platelets."

Quantifies the reconstitution achievable by the same strategy applied to the GPIbbeta route.

PMID:37416759 SUPPORT In Vitro

"Finally, hematopoietic stem cells from two unrelated BSS type C patients were transduced with the gene therapy vectors and differentiated to produce GPIX-expressing megakaryocytes and platelets with a reduced size."

The most advanced human evidence in this disease, correcting expression and platelet size in cells from two patients. PARTIAL because it is ex vivo correction of patient-derived cells rather than treatment of patients.

🔬

Diagnosis

2

Diagnostic Triad and Confirmatory Testing

Diagnosis rests on prolonged skin bleeding time, a small number of very large platelets, defective ristocetin-induced agglutination, and low or absent GPIb-IX-V expression. Flow cytometry for surface complex expression is the modern confirmatory test in biallelic disease. Prothrombin consumption is markedly reduced, a finding that reports on the coagulation-support arm rather than the adhesion arm.

Show evidence (1 reference)

PMID:17109744 SUPPORT Human Clinical

"Diagnosis is based on a prolonged skin bleeding time, the presence of a small number of very large platelets (macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent expression of the GPIb-V-IX complex."

Sets out the classic diagnostic criteria.

Genetic Testing, Essential in Monoallelic Disease

In biallelic disease the laboratory phenotype is unambiguous. In monoallelic disease it is not: platelets are large rather than giant, the ristocetin response may be decreased or normal, and complex expression may be only partially reduced or normal, so genetic testing is what makes the diagnosis and separates it from immune thrombocytopenic purpura.

Show evidence (1 reference)

PMID:39191409 SUPPORT Human Clinical

"In biallelic BSS, giant platelets in the peripheral blood smear, absence of ristocetin-induced platelet aggregation (RIPA) using light transmission aggregometry (LTA), and complete loss of GPIbIX complex in flow cytometry are observed, whereas in monoallelic forms, genetic diagnosis is..."

Establishes why genetic testing is required for the monoallelic form.

📈

Progression

2

Presentation

Biallelic disease presents in infancy or early childhood, typically with mucocutaneous bleeding. Monoallelic disease presents later, often in adulthood, and is frequently misdiagnosed as immune thrombocytopenic purpura, which matters because the two diseases are managed completely differently.

Show evidence (1 reference)

PMID:39191409 SUPPORT Human Clinical

"Patients with biallelic form are usually diagnosed at a young age, typically with mucocutaneous bleeding, whereas monoallelic forms are generally identified later in life and are frequently misdiagnosed with immune thrombocytopenic purpura (ITP)."

Contrasts the presentation age and the characteristic misdiagnosis of the two forms.

Lifelong episodic course

The underlying defect is static from birth, so the disease does not progress in the usual sense. What changes is exposure: menarche, trauma, surgery, dental procedures, and pregnancy each produce discrete bleeding events against a stable baseline. Prognosis is generally good with adequate supportive care.

Show evidence (1 reference)

PMID:17109744 SUPPORT Human Clinical

"The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."

Establishes the episodic, exposure-driven course against a good baseline prognosis.

📊

Prevalence

1

Worldwide

Cases In Literature Ultra Rare

Approximately 100 cases had been reported in the literature as of the 2006 Orphanet review; the international consortium subsequently assembled 211 genotyped families. These are counts of reported cases and families, not a population rate, and no validated population prevalence estimate was found.

Show evidence (2 references)

PMID:17109744 SUPPORT Human Clinical

"This syndrome is extremely rare as only approximately 100 cases have been reported in the literature."

Gives the reported case count that grounds the ULTRA_RARE band, with the caveat that this is a literature count.

PMID:24934643 SUPPORT Human Clinical

"In order to collect information on BSS patients, we established an International Consortium for the study of BSS, allowing us to enrol and genotype 132 families (56 previously unreported)."

Documents the size of the largest assembled cohort, which updates the older case count.

⚖️

Clinical Burden

Moderate

Prognosis is generally good with adequate supportive care, and the disease is non-progressive, but the burden is real and chronic: near-universal menorrhagia in reproductive-age women, recurrent mucocutaneous bleeding, iron deficiency, and dependence on platelet transfusion with its alloimmunization risk. A recent multi-instrument quality-of-life study found the relationship between quality-of-life scores and bleeding-assessment score was weak, which is worth taking seriously: event count is not the same thing as lived burden, and the drivers appear to be chronic anemia, fatigue, treatment access, and disruption to school and work.

Show evidence (2 references)

PMID:17109744 SUPPORT Human Clinical

"The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."

Supports a moderate rather than high burden level given adequate care.

PMID:41100648 SUPPORT Human Clinical

"The relationship between quality of life (QoL) scores and ISTH-BAT score was weak."

Establishes the decoupling of measured bleeding severity from lived quality of life, which is why burden cannot be read off event counts.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Bernard-Soulier Syndrome:

Immune Thrombocytopenic Purpura

Overlapping Features The most consequential misdiagnosis, and the one monoallelic disease routinely receives. The two are managed completely differently, so getting it wrong means immunosuppression and sometimes splenectomy for a structural receptor defect that will not respond. Chronic persistent thrombocytopenia, a positive family history, unresponsive immune thrombocytopenic purpura treatment, macrothrombocytopenia, and an absent ristocetin response should all prompt reconsideration.

Distinguishing Features

Lifelong and familial rather than acquired
Large or giant platelets rather than normal-sized
Absent or reduced ristocetin-induced aggregation
Failure to respond to immune thrombocytopenic purpura therapy

Show evidence (1 reference)

PMID:39191409 SUPPORT Human Clinical

"Thus, BSS should be kept in mind in the presence of individuals with chronic persistent thrombocytopenia, positive family history, unresponsive ITP treatment, macrothrombocytopenia, and absence of RIPA response."

Sets out the specific features that should prompt reconsideration of an immune thrombocytopenic purpura diagnosis.

von Willebrand Disease

Overlapping Features The other disease of the von Willebrand factor to GPIbalpha axis, approached from the opposite side. In von Willebrand disease the plasma ligand is deficient or defective; here the platelet receptor is. The discriminating test is whether adding normal plasma corrects the ristocetin response: it does in von Willebrand disease and it cannot here, because the receptor is simply not there.

Distinguishing Features

Ristocetin response corrected by normal plasma in von Willebrand disease, not in Bernard-Soulier syndrome
Platelet count and size normal in most von Willebrand disease
Plasma von Willebrand factor antigen and activity abnormal in von Willebrand disease

Show evidence (1 reference)

PMID:24934643 SUPPORT Human Clinical

"As a consequence, platelets are unable to adhere to the vascular subendothelium and agglutinate in response to ristocetin."

The platelet-intrinsic basis of the ristocetin failure, which is what makes it uncorrectable by normal plasma.

Acquired (Autoantibody-Mediated) Bernard-Soulier Phenotype

Overlapping Features Anti-GPIb/IX autoantibodies can produce a phenocopy in a person with normal genes. It presents later, without a family history, and it is a different disease requiring immunomodulation rather than supportive hemostatic care. A recent Moroccan series of seven patients included one such case, which is a useful reminder that the laboratory phenotype alone does not establish the genetic diagnosis.

Distinguishing Features

Acquired later-life onset without family history
Anti-GPIb/IX autoantibodies detectable
No pathogenic GP1BA, GP1BB, or GP9 variant

Show evidence (1 reference)

PMID:40703326 SUPPORT Human Clinical

"the diagnosis of constitutional BSS was established in six patients, while only one case was idiopathic acquired BSS."

Documents an acquired case alongside constitutional cases in the same series.

🔬

Clinical Trials

1

NCT02422394 PHASE_II COMPLETED

The eltrombopag phase 2 in inherited thrombocytopenias, published as PMID:31273088. Relevant here only in part: the cohort was mixed across several inherited thrombocytopenias and included monoallelic Bernard-Soulier syndrome only, so it is not evidence for the biallelic disease, and raising the count of platelets that still cannot bind von Willebrand factor addresses one branch at most.

Target Phenotypes: Macrothrombocytopenia HP:0040185

Show evidence (2 references)

clinicaltrials:NCT02422394 SUPPORT Human Clinical

"Eltrombopag is a drug, available in tablets, which stimulates the production of platelets by the bone marrow."

Registry record establishing the agent and its mechanism, which acts on platelet production rather than on platelet adhesion.

PMID:31273088 SUPPORT Human Clinical

"We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia."

Documents the mixed cohort and the restriction to monoallelic disease, which is why the result does not transfer to biallelic Bernard-Soulier syndrome.

🧫

Experimental Models

1

Patient-derived megakaryocyte culture (Bolzano heterozygotes) PRIMARY_CELL_CULTURE

Megakaryocytes differentiated from cord blood and peripheral blood of patients heterozygous for the Bolzano variant. This is what makes the thrombopoietic branch a human finding rather than a mouse one: differentiation is normal, but proplatelet formation is halved, proplatelet tips are enlarged in proportion to the enlarged circulating platelets, and alpha-tubulin distribution is severely deranged.

Publication

PMID:19067792

Pathograph links

Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton recapitulates fidelity: high Reproduces the proplatelet-formation defect and the microtubule derangement in human patient cells, converging with the mouse knockouts.

Limitations: The patients studied were monoallelic Bolzano heterozygotes with mild disease, so the magnitude of the defect in biallelic disease is not directly measured here. Cultured megakaryocytes may not reproduce the marrow microenvironment that governs proplatelet release in vivo.

Readouts

Proplatelet formation by cultured patient megakaryocytes

Direction: DECREASED

Interpretation: A 50% reduction in proplatelet formation in human patient megakaryocytes against normal differentiation is the human counterpart of the mouse result.

Show evidence (1 reference)

PMID:19067792 SUPPORT In Vitro

"Megakaryocyte differentiation from both cord blood (one patient) and peripheral blood (five patients) was comparable to controls. However, proplatelet formation was reduced by about 50% with respect to controls."

Quantifies the human proplatelet formation deficit against normal differentiation.

Show evidence (1 reference)

PMID:19067792 SUPPORT In Vitro

"These results suggest that a defect of platelet formation contributes to macrothrombocytopenia associated to the Bolzano mutation, and indicate a key role for GPIb alpha in proplatelet formation."

States the authors' conclusion that a platelet-formation defect contributes to the macrothrombocytopenia in humans.

🐁

Animal Models

3

GPIbalpha-null mouse

The mouse that resolved a 50-year-old question. Disrupting the gene encoding the alpha subunit reproduces the hallmark features of the human disease, and critically established that the giant-platelet and thrombocytopenia phenotype is a direct consequence of the missing receptor rather than an incidental association. Transgenic expression of human GPIbalpha rescues the phenotype, closing the causal loop.

Species

Mouse

Genotype

GP Ibalpha knockout

Publication

PMID:10706630

Pathograph links

Release of Fewer, Abnormally Large Platelets recapitulates fidelity: high The knockout reproduces mild thrombocytopenia with giant platelets and a bleeding phenotype, and rescue by transgenic human GPIbalpha demonstrates the dependency directly.

Limitations: Mouse platelets differ from human in size and count baselines, and the model addresses the GP1BA route only, so it says nothing about how GP1BB or GP9 variants produce the same phenotype. Murine bleeding assays (tail bleeding time) correspond only loosely to human mucocutaneous bleeding.

Show evidence (1 reference)

PMID:10706630 SUPPORT Model Organism

"We have disrupted the gene encoding the alpha-subunit of mouse GP Ib-IX-V (GP Ibalpha) and describe a murine model recapitulating the hallmark characteristics of the human Bernard-Soulier syndrome."

States that the model recapitulates the hallmark features of the human disease.

Cocker Spaniel GP9 large-deletion natural model

The only naturally occurring animal model of this disease, and worth listing alongside two engineered knockouts precisely because nobody built it. Four Cocker Spaniels with a mild to severe bleeding disorder showed macrothrombocytopenia and absent functional GPIb-IX-V, and whole genome sequencing identified a 2460 bp deletion removing most of the single coding exon of canine GP9, with recessive inheritance confirmed by genotyping and the homozygous genotype absent from 98 control Cocker Spaniels. It is the canine counterpart of human BSS type C.

Species

Dog

Genotype

Homozygous 2460 bp deletion in the single coding exon of canine GP9

Publication

PMID:31484196

Pathograph links

Failure of GPIb-IX-V Complex Assembly and Surface Expression recapitulates fidelity: high A spontaneous GP9 null produces absent functional GPIb-IX-V with macrothrombocytopenia and a bleeding phenotype, arrived at naturally rather than by engineering.

Limitations: Four dogs from one breed, so the phenotypic range is not established, and canine platelet biology differs from human in baseline count and size. Characterization is at the level of platelet count, morphology, and immunocytochemistry; the proplatelet-formation and adhesion assays that anchor the two-branch model in the mouse have not been run here.

Readouts

Functional GPIb-IX-V on canine platelets by immunocytochemistry

Direction: ABOLISHED

Interpretation: Absent functional complex is the direct correlate of the GP9 null, and the same readout that defines the human disease.

Show evidence (1 reference)

PMID:31484196 SUPPORT Model Organism

"Furthermore, the lack of functional GPIb-IX-V was demonstrated by immunocytochemistry."

Reports the measured absence of functional complex in the affected dogs.

Show evidence (2 references)

PMID:31484196 SUPPORT Model Organism

"The affected dogs showed a platelet adhesion defect characterized by macrothrombocytopenia with variable platelet counts resembling human Bernard-Soulier syndrome (BSS)."

Establishes the phenotypic correspondence to the human disease.

+ 1 more reference

GPIbbeta-null mouse

The model that localized the thrombopoietic defect. Megakaryocyte progenitor number, differentiation, maturation class, and endoreplication are all normal; the failure is specifically at the proplatelet-formation stage, with a poorly developed demarcation membrane system and a doubled marginal microtubule ring.

Species

Mouse

Genotype

GPIbbeta knockout

Publication

PMID:19377075

Pathograph links

Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton recapitulates fidelity: high Proplatelet extension is reduced by 41% in cultured knockout megakaryocytes with normal upstream differentiation, localizing the lesion precisely to proplatelet formation.

Limitations: The proportional reduction in proplatelet formation is measured in cultured fetal-liver-derived megakaryocytes rather than in vivo, and the mouse addresses the GP1BB route only. Human patient megakaryocyte culture is needed to confirm translation, and does.

Readouts

Proportion of megakaryocytes extending proplatelets

Direction: DECREASED

Interpretation: A 41% reduction in proplatelet-forming capacity with normal upstream differentiation is the quantitative core of the thrombopoietic branch.

Show evidence (1 reference)

PMID:19377075 SUPPORT Model Organism

"GPIbbeta(-/-) megakaryocytes could be differentiated in culture from Lin(-) fetal liver cells in normal amounts but the proportion of cells able to extend proplatelets was decreased by 41%."

Quantifies the proplatelet formation deficit against normal differentiation.

Show evidence (1 reference)

PMID:19377075 SUPPORT Model Organism

"Altogether, these findings point to a role of the GPIb-V-IX complex intrinsic to megakaryocytes at the stage of proplatelet formation and suggest a functional link with the underlying microtubular cytoskeleton in platelet biogenesis."

The authors' own conclusion locating the defect at proplatelet formation and linking it to the microtubular cytoskeleton.

{ }

Source YAML

click to show

name: Bernard-Soulier Syndrome
creation_date: "2026-08-15T00:00:00Z"
category: Mendelian
parents:
- Inherited Platelet Disorder
- Bleeding Disorder
disease_term:
  preferred_term: Bernard-Soulier Syndrome
  term:
    id: MONDO:0009276
    label: Bernard-Soulier syndrome
synonyms:
- BSS
- hemorrhagiparous thrombocytic dystrophy
- congenital hemorrhagiparous thrombocytic dystrophy
- giant platelet syndrome
- macrothrombocytopenia, Bernard-Soulier type
description: >-
  Bernard-Soulier syndrome is an inherited bleeding disorder of the
  megakaryocyte and platelet lineage caused by absence, deficiency, or
  dysfunction of the platelet GPIb-IX-V complex, the receptor that captures von
  Willebrand factor. The clinical triad is a bleeding tendency out of proportion
  to the platelet count, abnormally large platelets, and moderate
  thrombocytopenia. What makes the disease conceptually neat is that the
  receptor turns out to be doing two unrelated jobs at once. Its ectodomain is
  the grappling hook a platelet throws at a damaged vessel wall under arterial
  shear; its cytoplasmic tail is a structural anchor tying the membrane skeleton
  to the cytoskeleton while a megakaryocyte extrudes proplatelets. Lose the
  complex and both jobs fail, which is why one gene defect produces a platelet
  that cannot stick and a platelet that was built wrong in the first place.
  Biallelic variants in GP1BA, GP1BB, or GP9 cause the classic recessive disease;
  monoallelic GP1BA and GP1BB variants cause a milder dominant form that is
  routinely misdiagnosed as immune thrombocytopenic purpura. No BSS-causing
  variant has ever been reported in GP5, the fourth subunit. Treatment is
  supportive, built on antifibrinolytics and platelet transfusion, with the
  central long-term hazard being alloimmunization from repeated transfusion.
has_subtypes:
- name: A1
  display_name: BSS type A1 (GP1BA-related, biallelic)
  subtype_term:
    preferred_term: GP1BA-related Bernard-Soulier syndrome
    term:
      id: MONDO:1060238
      label: GP1BA-related Bernard-Soulier syndrome
  description: >-
    Biallelic GP1BA variants, accounting for 28% of genotyped families in the
    international consortium. GP1BA encodes GPIbalpha, the ligand-binding subunit.
  genes:
  - preferred_term: GP1BA
    term:
      id: hgnc:4439
      label: GP1BA
- name: B
  display_name: BSS type B (GP1BB-related, biallelic)
  subtype_term:
    preferred_term: GP1BB-related Bernard-Soulier syndrome
    term:
      id: MONDO:1060239
      label: GP1BB-related Bernard-Soulier syndrome
  description: >-
    Biallelic GP1BB variants, 28% of genotyped families. GP1BB sits inside the
    commonly deleted 22q11.2 interval, so every patient with 22q11.2 deletion
    syndrome is an obligate carrier and a second hit on the retained allele
    produces full disease.
  genes:
  - preferred_term: GP1BB
    term:
      id: hgnc:4440
      label: GP1BB
- name: C
  display_name: BSS type C (GP9-related, biallelic)
  subtype_term:
    preferred_term: GP9-related Bernard-Soulier syndrome
    term:
      id: MONDO:1060237
      label: GP9-related Bernard-Soulier syndrome
  description: >-
    Biallelic GP9 variants, the commonest genotype at 44% of genotyped families.
  genes:
  - preferred_term: GP9
    term:
      id: hgnc:4444
      label: GP9
- name: A2
  display_name: BSS type A2 (monoallelic, autosomal dominant)
  subtype_term:
    preferred_term: Bernard-Soulier syndrome, type A2, autosomal dominant
    term:
      id: MONDO:0007930
      label: Bernard-Soulier syndrome, type A2, autosomal dominant
  description: >-
    The dominant monoallelic form, caused by heterozygous GP1BA or GP1BB
    variants. Milder, later-presenting, and frequently mistaken for immune
    thrombocytopenic purpura. The best-characterized allele is the southern
    Italian Bolzano founder variant GP1BA c.515C>T, which accounted for 20% of
    inherited thrombocytopenia patients at two Italian referral centers over a
    decade. Platelet aggregation is often normal here, so genetic testing rather
    than aggregometry is what makes the diagnosis.
  genes:
  - preferred_term: GP1BA
    term:
      id: hgnc:4439
      label: GP1BA
  evidence:
  - reference: PMID:21933849
    reference_title: "Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although the clinical expression was variable, patients with this mutation typically had a mild form of Bernard-Soulier syndrome with mild thrombocytopenia and bleeding tendency."
    explanation: >-
      Characterizes the monoallelic Bolzano form as a mild variant of the
      syndrome.
pathophysiology:
- name: Biallelic Loss of Function in GP1BA, GP1BB, or GP9
  biological_scale: MOLECULAR
  conforms_to: "primary_hemostatic_plug_failure#Loss of a Platelet Primary-Hemostatic Component"
  description: >-
    Pathogenic variants in any one of the three genes encoding the GPIbalpha,
    GPIbbeta, or GPIX subunits cause the disease. Across 211 genotyped families
    the burden splits GP9 44%, GP1BA 28%, GP1BB 28%, spanning 112 distinct
    variants of every class, and 85% of probands are homozygous with founder
    effects in several regions. The fourth subunit gene, GP5, has never been
    implicated, which is a genuine negative finding rather than an absence of
    looking.
  genes:
  - preferred_term: GP1BA
    term:
      id: hgnc:4439
      label: GP1BA
  - preferred_term: GP1BB
    term:
      id: hgnc:4440
      label: GP1BB
  - preferred_term: GP9
    term:
      id: hgnc:4444
      label: GP9
  downstream:
  - target: Failure of GPIb-IX-V Complex Assembly and Surface Expression
    description: >-
      Loss of any one subunit prevents the complex reaching the platelet
      membrane, because assembly is obligately stoichiometric.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:24934643
    reference_title: Spectrum of the mutations in Bernard-Soulier syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With 79 additional families for which molecular data were gleaned from the literature, the 211 families characterized so far have mutations in the GP1BA (28%), GP1BB (28%), or GP9 (44%) genes."
    explanation: >-
      Gives the genotype distribution across the largest assembled cohort.
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genes coding for the four subunits of the receptor, GPIBA, GPIBB, GP5 and GP9, map to chromosomes 17p12, 22q11.2, 3q29, and 3q21, respectively. Defects have been identified in GPIBA, GPIBB, and GP9 but not in GP5."
    explanation: >-
      Establishes the three causal genes and the negative finding for GP5.
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, no BSS mutations in the GP5 gene have been reported."
    explanation: >-
      Independently restates the GP5-negative finding in the current definitive
      review.
- name: Failure of GPIb-IX-V Complex Assembly and Surface Expression
  biological_scale: CELLULAR
  description: >-
    The dominant molecular consequence is failure of the complex to reach the
    platelet surface at all, because assembly is obligately stoichiometric and a
    single null subunit sinks the whole receptor. A minority of variants instead
    permit surface expression but abolish von Willebrand factor binding, a
    genuinely separate mechanism with the same clinical result. Surface
    GPIbalpha in biallelic disease is consistently under 10% of control values.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  - preferred_term: megakaryocyte
    term:
      id: CL:0000556
      label: megakaryocyte
  cellular_components:
  - preferred_term: glycoprotein Ib-IX-V complex
    term:
      id: GO:1990779
      label: glycoprotein Ib-IX-V complex
    modifier: ABSENT
  downstream:
  - target: Loss of von Willebrand Factor Capture Under Shear
    description: >-
      Without surface receptor there is no von Willebrand factor A1 domain
      capture, so platelet tethering under arterial shear never begins.
    causal_link_type: DIRECT
  - target: Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton
    description: >-
      Loss of the complex removes the cytoplasmic-tail linkage to filamin A and
      14-3-3 zeta that anchors the membrane skeleton during proplatelet
      extrusion.
    causal_link_type: DIRECT
  - target: Loss of Platelet-Surface Coagulation Factor Binding
    description: >-
      GPIbalpha also binds thrombin, factor XI, factor XII, and
      high-molecular-weight kininogen, so its absence degrades
      platelet-supported coagulation as well as adhesion.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:24934643
    reference_title: Spectrum of the mutations in Bernard-Soulier syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most of the mutations identified in the genes encoding for the GP1BA (GPIbα), GP1BB (GPIbβ), and GP9 (GPIX) subunits prevent expression of the complex at the platelet membrane or more rarely its interaction with VWF."
    explanation: >-
      Establishes the two molecular consequence classes, failed surface
      expression and, more rarely, failed ligand interaction.
  - reference: PMID:21173099
    reference_title: "Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consistent with expression levels of GPIbα always lower than 10% of control values, platelet aggregation was absent or severely reduced."
    explanation: >-
      Quantifies the residual surface expression in biallelic disease and links it
      to the functional readout.
- name: Loss of von Willebrand Factor Capture Under Shear
  biological_scale: CELLULAR
  conforms_to: "primary_hemostatic_plug_failure#Impaired Platelet Adhesion to the Injured Vessel Wall"
  description: >-
    Under arterial shear, von Willebrand factor unfurls on exposed subendothelium
    and its A1 domain is the only thing fast enough to catch a platelet moving at
    that velocity. GPIbalpha is the catcher's mitt. Without it there is no capture
    step, so nothing downstream ever starts: no rolling, no outside-in signaling,
    no inside-out activation of the integrin alphaIIb-beta3, no firm adhesion.
    The laboratory expression of this node is the absent ristocetin-induced
    agglutination that is not corrected by adding normal plasma, which is the
    entire diagnostic logic of the disease in one sentence.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: primary hemostasis
    term:
      id: GO:0007599
      label: hemostasis
    modifier: DECREASED
  downstream:
  - target: Failure of Primary Hemostatic Plug Formation
    description: >-
      Without the capture step no platelet aggregate forms at the site of vessel
      injury.
    causal_link_type: DIRECT
  - target: Impaired Ristocetin-Induced Platelet Aggregation
    description: >-
      Ristocetin artificially promotes von Willebrand factor to GPIbalpha
      engagement, so a platelet lacking the receptor cannot agglutinate however
      much normal plasma is supplied.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:24934643
    reference_title: Spectrum of the mutations in Bernard-Soulier syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As a consequence, platelets are unable to adhere to the vascular subendothelium and agglutinate in response to ristocetin."
    explanation: >-
      States both the adhesion failure and its diagnostic laboratory correlate.
  - reference: PMID:23336709
    reference_title: "The organizing principle of the platelet glycoprotein Ib-IX-V complex."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The glycoprotein (GP)Ib-IX-V complex is the platelet receptor for von Willebrand factor and many other molecules that are critically involved in hemostasis and thrombosis."
    explanation: >-
      Establishes the receptor identity and its role as a multi-ligand hemostatic
      hub.
- name: Loss of Platelet-Surface Coagulation Factor Binding
  biological_scale: MOLECULAR
  description: >-
    GPIbalpha is not only a von Willebrand factor receptor. It also binds
    thrombin, factor XI, factor XII, high-molecular-weight kininogen, P-selectin,
    and the leukocyte integrin Mac-1. Losing this hub degrades
    platelet-supported coagulation and platelet-leukocyte crosstalk on top of the
    adhesion defect, and the clinical fingerprint of that second loss is the
    markedly reduced prothrombin consumption seen in these patients. This is the
    arm that gets dropped from modern write-ups, and it is part of why bleeding is
    worse than a pure adhesion defect would predict.
  cellular_components:
  - preferred_term: glycoprotein Ib-IX-V complex
    term:
      id: GO:1990779
      label: glycoprotein Ib-IX-V complex
    modifier: ABSENT
  biological_processes:
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
    modifier: DECREASED
  downstream:
  - target: Failure of Primary Hemostatic Plug Formation
    description: >-
      Loss of platelet-supported coagulation compounds the adhesion failure at the
      site of injury.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prothrombin consumption is markedly reduced."
    explanation: >-
      The laboratory fingerprint of impaired platelet-supported coagulation,
      distinct from the adhesion defect.
  - reference: PMID:23336709
    reference_title: "The organizing principle of the platelet glycoprotein Ib-IX-V complex."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The glycoprotein (GP)Ib-IX-V complex is the platelet receptor for von Willebrand factor and many other molecules that are critically involved in hemostasis and thrombosis."
    explanation: >-
      Supports the multi-ligand character of the receptor beyond von Willebrand
      factor.
- name: Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton
  biological_scale: CELLULAR
  description: >-
    The second job. The GPIbalpha cytoplasmic tail binds filamin A and 14-3-3
    zeta, anchoring the membrane skeleton to the underlying cytoskeleton while a
    megakaryocyte extrudes proplatelets. Without it, megakaryocyte progenitor
    numbers, differentiation, and endoreplication are all normal, but the mature
    cells have a thickened peripheral zone and a poorly developed demarcation
    membrane system, proplatelet extension falls by about 41%, and the marginal
    microtubular ring contains twice as many tubulin fibers. The same defect is
    demonstrable in cultured human megakaryocytes from patients, with proplatelet
    formation reduced about 50%, enlarged proplatelet tips, and severely deranged
    alpha-tubulin distribution. Human and mouse converge here unusually well for a
    rare disease.
  cell_types:
  - preferred_term: megakaryocyte
    term:
      id: CL:0000556
      label: megakaryocyte
  biological_processes:
  - preferred_term: platelet formation
    term:
      id: GO:0030220
      label: platelet formation
    modifier: DECREASED
  downstream:
  - target: Release of Fewer, Abnormally Large Platelets
    description: >-
      Deranged proplatelet formation yields fewer platelets, each larger than
      normal.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:19377075
    reference_title: "Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The number of megakaryocyte progenitors, their differentiation and progressive maturation into distinct classes and their level of endoreplication were normal in GPIbbeta(-/-) bone marrow. However, the more mature cells exhibited ultrastructural anomalies with a thicker peripheral zone and a less well developed demarcation membrane system."
    explanation: >-
      Localizes the defect to late megakaryocyte maturation rather than to
      progenitor number or differentiation.
  - reference: PMID:19377075
    reference_title: "Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The marginal microtubular ring contained twice as many tubulin fibers in GPIbbeta(-/-) proplatelet buds in cultured and circulating platelets."
    explanation: >-
      Provides the cytoskeletal abnormality that accompanies the proplatelet
      defect.
  - reference: PMID:19067792
    reference_title: "Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Morphological evaluation of proplatelet formation revealed an increased size of proplatelet tips, which was consistent with the increased diameters of patients' blood platelets. Moreover, alpha-tubulin distribution within proplatelets was severely deranged."
    explanation: >-
      Demonstrates the same proplatelet and microtubule abnormality in cultured
      human patient megakaryocytes, not only in mouse.
- name: Release of Fewer, Abnormally Large Platelets
  biological_scale: TISSUE
  description: >-
    The output of the thrombopoietic branch: a moderate thrombocytopenia,
    typically not severe, with platelets that can approach lymphocyte size. The
    two arms of the disease are cleanly dissociable at the domain level. A
    chimeric receptor swapping the GPIbalpha ectodomain for an unrelated one
    doubles the circulating platelet count and halves platelet size while leaving
    the bleeding phenotype severe, so the cytoplasmic tail drives size and count
    and the ectodomain drives hemostasis.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  downstream:
  - target: Macrothrombocytopenia
    description: Fewer and larger circulating platelets.
    causal_link_type: DIRECT
  - target: Giant Platelets
    description: Released platelets are abnormally large.
    causal_link_type: DIRECT
  - target: Increased Mean Platelet Volume
    description: The size shift raises measured mean platelet volume.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:10706630
    reference_title: "Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The results demonstrate a direct link between expression of a GP Ib-IX-V complex and normal megakaryocytopoiesis and platelet morphogenesis."
    explanation: >-
      Establishes the causal link between the receptor and platelet production,
      which had been assumed but unproven for decades.
  - reference: PMID:12200373
    reference_title: "Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The characterization of these mice revealed a 2-fold increase in circulating platelet count and a 50% reduction in platelet size when compared with platelets from the mouse model of the Bernard-Soulier syndrome."
    explanation: >-
      The chimeric-receptor rescue quantifying how much of the size and count
      phenotype is attributable to the cytoplasmic tail rather than the
      ectodomain.
  - reference: PMID:12200373
    reference_title: "Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mice expressing the chimeric receptor retain a severe bleeding phenotype, confirming a critical role for the GP Ibalpha extracytoplasmic domain in hemostasis."
    explanation: >-
      The other half of the dissociation: rescuing size and count does not rescue
      bleeding, so the two branches are separable.
- name: Failure of Primary Hemostatic Plug Formation
  biological_scale: ORGANISM
  conforms_to: "primary_hemostatic_plug_failure#Failure of Primary Hemostatic Plug Formation"
  description: >-
    The convergence of both hemostatic losses, adhesion and platelet-supported
    coagulation. The clinical signature is bleeding disproportionate to the
    platelet count, which is the observation that separates this from a simple
    thrombocytopenia and which drove the search for a receptor defect in the
    first place.
  biological_processes:
  - preferred_term: platelet aggregation
    term:
      id: GO:0070527
      label: platelet aggregation
    modifier: DECREASED
  downstream:
  - target: Epistaxis
    description: Mucocutaneous bleeding from the nasal mucosa.
    causal_link_type: DIRECT
  - target: Menorrhagia
    description: Heavy menstrual bleeding, consistently reported in all
      post-menarchal females in case series.
    causal_link_type: DIRECT
  - target: Gingival Bleeding
    description: Mucosal bleeding from the gums.
    causal_link_type: DIRECT
  - target: Bruising Susceptibility
    description: Easy bruising and ecchymoses from minor trauma.
    causal_link_type: DIRECT
  - target: Petechiae
    description: Cutaneous petechial hemorrhage.
    causal_link_type: DIRECT
  - target: Gastrointestinal Hemorrhage
    description: Mucosal bleeding from the gastrointestinal tract.
    causal_link_type: DIRECT
  - target: Prolonged Bleeding After Surgery
    description: >-
      Surgical, dental, and obstetric procedures provoke prolonged bleeding.
    causal_link_type: DIRECT
  - target: Post-Partum Hemorrhage
    description: Delivery is a high-risk bleeding event.
    causal_link_type: DIRECT
  - target: Intracranial Hemorrhage
    description: >-
      The rare but principal life-threatening bleeding site.
    causal_link_type: DIRECT
  - target: Prolonged Bleeding Time
    description: >-
      Failure of primary hemostasis prolongs the skin bleeding time.
    causal_link_type: DIRECT
  - target: Iron Deficiency Anemia
    description: >-
      Chronic mucosal blood loss depletes iron stores, particularly in menstruating
      women.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The underlying defect is a deficiency or dysfunction of the glycoprotein GPIb-V-IX complex, a platelet-restricted multisubunit receptor required for normal primary hemostasis."
    explanation: >-
      Human clinical source establishing that the receptor is required for normal
      primary hemostasis, which is what fails at this node.
  - reference: PMID:10706630
    reference_title: "Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The bleeding in patients with the Bernard-Soulier syndrome is disproportionately more severe than suggested by the reduced platelet count and is explained by a defect in primary hemostasis owing to the absence of the platelet glycoprotein (GP) Ib-IX-V membrane receptor."
    explanation: >-
      States the defining clinical observation that bleeding is disproportionate to
      the platelet count. Tagged MODEL_ORGANISM because the study this sentence
      introduces is a mouse knockout paper, and evidence_source classifies the
      publication's study type rather than the topic of the quoted sentence.
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations usually include purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding."
    explanation: >-
      Enumerates the mucocutaneous bleeding phenotypes downstream of this node.
mechanistic_hypotheses:
- hypothesis_group_id: shear_mechanosensor_platelet_clearance
  hypothesis_label: GPIbalpha Mechanosensory Domain Unfolding as a Platelet-Clearance Timer
  status: EMERGING
  description: >-
    A third, newer contributor to the thrombocytopenia that is not part of the
    canonical two-branch model. GPIbalpha contains a relatively unstable
    mechanosensory domain; von Willebrand factor binding under physiological shear
    unfolds it, and the unfolded domain triggers intracellular signaling and rapid
    platelet clearance. If a BSS-causing missense variant destabilized that domain,
    it could in principle shorten platelet survival independently of production,
    adding a clearance mechanism alongside the production defect. The direct link
    from BSS-causing variants to accelerated clearance in patients has not been
    demonstrated, which is why this is EMERGING and is deliberately not modeled as
    a pathophysiology node.
  evidence:
  - reference: PMID:27670775
    reference_title: Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The unfolded MSD, particularly the juxtamembrane 'Trigger' sequence therein, leads to intracellular signalling and rapid platelet clearance."
    explanation: >-
      Establishes the mechanosensory-unfolding to clearance link in the receptor,
      which is the basis for the hypothesis.
phenotypes:
- name: Macrothrombocytopenia
  category: Hematologic
  description: >-
    The defining laboratory finding: a reduced platelet count combined with
    abnormally large platelets. Thrombocytopenia is characteristically moderate
    rather than severe, which is part of why the bleeding severity surprises
    people.
  phenotype_term:
    preferred_term: Macrothrombocytopenia
    term:
      id: HP:0040185
      label: Macrothrombocytopenia
  frequency: OBLIGATE
  diagnostic: true
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on a prolonged skin bleeding time, the presence of a small number of very large platelets (macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent expression of the GPIb-V-IX complex."
    explanation: >-
      Establishes macrothrombocytopenia as part of the diagnostic definition,
      supporting an OBLIGATE band.
  - reference: PMID:21173099
    reference_title: "Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients all had a moderate thrombocytopenia with giant platelets and a bleeding tendency whose severity varied among individuals."
    explanation: >-
      All 13 patients in the largest single-center series had moderate
      thrombocytopenia with giant platelets.
- name: Giant Platelets
  category: Hematologic
  description: >-
    Platelets abnormally large on peripheral smear, sometimes approaching
    lymphocyte size, arising from the proplatelet formation defect rather than
    from accelerated turnover.
  phenotype_term:
    preferred_term: Giant platelets
    term:
      id: HP:0001902
      label: Giant platelets
  frequency: OBLIGATE
  diagnostic: true
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bernard-Soulier syndrome (BSS), also known as Hemorrhagiparous thrombocytic dystrophy, is a hereditary bleeding disorder affecting the megakaryocyte/platelet lineage and characterized by bleeding tendency, giant blood platelets and low platelet counts."
    explanation: >-
      Giant platelets are part of the defining description of the disease.
- name: Increased Mean Platelet Volume
  category: Hematologic
  description: >-
    The quantitative expression of the giant-platelet phenotype on automated
    counting, and a reason automated analyzers can underreport the platelet count
    by excluding the largest platelets from the gate.
  phenotype_term:
    preferred_term: Increased mean platelet volume
    term:
      id: HP:0011877
      label: Increased mean platelet volume
  evidence:
  - reference: PMID:19067792
    reference_title: "Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Morphological evaluation of proplatelet formation revealed an increased size of proplatelet tips, which was consistent with the increased diameters of patients' blood platelets."
    explanation: >-
      Documents increased platelet diameter in patients and ties it to the
      proplatelet defect.
- name: Impaired Ristocetin-Induced Platelet Aggregation
  category: Hematologic
  description: >-
    Absent or severely reduced agglutination in response to ristocetin, and
    crucially not corrected by adding normal plasma, which is what separates this
    from von Willebrand disease where the missing element is in the plasma rather
    than on the platelet. In monoallelic disease the response may be reduced or
    even normal, which is why genetic testing rather than aggregometry makes that
    diagnosis.
  phenotype_term:
    preferred_term: Impaired ristocetin-induced platelet aggregation
    term:
      id: HP:0011871
      label: Impaired ristocetin-induced platelet aggregation
  frequency: OBLIGATE
  diagnostic: true
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In biallelic BSS, giant platelets in the peripheral blood smear, absence of ristocetin-induced platelet aggregation (RIPA) using light transmission aggregometry (LTA), and complete loss of GPIbIX complex in flow cytometry are observed, whereas in monoallelic forms, genetic diagnosis is recommended due to the presence of large platelets in the peripheral blood smear, decreased or normal RIPA response in LTA, and partial loss or normal GPIbIX complex in flow cytometry."
    explanation: >-
      Distinguishes the obligate absent response in biallelic disease from the
      variable response in monoallelic disease.
- name: Prolonged Bleeding Time
  category: Hematologic
  description: >-
    Prolonged skin bleeding time, historically part of the diagnostic definition
    though largely superseded by flow cytometry and genetic testing.
  phenotype_term:
    preferred_term: Prolonged bleeding time
    term:
      id: HP:0003010
      label: Prolonged bleeding time
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on a prolonged skin bleeding time, the presence of a small number of very large platelets (macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent expression of the GPIb-V-IX complex."
    explanation: >-
      Lists prolonged skin bleeding time among the diagnostic findings.
- name: Epistaxis
  category: Hematologic
  description: >-
    Nosebleeds, consistently the commonest presenting bleeding symptom across
    series.
  phenotype_term:
    preferred_term: Epistaxis
    term:
      id: HP:0000421
      label: Epistaxis
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."
    explanation: >-
      Epistaxis is named first among the commonest manifestations in a 76-patient
      natural history study.
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations usually include purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding."
    explanation: >-
      Lists epistaxis among the usual clinical manifestations.
- name: Menorrhagia
  category: Hematologic
  description: >-
    Heavy menstrual bleeding, reported in all post-menarchal females in a recent
    Indian series, and a major driver of the iron deficiency that underlies much
    of the day-to-day symptom burden.
  phenotype_term:
    preferred_term: Menorrhagia
    term:
      id: HP:0000132
      label: Menorrhagia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Menorrhagia was seen in all females in the reproductive age group."
    explanation: >-
      Universal among reproductive-age females in this cohort, supporting a
      VERY_FREQUENT band.
- name: Gingival Bleeding
  category: Hematologic
  description: >-
    Bleeding from the gums, both spontaneous and provoked by dental care, and one
    reason meticulous dental hygiene is a genuine preventive measure here.
  phenotype_term:
    preferred_term: Gingival bleeding
    term:
      id: HP:0000225
      label: Gingival bleeding
  frequency: FREQUENT
  evidence:
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."
    explanation: >-
      Gingival bleeding is among the commonest manifestations reported.
- name: Bruising Susceptibility
  category: Hematologic
  description: >-
    Easy bruising and ecchymoses from trivial trauma, among the commonest
    manifestations reported.
  phenotype_term:
    preferred_term: Bruising susceptibility
    term:
      id: HP:0000978
      label: Bruising susceptibility
  frequency: FREQUENT
  evidence:
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."
    explanation: >-
      Ecchymosis is listed among the commonest manifestations.
- name: Petechiae
  category: Hematologic
  description: >-
    Pinpoint cutaneous hemorrhages, part of the purpuric presentation.
  phenotype_term:
    preferred_term: Petechiae
    term:
      id: HP:0000967
      label: Petechiae
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations usually include purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding."
    explanation: >-
      Purpura is named among the usual manifestations. PARTIAL because petechiae
      specifically are not separately enumerated in this source.
- name: Gastrointestinal Hemorrhage
  category: Gastrointestinal
  description: >-
    Bleeding from the gastrointestinal mucosa, a recurring source of chronic blood
    loss and a contributor to iron deficiency.
  phenotype_term:
    preferred_term: Gastrointestinal hemorrhage
    term:
      id: HP:0002239
      label: Gastrointestinal hemorrhage
  frequency: FREQUENT
  evidence:
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations."
    explanation: >-
      Gastrointestinal bleeding is among the commonest manifestations reported.
- name: Prolonged Bleeding After Surgery
  category: Hematologic
  description: >-
    Surgery, dental extraction, and circumcision provoke prolonged bleeding and
    are the settings in which prophylactic platelet transfusion is usually
    required.
  phenotype_term:
    preferred_term: Prolonged bleeding after surgery
    term:
      id: HP:0004846
      label: Prolonged bleeding after surgery
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."
    explanation: >-
      Identifies surgical procedures as a trigger for severe bleeding episodes.
- name: Post-Partum Hemorrhage
  category: Obstetric
  description: >-
    Delivery is one of the highest-risk bleeding events in this disease, and late
    postpartum hemorrhage occurs at least as often as early, which means the risk
    window extends well past the delivery room.
  phenotype_term:
    preferred_term: Post-partum hemorrhage
    term:
      id: HP:0011891
      label: Post-partum hemorrhage
  frequency: FREQUENT
  evidence:
  - reference: PMID:36889343
    reference_title: "Bernard-Soulier Syndrome from the Perspective of the Obstetrician: A Case Report with a Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the literature review, postpartum hemorrhage (PPH) was found in 52.9% (27/51) of deliveries. Late PPH occurred more frequently than early PPH (35.3 and 31.4%, respectively)."
    explanation: >-
      52.9% of 51 reported deliveries, within the FREQUENT band of 30 to 79%. The
      denominator is published deliveries rather than all pregnancies in this
      disease, so the figure is ascertainment-biased upward and the band should be
      read as applying to reported pregnancies.
- name: Intracranial Hemorrhage
  category: Neurologic
  description: >-
    The rare but principal life-threatening bleeding site, and the reason the
    otherwise good prognosis is qualified.
  phenotype_term:
    preferred_term: Intracranial hemorrhage
    term:
      id: HP:0002170
      label: Intracranial hemorrhage
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."
    explanation: >-
      Establishes that severe bleeding episodes occur despite a generally good
      prognosis. PARTIAL because intracranial hemorrhage is not separately named
      in this source, so no frequency band is assigned.
- name: Iron Deficiency Anemia
  category: Hematologic
  description: >-
    Chronic mucosal blood loss, dominated by menorrhagia in reproductive-age
    women, depletes iron stores. Iron repletion is routine, under-prescribed, and
    plausibly a larger contributor to lived quality of life than event count.
  phenotype_term:
    preferred_term: Iron deficiency anemia
    term:
      id: HP:0001891
      label: Iron deficiency anemia
    temporality: CHRONIC
  evidence:
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Menorrhagia was seen in all females in the reproductive age group."
    explanation: >-
      Establishes the dominant chronic blood-loss route. PARTIAL because iron
      deficiency anemia itself is not quantified in this snippet.
genetic:
- name: GP1BA, GP1BB, and GP9 Biallelic Loss of Function
  gene_term:
    preferred_term: GP1BA
    term:
      id: hgnc:4439
      label: GP1BA
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: >-
    Biallelic pathogenic variants in GP1BA (17p13.2), GP1BB (22q11.21), or GP9
    (3q21.3) cause classic autosomal recessive disease. Across 211 genotyped
    families the distribution is GP9 44%, GP1BA 28%, GP1BB 28%, with 112 distinct
    variants spanning missense, nonsense, frameshift, splice-site, and larger
    deletions. Eighty-five percent of probands are homozygous, with founder
    effects in several regions and consanguinity the dominant population-level
    risk multiplier. GP5, the fourth subunit gene, has never been implicated.
    Monoallelic GP1BA and GP1BB variants cause the milder dominant type A2,
    including the southern Italian Bolzano founder allele GP1BA c.515C>T.
  frequency: OBLIGATE
  evidence:
  - reference: PMID:24934643
    reference_title: Spectrum of the mutations in Bernard-Soulier syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a wide spectrum of mutations with 112 different variants, including 22 novel alterations."
    explanation: >-
      Quantifies the allelic heterogeneity across the international consortium.
  - reference: PMID:24934643
    reference_title: Spectrum of the mutations in Bernard-Soulier syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consistent with the rarity of the disease, 85% of the probands carry homozygous mutations with evidence of founder effects in some geographical areas."
    explanation: >-
      Documents the predominance of homozygosity and the founder effects that
      follow from consanguinity.
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with autosomal recessively inherited biallelic BSS have a homozygous or compound heterozygous expression in the GPIbalpha, GPIbbeta, and GPIX subunits of the GPIbIX complex. Patients with autosomal dominantly inherited monoallelic BSS have a heterozygous expression in only the GPIbalpha and GPIbbeta subunits of the GPIbIX complex."
    explanation: >-
      Establishes the two inheritance modes and which subunits each involves.
- name: GP1BA Bolzano Founder Variant (c.515C>T)
  gene_term:
    preferred_term: GP1BA
    term:
      id: hgnc:4439
      label: GP1BA
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: A2
  features: >-
    A monoallelic GP1BA c.515C>T transition originating in southern Italy and
    inherited dominantly. It matters far out of proportion to its mild severity
    because it is common: it accounted for 20% of patients with inherited
    thrombocytopenia recruited at two Italian institutions over ten years, making
    it the single most frequent cause of inherited thrombocytopenia in Italy.
    Southern Italian emigration over the last century means it is likely present
    in other countries under other diagnoses.
  evidence:
  - reference: PMID:21933849
    reference_title: "Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study indicates that monoallelic Bolzano mutation is the most frequent cause of inherited thrombocytopenia in Italy, affecting 20% of patients recruited at our institutions during the last 10 years."
    explanation: >-
      Quantifies the contribution of this single allele to the inherited
      thrombocytopenia caseload in Italy.
  - reference: PMID:21933849
    reference_title: "Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because many people from southern Italy have emigrated during the last century, this mutation may have spread to other countries."
    explanation: >-
      Notes the likely geographic spread of the founder allele beyond Italy.
- name: 22q11.2 Deletion Conferring GP1BB Hemizygosity
  gene_term:
    preferred_term: GP1BB
    term:
      id: hgnc:4440
      label: GP1BB
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  features: >-
    GP1BB lies inside the commonly deleted 22q11.2 interval, so every patient with
    22q11.2 deletion syndrome is an obligate carrier of Bernard-Soulier syndrome.
    A second-hit pathogenic variant on the retained allele then produces full
    disease. Recorded as a predisposing structural context rather than as a
    differential diagnosis, because it is not a phenotypic mimic: it is a
    contiguous-gene deletion that halves gene dosage and unmasks a monoallelic
    GP1BB variant. Worth testing in any 22q11.2 deletion patient with unexplained
    macrothrombocytopenia.
  evidence:
  - reference: PMID:38625506
    reference_title: "Bernard-Soulier syndrome caused by a novel GP1BB variant and 22q11.2 deletion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with 22q11.2 deletion syndrome (22q11.2DS) are obligate carriers of BSS because GP1BB resides on chromosome 22q11.2."
    explanation: >-
      States the structural basis for obligate carrier status in 22q11.2 deletion
      syndrome.
  - reference: PMID:38625506
    reference_title: "Bernard-Soulier syndrome caused by a novel GP1BB variant and 22q11.2 deletion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gene panel testing revealed a novel variant in GP1BB, p.(Val169_Leu172del)."
    explanation: >-
      Documents the second-hit variant on the retained allele that converts
      carrier status into disease.
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Classic Bernard-Soulier syndrome is autosomal recessive, with 85% of probands
    homozygous and consanguinity the dominant risk multiplier. Obligate carriers
    are generally indistinguishable from controls, though carriers of some GP9
    variants show reduced complex expression and defective aggregation, so
    heterozygosity is not always silent. A separate autosomal dominant form
    exists, caused by monoallelic GP1BA or GP1BB variants.
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The syndrome is transmitted as an autosomal recessive trait."
    explanation: >-
      States the inheritance pattern of the classic form.
  - reference: PMID:21173099
    reference_title: "Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Except for obligate carriers of a GP9 mutation with a reduced GPIb/IX/V expression and defective aggregation, all the other carriers had no obvious anomalies."
    explanation: >-
      Documents that carriers are usually unremarkable but not invariably so.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Approximately 100 cases had been reported in the literature as of the 2006
    Orphanet review; the international consortium subsequently assembled 211
    genotyped families. These are counts of reported cases and families, not a
    population rate, and no validated population prevalence estimate was found.
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This syndrome is extremely rare as only approximately 100 cases have been reported in the literature."
    explanation: >-
      Gives the reported case count that grounds the ULTRA_RARE band, with the
      caveat that this is a literature count.
  - reference: PMID:24934643
    reference_title: Spectrum of the mutations in Bernard-Soulier syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In order to collect information on BSS patients, we established an International Consortium for the study of BSS, allowing us to enrol and genotype 132 families (56 previously unreported)."
    explanation: >-
      Documents the size of the largest assembled cohort, which updates the older
      case count.
progression:
- phase: Presentation
  notes: >-
    Biallelic disease presents in infancy or early childhood, typically with
    mucocutaneous bleeding. Monoallelic disease presents later, often in
    adulthood, and is frequently misdiagnosed as immune thrombocytopenic purpura,
    which matters because the two diseases are managed completely differently.
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with biallelic form are usually diagnosed at a young age, typically with mucocutaneous bleeding, whereas monoallelic forms are generally identified later in life and are frequently misdiagnosed with immune thrombocytopenic purpura (ITP)."
    explanation: >-
      Contrasts the presentation age and the characteristic misdiagnosis of the two
      forms.
- phase: Lifelong episodic course
  notes: >-
    The underlying defect is static from birth, so the disease does not progress
    in the usual sense. What changes is exposure: menarche, trauma, surgery,
    dental procedures, and pregnancy each produce discrete bleeding events against
    a stable baseline. Prognosis is generally good with adequate supportive care.
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."
    explanation: >-
      Establishes the episodic, exposure-driven course against a good baseline
      prognosis.
clinical_burden:
  burden_level: MODERATE
  rationale: >-
    Prognosis is generally good with adequate supportive care, and the disease is
    non-progressive, but the burden is real and chronic: near-universal
    menorrhagia in reproductive-age women, recurrent mucocutaneous bleeding,
    iron deficiency, and dependence on platelet transfusion with its
    alloimmunization risk. A recent multi-instrument quality-of-life study found
    the relationship between quality-of-life scores and bleeding-assessment score
    was weak, which is worth taking seriously: event count is not the same thing
    as lived burden, and the drivers appear to be chronic anemia, fatigue,
    treatment access, and disruption to school and work.
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."
    explanation: >-
      Supports a moderate rather than high burden level given adequate care.
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The relationship between quality of life (QoL) scores and ISTH-BAT score was weak."
    explanation: >-
      Establishes the decoupling of measured bleeding severity from lived quality
      of life, which is why burden cannot be read off event counts.
diagnosis:
- name: Diagnostic Triad and Confirmatory Testing
  description: >-
    Diagnosis rests on prolonged skin bleeding time, a small number of very large
    platelets, defective ristocetin-induced agglutination, and low or absent
    GPIb-IX-V expression. Flow cytometry for surface complex expression is the
    modern confirmatory test in biallelic disease. Prothrombin consumption is
    markedly reduced, a finding that reports on the coagulation-support arm rather
    than the adhesion arm.
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on a prolonged skin bleeding time, the presence of a small number of very large platelets (macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent expression of the GPIb-V-IX complex."
    explanation: >-
      Sets out the classic diagnostic criteria.
- name: Genetic Testing, Essential in Monoallelic Disease
  description: >-
    In biallelic disease the laboratory phenotype is unambiguous. In monoallelic
    disease it is not: platelets are large rather than giant, the ristocetin
    response may be decreased or normal, and complex expression may be only
    partially reduced or normal, so genetic testing is what makes the diagnosis
    and separates it from immune thrombocytopenic purpura.
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In biallelic BSS, giant platelets in the peripheral blood smear, absence of ristocetin-induced platelet aggregation (RIPA) using light transmission aggregometry (LTA), and complete loss of GPIbIX complex in flow cytometry are observed, whereas in monoallelic forms, genetic diagnosis is recommended due to the presence of large platelets in the peripheral blood smear, decreased or normal RIPA response in LTA, and partial loss or normal GPIbIX complex in flow cytometry."
    explanation: >-
      Establishes why genetic testing is required for the monoallelic form.
treatments:
- name: Antifibrinolytic Therapy
  description: >-
    Tranexamic acid, oral, topical as a mouthwash, or intravenous, is first-line
    for mucocutaneous bleeding and menorrhagia and is used peripartum alongside
    platelet transfusion. It is contraindicated in upper urinary tract bleeding
    because of the risk of clot obstruction, and generally avoided in pulmonary
    hemorrhage.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tranexamic acid
      term:
        id: CHEBI:48669
        label: tranexamic acid
  target_mechanisms:
  - target: Failure of Primary Hemostatic Plug Formation
    treatment_effect: MODULATES
    description: >-
      Antifibrinolytics do not restore platelet adhesion. They stabilize the clot
      that does form by blocking its breakdown, which is why they help
      mucocutaneous bleeding without touching the receptor defect. MODULATES
      rather than RESTORES for exactly that reason.
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Antifibrinolytics and oral contraceptives are utilized as supplementary treatments."
    explanation: >-
      Establishes antifibrinolytics as supplementary therapy in the current
      definitive review.
  - reference: PMID:36889343
    reference_title: "Bernard-Soulier Syndrome from the Perspective of the Obstetrician: A Case Report with a Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Single donor platelet transfusions and oral tranexamic acid were administered as prophylaxis at the peripartum period."
    explanation: >-
      Documents peripartum use of tranexamic acid alongside platelet transfusion.
- name: Platelet Transfusion
  description: >-
    The mainstay of treatment for significant bleeding and for procedural
    prophylaxis, preferably HLA-matched, leukoreduced, single-donor apheresis
    product. Its central hazard is what makes the whole treatment algorithm
    escalate: repeated exposure drives HLA and anti-GPIb alloimmunization,
    producing refractoriness, and in mothers transplacental antibody can cause
    fetal or neonatal alloimmune thrombocytopenia.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: platelet transfusion
    term:
      id: NCIT:C15366
      label: Platelet Transfusion
  target_mechanisms:
  - target: Failure of Primary Hemostatic Plug Formation
    treatment_effect: RESTORES
    description: >-
      Transfused donor platelets carry a functional GPIb-IX-V complex and can
      execute the capture and plug-formation steps the patient's own platelets
      cannot.
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Platelet transfusion is the main therapy but recombinant factor VIIa is advised in alloimmunized patients, and allogeneic stem cell transplantation is suggested in refractory cases."
    explanation: >-
      Establishes platelet transfusion as the main therapy and sets out the
      escalation path when alloimmunization occurs.
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment of bleeding or prophylaxis during surgical procedures usually requires platelet transfusion."
    explanation: >-
      Confirms platelet transfusion as the standard for both treatment and
      procedural prophylaxis.
- name: Recombinant Activated Factor VIIa
  description: >-
    Licensed for Glanzmann thrombasthenia rather than for this disease, so its use
    here is off-label but guideline-endorsed, and it is specifically advised where
    alloimmunization has made platelet transfusion ineffective. It works by
    bypassing the GPIb-dependent adhesion step entirely and driving thrombin
    generation on the platelet surface. Recent case-report evidence suggests a
    prophylactic weekly schedule can reduce bleeding frequency, but that is two
    patients, and access is a real constraint: none of the patients in a
    76-participant Indian natural-history cohort were receiving it.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Failure of Primary Hemostatic Plug Formation
    treatment_effect: BYPASSES
    description: >-
      Drives thrombin generation on the platelet surface without requiring the
      GPIb-dependent capture step, which is why it works in a receptor-deficient
      platelet.
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Platelet transfusion is the main therapy but recombinant factor VIIa is advised in alloimmunized patients, and allogeneic stem cell transplantation is suggested in refractory cases."
    explanation: >-
      Establishes the indication for recombinant factor VIIa in alloimmunized
      patients.
  - reference: PMID:41259294
    reference_title: "Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Following initiation of prophylaxis, both patients experienced a marked reduction in the frequency and severity of bleeding episodes."
    explanation: >-
      Supports a prophylactic schedule. PARTIAL because this is a case report of
      two siblings, with the authors themselves calling for studies to establish
      standardized protocols.
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Platelet transfusion was the main mode of treatment; none of the patients in the present series were on activated recombinant factor VII (rFVIIa) therapy."
    explanation: >-
      Documents the real-world access gap for this therapy outside well-resourced
      settings.
- name: Hormonal Control of Menorrhagia
  description: >-
    Combined oral contraceptives, levonorgestrel-releasing intrauterine systems,
    progestins, and gonadotropin-releasing hormone agonists. Given that menorrhagia
    is close to universal in reproductive-age women with this disease and is the
    dominant route to iron deficiency, this is arguably the highest-yield routine
    intervention available.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levonorgestrel
      term:
        id: CHEBI:6443
        label: levonorgestrel
  target_mechanisms:
  - target: Menorrhagia
    treatment_effect: MODULATES
    description: >-
      Hormonal suppression reduces endometrial bleeding volume. It acts on the
      bleeding substrate rather than on the platelet, which is why it is effective
      for the single highest-burden manifestation while leaving the receptor
      defect untouched.
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Antifibrinolytics and oral contraceptives are utilized as supplementary treatments."
    explanation: >-
      Names oral contraceptives among the supplementary treatments.
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  description: >-
    Curative in principle, because the defect is intrinsic to the
    megakaryocyte lineage, and the only curative option currently available in
    the clinic; lentiviral gene therapy addresses the same origin but remains
    preclinical. Suggested for refractory disease. Reserved for
    severe transfusion-dependent or alloimmunized patients given the
    transplant-related morbidity and mortality.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Biallelic Loss of Function in GP1BA, GP1BB, or GP9
    treatment_effect: BYPASSES
    description: >-
      Replaces the patient's megakaryocyte lineage with donor cells carrying
      functional alleles, addressing both branches of the disease at once.
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Platelet transfusion is the main therapy but recombinant factor VIIa is advised in alloimmunized patients, and allogeneic stem cell transplantation is suggested in refractory cases."
    explanation: >-
      Places allogeneic transplantation at the top of the escalation ladder for
      refractory disease.
- name: Eltrombopag
  description: >-
    A thrombopoietin-receptor agonist trialed in a mixed cohort of inherited
    thrombocytopenias that included monoallelic Bernard-Soulier syndrome. Response
    rates were substantial, but two caveats govern how far this generalizes. The
    trial included only monoallelic disease and only as part of a mixed cohort, so
    it is not evidence for biallelic disease. And mechanistically, raising the
    count of platelets that still cannot bind von Willebrand factor addresses only
    the thrombopoietic branch, leaving the adhesion defect untouched.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: eltrombopag
      term:
        id: CHEBI:85010
        label: eltrombopag
  target_mechanisms:
  - target: Release of Fewer, Abnormally Large Platelets
    treatment_effect: MODULATES
    description: >-
      Thrombopoietin-receptor agonism raises platelet count. It does not act on the
      adhesion branch, so it addresses half the disease at most.
  evidence:
  - reference: PMID:31273088
    reference_title: "Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 23 patients evaluable for response, 11 (47.8%) achieved a major response (platelet count >100 ×109/L), ten (43.5%) had a minor response (platelet count at least twice the baseline value), and two patients (8.7%) did not respond."
    explanation: >-
      Reports the response rates. PARTIAL because the cohort was mixed and included
      only monoallelic Bernard-Soulier syndrome, so the result does not transfer to
      biallelic disease.
  - reference: PMID:31273088
    reference_title: "Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia."
    explanation: >-
      Documents the mixed cohort and the restriction to monoallelic disease, which
      is the basis for the PARTIAL grading above.
- name: Lentiviral Gene Therapy (Investigational)
  description: >-
    The most active research front, and the reason the transplantation entry
    above should not be read as the only conceivable cure. Lentiviral delivery of
    the missing subunit under a platelet-specific promoter has corrected the
    phenotype across all three genes: in GPIbalpha-null mice it corrected the tail
    bleeding time and improved the macrothrombocytopenia with sustained expression
    through serial transplant; in GPIbbeta-null mice it restored GPIb-IX in 97% of
    circulating platelets with normal bleeding times; and for type C it has
    reached patient material, correcting GPIX expression and platelet size in
    hematopoietic stem cells from two unrelated patients. No clinical trial of
    gene therapy in this disease has been conducted, so this is preclinical
    throughout and is curated as investigational.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Failure of GPIb-IX-V Complex Assembly and Surface Expression
    treatment_effect: RESTORES
    description: >-
      Delivering a functional copy of the missing subunit to hematopoietic stem
      cells restores assembly and surface expression of the complex on the
      platelets those cells go on to produce, which addresses both branches of the
      disease at their shared origin.
  evidence:
  - reference: PMID:22044935
    reference_title: Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Therapeutic levels of hGPIbα expression were achieved that corrected the tail bleeding time and improved the macrothrombocytopenia."
    explanation: >-
      Demonstrates correction of both the hemostatic and the thrombopoietic arm in
      the GPIbalpha-null mouse.
  - reference: PMID:27148783
    reference_title: Lentiviral gene rescue of a Bernard-Soulier mouse model to study platelet glycoprotein Ibβ function.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "hGPIbβ transplanted into the bone marrow of GPIbβ(null) mice rescued GPIb-IX expression in 97% of circulating platelets."
    explanation: >-
      Quantifies the reconstitution achievable by the same strategy applied to the
      GPIbbeta route.
  - reference: PMID:37416759
    reference_title: Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Finally, hematopoietic stem cells from two unrelated BSS type C patients were transduced with the gene therapy vectors and differentiated to produce GPIX-expressing megakaryocytes and platelets with a reduced size."
    explanation: >-
      The most advanced human evidence in this disease, correcting expression and
      platelet size in cells from two patients. PARTIAL because it is ex vivo
      correction of patient-derived cells rather than treatment of patients.
animal_models:
- name: GPIbalpha-null mouse
  species: Mouse
  genotype: GP Ibalpha knockout
  description: >-
    The mouse that resolved a 50-year-old question. Disrupting the gene encoding
    the alpha subunit reproduces the hallmark features of the human disease, and
    critically established that the giant-platelet and thrombocytopenia phenotype
    is a direct consequence of the missing receptor rather than an incidental
    association. Transgenic expression of human GPIbalpha rescues the phenotype,
    closing the causal loop.
  publication: PMID:10706630
  modeled_mechanisms:
  - target: Release of Fewer, Abnormally Large Platelets
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      The knockout reproduces mild thrombocytopenia with giant platelets and a
      bleeding phenotype, and rescue by transgenic human GPIbalpha demonstrates the
      dependency directly.
    limitations: >-
      Mouse platelets differ from human in size and count baselines, and the model
      addresses the GP1BA route only, so it says nothing about how GP1BB or GP9
      variants produce the same phenotype. Murine bleeding assays (tail bleeding
      time) correspond only loosely to human mucocutaneous bleeding.
    evidence:
    - reference: PMID:10706630
      reference_title: "Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We have disrupted the gene encoding the alpha-subunit of mouse GP Ib-IX-V (GP Ibalpha) and describe a murine model recapitulating the hallmark characteristics of the human Bernard-Soulier syndrome."
      explanation: >-
        States that the model recapitulates the hallmark features of the human
        disease.
- name: Cocker Spaniel GP9 large-deletion natural model
  species: Dog
  genotype: Homozygous 2460 bp deletion in the single coding exon of canine GP9
  description: >-
    The only naturally occurring animal model of this disease, and worth listing
    alongside two engineered knockouts precisely because nobody built it. Four
    Cocker Spaniels with a mild to severe bleeding disorder showed
    macrothrombocytopenia and absent functional GPIb-IX-V, and whole genome
    sequencing identified a 2460 bp deletion removing most of the single coding
    exon of canine GP9, with recessive inheritance confirmed by genotyping and
    the homozygous genotype absent from 98 control Cocker Spaniels. It is the
    canine counterpart of human BSS type C.
  publication: PMID:31484196
  modeled_mechanisms:
  - target: Failure of GPIb-IX-V Complex Assembly and Surface Expression
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      A spontaneous GP9 null produces absent functional GPIb-IX-V with
      macrothrombocytopenia and a bleeding phenotype, arrived at naturally rather
      than by engineering.
    limitations: >-
      Four dogs from one breed, so the phenotypic range is not established, and
      canine platelet biology differs from human in baseline count and size.
      Characterization is at the level of platelet count, morphology, and
      immunocytochemistry; the proplatelet-formation and adhesion assays that
      anchor the two-branch model in the mouse have not been run here.
    readouts:
    - name: Functional GPIb-IX-V on canine platelets by immunocytochemistry
      target: Failure of GPIb-IX-V Complex Assembly and Surface Expression
      direction: ABOLISHED
      interpretation: >-
        Absent functional complex is the direct correlate of the GP9 null, and the
        same readout that defines the human disease.
      evidence:
      - reference: PMID:31484196
        reference_title: A large deletion in the GP9 gene in Cocker Spaniel dogs with Bernard-Soulier syndrome.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Furthermore, the lack of functional GPIb-IX-V was demonstrated by immunocytochemistry."
        explanation: >-
          Reports the measured absence of functional complex in the affected dogs.
    evidence:
    - reference: PMID:31484196
      reference_title: A large deletion in the GP9 gene in Cocker Spaniel dogs with Bernard-Soulier syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The affected dogs showed a platelet adhesion defect characterized by macrothrombocytopenia with variable platelet counts resembling human Bernard-Soulier syndrome (BSS)."
      explanation: >-
        Establishes the phenotypic correspondence to the human disease.
    - reference: PMID:31484196
      reference_title: A large deletion in the GP9 gene in Cocker Spaniel dogs with Bernard-Soulier syndrome.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These findings provide the first large animal GP9 model for this group of inherited platelet disorders and greatly facilitate the diagnosis and identification of affected and/or normal carriers in Cocker Spaniels."
      explanation: >-
        The authors' own framing of the model's value as the first large-animal
        GP9 model.
- name: GPIbbeta-null mouse
  species: Mouse
  genotype: GPIbbeta knockout
  description: >-
    The model that localized the thrombopoietic defect. Megakaryocyte progenitor
    number, differentiation, maturation class, and endoreplication are all normal;
    the failure is specifically at the proplatelet-formation stage, with a poorly
    developed demarcation membrane system and a doubled marginal microtubule ring.
  publication: PMID:19377075
  modeled_mechanisms:
  - target: Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Proplatelet extension is reduced by 41% in cultured knockout megakaryocytes
      with normal upstream differentiation, localizing the lesion precisely to
      proplatelet formation.
    limitations: >-
      The proportional reduction in proplatelet formation is measured in cultured
      fetal-liver-derived megakaryocytes rather than in vivo, and the mouse
      addresses the GP1BB route only. Human patient megakaryocyte culture is needed
      to confirm translation, and does.
    readouts:
    - name: Proportion of megakaryocytes extending proplatelets
      target: Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton
      direction: DECREASED
      interpretation: >-
        A 41% reduction in proplatelet-forming capacity with normal upstream
        differentiation is the quantitative core of the thrombopoietic branch.
      evidence:
      - reference: PMID:19377075
        reference_title: "Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "GPIbbeta(-/-) megakaryocytes could be differentiated in culture from Lin(-) fetal liver cells in normal amounts but the proportion of cells able to extend proplatelets was decreased by 41%."
        explanation: >-
          Quantifies the proplatelet formation deficit against normal
          differentiation.
    evidence:
    - reference: PMID:19377075
      reference_title: "Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Altogether, these findings point to a role of the GPIb-V-IX complex intrinsic to megakaryocytes at the stage of proplatelet formation and suggest a functional link with the underlying microtubular cytoskeleton in platelet biogenesis."
      explanation: >-
        The authors' own conclusion locating the defect at proplatelet formation
        and linking it to the microtubular cytoskeleton.
experimental_models:
- name: Patient-derived megakaryocyte culture (Bolzano heterozygotes)
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    Megakaryocytes differentiated from cord blood and peripheral blood of patients
    heterozygous for the Bolzano variant. This is what makes the thrombopoietic
    branch a human finding rather than a mouse one: differentiation is normal,
    but proplatelet formation is halved, proplatelet tips are enlarged in
    proportion to the enlarged circulating platelets, and alpha-tubulin
    distribution is severely deranged.
  publication: PMID:19067792
  modeled_mechanisms:
  - target: Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the proplatelet-formation defect and the microtubule derangement
      in human patient cells, converging with the mouse knockouts.
    limitations: >-
      The patients studied were monoallelic Bolzano heterozygotes with mild
      disease, so the magnitude of the defect in biallelic disease is not directly
      measured here. Cultured megakaryocytes may not reproduce the marrow
      microenvironment that governs proplatelet release in vivo.
    readouts:
    - name: Proplatelet formation by cultured patient megakaryocytes
      target: Uncoupling of the Membrane Skeleton from the Megakaryocyte Cytoskeleton
      direction: DECREASED
      interpretation: >-
        A 50% reduction in proplatelet formation in human patient megakaryocytes
        against normal differentiation is the human counterpart of the mouse
        result.
      evidence:
      - reference: PMID:19067792
        reference_title: "Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Megakaryocyte differentiation from both cord blood (one patient) and peripheral blood (five patients) was comparable to controls. However, proplatelet formation was reduced by about 50% with respect to controls."
        explanation: >-
          Quantifies the human proplatelet formation deficit against normal
          differentiation.
    evidence:
    - reference: PMID:19067792
      reference_title: "Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "These results suggest that a defect of platelet formation contributes to macrothrombocytopenia associated to the Bolzano mutation, and indicate a key role for GPIb alpha in proplatelet formation."
      explanation: >-
        States the authors' conclusion that a platelet-formation defect contributes
        to the macrothrombocytopenia in humans.
discussions:
- discussion_id: bss_no_genotype_phenotype_correlation
  kind: KNOWLEDGE_GAP
  prompt: >-
    What determines bleeding severity in Bernard-Soulier syndrome, given that it
    does not track genotype, platelet count, or receptor expression level?
  attaches_to:
  - pathophysiology#Failure of Primary Hemostatic Plug Formation
  rationale: >-
    In the largest systematically evaluated single-center series, bleeding
    severity varied widely between individuals while thrombocytopenia was
    uniformly moderate and GPIbalpha expression uniformly under 10% of control.
    The authors were explicit that they could define no correlations. That
    combination, a variable output with the measured inputs pinned, is the shape
    you would expect if unidentified modifiers were doing the work. No modifier
    allele has been established. This is a genuine gap in the literature rather
    than a gap in searching, and it has direct clinical consequence because there
    is currently no way to predict which patient will bleed badly.
  evidence:
  - reference: PMID:21173099
    reference_title: "Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regardless of mutations identified, the patients' bleeding diathesis did not correlate with thrombocytopenia, which was always moderate, and platelet GPIbalpha expression, which was always severely impaired."
    explanation: >-
      Establishes the absence of correlation with the two obvious candidate
      predictors.
  - reference: PMID:21173099
    reference_title: "Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aware of the limitations of our cohort, we cannot define any correlations."
    explanation: >-
      The authors' own statement of the negative result, with its cohort-size
      caveat.
- discussion_id: bss_gp5_never_implicated
  kind: OPEN_QUESTION
  prompt: >-
    Why has no Bernard-Soulier-causing variant ever been found in GP5, the fourth
    subunit of the complex?
  attaches_to:
  - pathophysiology#Biallelic Loss of Function in GP1BA, GP1BB, or GP9
  rationale: >-
    GP5 encodes GPV, the fourth subunit, and it maps to a known locus like the
    other three, yet across 211 genotyped families and two decades of review no
    disease-causing GP5 variant has been reported. The straightforward reading is
    that GPV is dispensable for complex assembly and surface expression, so losing
    it does not produce the phenotype. This is a real curatable negative rather
    than an artifact of ascertainment, and it constrains any model of how the
    complex assembles.
  evidence:
  - reference: PMID:17109744
    reference_title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genes coding for the four subunits of the receptor, GPIBA, GPIBB, GP5 and GP9, map to chromosomes 17p12, 22q11.2, 3q29, and 3q21, respectively. Defects have been identified in GPIBA, GPIBB, and GP9 but not in GP5."
    explanation: >-
      States the negative finding alongside the three positive genes.
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, no BSS mutations in the GP5 gene have been reported."
    explanation: >-
      Confirms the negative finding still stands in the current definitive review,
      nearly twenty years later.
- discussion_id: bss_gene_therapy_no_clinical_trial
  kind: KNOWLEDGE_GAP
  prompt: >-
    Lentiviral gene therapy corrects the phenotype across all three causal genes
    and now works in patient-derived cells, so why has no clinical trial been
    conducted?
  attaches_to:
  - pathophysiology#Failure of GPIb-IX-V Complex Assembly and Surface Expression
  rationale: >-
    The preclinical package is unusually complete for a disease this rare:
    correction in GPIbalpha-null and GPIbbeta-null mice with sustained expression
    through serial transplant, and ex vivo correction of hematopoietic stem cells
    from two unrelated type C patients. What is missing is any clinical trial. The
    plausible obstacles are the conditioning regimen required for stem cell gene
    therapy against a disease whose prognosis is generally good with supportive
    care, the very small and geographically scattered patient population, and the
    absence of an agreed clinical endpoint given that bleeding score correlates
    only weakly with lived burden. None of these has been formally addressed in
    the literature, so the gap between a solved preclinical problem and an untried
    clinical one is recorded here rather than explained.
  evidence:
  - reference: PMID:37416759
    reference_title: Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These results demonstrate the potential of lentiviral-based gene therapy to rescue BSS type C."
    explanation: >-
      States the preclinical conclusion, which is as far as the evidence currently
      goes.
- discussion_id: bss_qol_decoupled_from_bleeding_score
  kind: OPEN_QUESTION
  prompt: >-
    Why is quality of life only weakly related to bleeding-assessment score in
    inherited platelet function disorders, and what should be measured instead?
  attaches_to:
  - phenotypes#Iron Deficiency Anemia
  rationale: >-
    A recent multi-instrument study using EQ-5D, SF-36, and FACIT alongside annual
    bleed rate and the ISTH bleeding assessment tool found the relationship
    between quality-of-life scores and bleeding score was weak. If event count does
    not predict lived burden, then trials and clinical follow-up anchored on bleed
    rate are measuring the wrong thing. The plausible drivers are chronic anemia
    and fatigue, treatment access, and disruption to schooling and work, none of
    which a bleeding score captures, but this has not been formally decomposed.
  evidence:
  - reference: PMID:41100648
    reference_title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The relationship between quality of life (QoL) scores and ISTH-BAT score was weak."
    explanation: >-
      The finding that motivates the question.
differential_diagnoses:
- name: Immune Thrombocytopenic Purpura
  description: >-
    The most consequential misdiagnosis, and the one monoallelic disease routinely
    receives. The two are managed completely differently, so getting it wrong
    means immunosuppression and sometimes splenectomy for a structural receptor
    defect that will not respond. Chronic persistent thrombocytopenia, a positive
    family history, unresponsive immune thrombocytopenic purpura treatment,
    macrothrombocytopenia, and an absent ristocetin response should all prompt
    reconsideration.
  distinguishing_features:
  - Lifelong and familial rather than acquired
  - Large or giant platelets rather than normal-sized
  - Absent or reduced ristocetin-induced aggregation
  - Failure to respond to immune thrombocytopenic purpura therapy
  evidence:
  - reference: PMID:39191409
    reference_title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, BSS should be kept in mind in the presence of individuals with chronic persistent thrombocytopenia, positive family history, unresponsive ITP treatment, macrothrombocytopenia, and absence of RIPA response."
    explanation: >-
      Sets out the specific features that should prompt reconsideration of an
      immune thrombocytopenic purpura diagnosis.
- name: von Willebrand Disease
  description: >-
    The other disease of the von Willebrand factor to GPIbalpha axis, approached
    from the opposite side. In von Willebrand disease the plasma ligand is
    deficient or defective; here the platelet receptor is. The discriminating test
    is whether adding normal plasma corrects the ristocetin response: it does in
    von Willebrand disease and it cannot here, because the receptor is simply not
    there.
  distinguishing_features:
  - Ristocetin response corrected by normal plasma in von Willebrand disease, not
    in Bernard-Soulier syndrome
  - Platelet count and size normal in most von Willebrand disease
  - Plasma von Willebrand factor antigen and activity abnormal in von Willebrand
    disease
  evidence:
  - reference: PMID:24934643
    reference_title: Spectrum of the mutations in Bernard-Soulier syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As a consequence, platelets are unable to adhere to the vascular subendothelium and agglutinate in response to ristocetin."
    explanation: >-
      The platelet-intrinsic basis of the ristocetin failure, which is what makes
      it uncorrectable by normal plasma.
- name: Acquired (Autoantibody-Mediated) Bernard-Soulier Phenotype
  description: >-
    Anti-GPIb/IX autoantibodies can produce a phenocopy in a person with normal
    genes. It presents later, without a family history, and it is a different
    disease requiring immunomodulation rather than supportive hemostatic care. A
    recent Moroccan series of seven patients included one such case, which is a
    useful reminder that the laboratory phenotype alone does not establish the
    genetic diagnosis.
  distinguishing_features:
  - Acquired later-life onset without family history
  - Anti-GPIb/IX autoantibodies detectable
  - No pathogenic GP1BA, GP1BB, or GP9 variant
  evidence:
  - reference: PMID:40703326
    reference_title: "Bernard-Soulier Syndrome: Case Studies From Morocco."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the diagnosis of constitutional BSS was established in six patients, while only one case was idiopathic acquired BSS."
    explanation: >-
      Documents an acquired case alongside constitutional cases in the same series.
clinical_trials:
- name: NCT02422394
  phase: PHASE_II
  status: COMPLETED
  description: >-
    The eltrombopag phase 2 in inherited thrombocytopenias, published as
    PMID:31273088. Relevant here only in part: the cohort was mixed across several
    inherited thrombocytopenias and included monoallelic Bernard-Soulier syndrome
    only, so it is not evidence for the biallelic disease, and raising the count of
    platelets that still cannot bind von Willebrand factor addresses one branch at
    most.
  target_phenotypes:
  - preferred_term: Macrothrombocytopenia
    term:
      id: HP:0040185
      label: Macrothrombocytopenia
  evidence:
  - reference: clinicaltrials:NCT02422394
    reference_title: Eltrombopag for Inherited Thrombocytopenias
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eltrombopag is a drug, available in tablets, which stimulates the production of platelets by the bone marrow."
    explanation: >-
      Registry record establishing the agent and its mechanism, which acts on
      platelet production rather than on platelet adhesion.
  - reference: PMID:31273088
    reference_title: "Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia."
    explanation: >-
      Documents the mixed cohort and the restriction to monoallelic disease, which
      is why the result does not transfer to biallelic Bernard-Soulier syndrome.

notes: >-
  The two-branch model is the organizing idea of this entry and it is
  experimentally earned rather than merely tidy. A chimeric receptor swapping the
  GPIbalpha ectodomain for an unrelated one doubles platelet count and halves
  platelet size while leaving the bleeding phenotype severe. Cytoplasmic tail
  drives size and count; ectodomain drives hemostasis. Two jobs, two domains,
  cleanly dissociable, which is why the pathograph branches at the
  surface-expression node rather than running as a single chain.

  A third contributor is recorded as an EMERGING mechanistic_hypotheses entry
  rather than as a node: shear-induced unfolding of the GPIbalpha mechanosensory
  domain triggers platelet clearance, so a destabilizing missense variant could in
  principle shorten platelet survival independently of production. The direct link
  from BSS-causing variants to accelerated clearance in patients has not been
  demonstrated, so it stays a hypothesis.

  GPIbbeta cytoplasmic-tail deletion in mouse produced enhanced arterial
  thrombosis, a repressor role that studies in heterologous cells had not
  predicted. It is not modeled here because it describes a gain of thrombotic
  function from a specific engineered deletion rather than anything observed in
  patients, but it is the kind of cell-line-versus-in-vivo discordance worth
  keeping in view when reasoning about this receptor.

  Prevalence is recorded as CASES_IN_LITERATURE rather than as a population rate.
  The available figures are a count of about 100 reported cases and 211 genotyped
  families; no validated population prevalence estimate was found, and converting
  a case count into a rate would be invention.

  Recombinant factor VIIa carries no therapeutic_agent binding. The available NCIT
  term for coagulation factor VIIa is not a reliable member of the therapeutic
  agent enum in this repository, and rather than force a binding that would fail
  validation the agent identity is carried in the treatment name and description.

  Deep research. Curated from a claude_code deep-research report
  (research/Bernard-Soulier_Syndrome-deep-research-claude_code.md), whose own
  reference validation reported 34/34 references verified with a confabulation
  rate of 0.0. Every snippet used here was independently re-verified against the
  cached PubMed record.
datasets:
references:
- reference: PMID:17109744
  title: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).
- reference: PMID:39191409
  title: "Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management."
- reference: PMID:24934643
  title: Spectrum of the mutations in Bernard-Soulier syndrome.
- reference: PMID:21173099
  title: "Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations."
- reference: PMID:21933849
  title: "Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation)."
- reference: PMID:10706630
  title: "Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome."
- reference: PMID:19377075
  title: "Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome."
- reference: PMID:19067792
  title: "Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano."
- reference: PMID:12200373
  title: "Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome."
- reference: PMID:23336709
  title: "The organizing principle of the platelet glycoprotein Ib-IX-V complex."
- reference: PMID:27670775
  title: Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor.
- reference: PMID:31273088
  title: "Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial."
- reference: PMID:36889343
  title: "Bernard-Soulier Syndrome from the Perspective of the Obstetrician: A Case Report with a Review of the Literature."
- reference: PMID:41100648
  title: "Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India."
- reference: PMID:41259294
  title: "Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome."
- reference: PMID:40703326
  title: "Bernard-Soulier Syndrome: Case Studies From Morocco."
- reference: PMID:38625506
  title: "Bernard-Soulier syndrome caused by a novel GP1BB variant and 22q11.2 deletion."

📚

References & Deep Research

References

17

PMID:17109744

Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy).

No top-level findings curated for this source.

PMID:39191409

Bernard-Soulier Syndrome: A Review of Epidemiology, Molecular Pathology, Clinical Features, Laboratory Diagnosis, and Therapeutic Management.

No top-level findings curated for this source.

PMID:24934643

Spectrum of the mutations in Bernard-Soulier syndrome.

No top-level findings curated for this source.

PMID:21173099

Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations.

No top-level findings curated for this source.

PMID:21933849

Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation).

No top-level findings curated for this source.

PMID:10706630

Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome.

No top-level findings curated for this source.

PMID:19377075

Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome.

No top-level findings curated for this source.

PMID:19067792

Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano.

No top-level findings curated for this source.

PMID:12200373

Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome.

No top-level findings curated for this source.

PMID:23336709

The organizing principle of the platelet glycoprotein Ib-IX-V complex.

No top-level findings curated for this source.

PMID:27670775

Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor.

No top-level findings curated for this source.

PMID:31273088

Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.

No top-level findings curated for this source.

PMID:36889343

Bernard-Soulier Syndrome from the Perspective of the Obstetrician: A Case Report with a Review of the Literature.

No top-level findings curated for this source.

PMID:41100648

Natural history & quality of life in Glanzmann thrombasthenia & Bernard Soulier syndrome: An observational study from India.

No top-level findings curated for this source.

PMID:41259294

Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome.

No top-level findings curated for this source.

PMID:40703326

Bernard-Soulier Syndrome: Case Studies From Morocco.

No top-level findings curated for this source.

PMID:38625506

Bernard-Soulier syndrome caused by a novel GP1BB variant and 22q11.2 deletion.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Bernard-Soulier Syndrome — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-opus-5[1m] 34 citations 2026-08-15T09:14:22.687379

Bernard-Soulier Syndrome — Comprehensive Research Report

Prepared 2026-08-15 for dismech KB curation. Everything with a PMID below was pulled from the live PubMed MEDLINE record during this session; quoted strings marked [verbatim] were transcribed straight out of the abstract text and are safe to use as evidence snippets. Ontology IDs marked [OLS-checked] were resolved against EBI OLS4 in this session; the rest are high-confidence-from-memory and must be run through just validate-terms before they go in a YAML file.

sup. so Bernard-Soulier is one of those disorders where the whole story hangs off a single receptor that turned out to be doing two completely unrelated jobs at once — a docking cleat and a piece of structural scaffolding. Break it and you get both a platelet that can't stick to anything and a platelet that got built wrong in the first place. Two failures, one gene. That double duty is the thing to keep in your head through this entire report.

1. Disease Information

Overview

Bernard-Soulier syndrome (BSS) is an inherited bleeding disorder of the megakaryocyte/platelet lineage caused by absence, deficiency, or dysfunction of the platelet GPIb-IX-V complex — the receptor that grabs von Willebrand factor (VWF). The clinical triad is (1) bleeding tendency out of proportion to the platelet count, (2) abnormally large platelets, and (3) thrombocytopenia.

[verbatim, PMID:17109744] "Bernard-Soulier syndrome (BSS), also known as Hemorrhagiparous thrombocytic dystrophy, is a hereditary bleeding disorder affecting the megakaryocyte/platelet lineage and characterized by bleeding tendency, giant blood platelets and low platelet counts." — Lanza F. Orphanet J Rare Dis. 2006 Nov 16;1:46. doi:10.1186/1750-1172-1-46

[verbatim, PMID:39191409] "Bernard-Soulier syndrome (BSS) is an inherited platelet function disorder caused by mutations in the genes that encode the glycoprotein (GP) Ibalpha and GPIbbeta subunits, as well as the GPIX subunit in the GPIbIX complex, which is located on the platelet surface and has roles in platelet adhesion and activation." — Kaya Z. Semin Thromb Hemost. 2025 Mar;51(2):209-218. doi:10.1055/s-0044-1789184 ← the current definitive review; use this one heavily

Key identifiers

Resource	ID	Status
MONDO	MONDO:0009276 — Bernard-Soulier syndrome	[OLS-checked]
MONDO (subtypes)	MONDO:1060238 GP1BA-related; MONDO:1060239 GP1BB-related; MONDO:1060237 GP9-related	[OLS-checked]
MONDO (dominant form)	MONDO:0007930 — Bernard-Soulier syndrome, type A2, autosomal dominant	[OLS-checked]
MONDO (veterinary)	MONDO:1010672 — Bernard-Soulier syndrome, GP9-related, dog	[OLS-checked]
MeSH	D001606 — Bernard-Soulier Syndrome	[verified via NLM `id.nlm.nih.gov/mesh` lookup]
Orphanet	ORPHA:274	high confidence; orpha.net was behind a bot-check this session — verify, and prefer citing the cached `ORPHA:274` structured record via `just structured-rebuild-orphanet`
OMIM	#231200 (BSS); #153670 (BSS type A2, AD); genes 606672 GP1BA, 138720 GP1BB, 173515 GP9, 173511 GP5	omim.org returned HTTP 403 — all OMIM numbers unverified this pass, check before curating
ICD-10	D69.1 Qualitative platelet defects	high confidence
ICD-11	not verified — the WHO browser is a JS app that WebFetch can't read. Use the ICD-11 Coding Tool.

Genes (HGNC) — [OLS-checked, all four]

Gene	HGNC	Protein	Locus
GP1BA	`hgnc:4439`	GPIbα	17p13.2 (Lanza 2006 says 17p12 — older mapping, use 17p13.2)
GP1BB	`hgnc:4440`	GPIbβ	22q11.21
GP9	`hgnc:4444`	GPIX	3q21.3
GP5	`hgnc:4443`	GPV	3q29 — never implicated in BSS

[verbatim, PMID:17109744] "Genes coding for the four subunits of the receptor, GPIBA, GPIBB, GP5 and GP9, map to chromosomes 17p12, 22q11.2, 3q29, and 3q21, respectively. Defects have been identified in GPIBA, GPIBB, and GP9 but not in GP5."

Synonyms / alternative names

Hemorrhagiparous thrombocytic dystrophy (the original, gorgeously archaic name)
Congenital hemorrhagiparous thrombocytic dystrophy
Giant platelet syndrome
BSS
Macrothrombocytopenia, Bernard-Soulier type
Gene-based subtype nomenclature (use this, it's the modern convention):

[verbatim, PMID:37416759] "According to the affected gene, we distinguish BSS type A1 (GP1BA), type B (GP1BB), or type C (GP9)." — Sánchez-Guiu et al. (Toledo/CIEMAT group). Mol Ther Nucleic Acids. 2023 Sep 12;33:75-92. doi:10.1016/j.omtn.2023.06.020

Type A2 is reserved for the autosomal dominant monoallelic GP1BA form.

Data provenance

Everything here is aggregated disease-level knowledge — case reports, single-center case series, and one international consortium — not EHR-derived. There is no population-scale BSS cohort. The single largest genotyped collection is:

[verbatim, PMID:24934643] "In order to collect information on BSS patients, we established an International Consortium for the study of BSS, allowing us to enrol and genotype 132 families (56 previously unreported). With 79 additional families for which molecular data were gleaned from the literature, the 211 families characterized so far have mutations in the GP1BA (28%), GP1BB (28%), or GP9 (44%) genes." — Savoia A et al. "Spectrum of the mutations in Bernard-Soulier syndrome." Hum Mutat. 2014 Sep;35(9):1033-45. doi:10.1002/humu.22607

2. Etiology

Primary cause: genetic, monogenic, no environmental trigger required

BSS is purely genetic. There is no toxin, no pathogen, no lifestyle exposure that causes it. What environment does do is decide how loudly the bleeding phenotype talks.

Two inheritance modes, two diseases in practice:

[verbatim, PMID:39191409] "Patients with autosomal recessively inherited biallelic BSS have a homozygous or compound heterozygous expression in the GPIbalpha, GPIbbeta, and GPIX subunits of the GPIbIX complex. Patients with autosomal dominantly inherited monoallelic BSS have a heterozygous expression in only the GPIbalpha and GPIbbeta subunits of the GPIbIX complex. To date, no BSS mutations in the GP5 gene have been reported."

That last sentence is worth a dedicated evidence item — the GP5-negative finding is a real, curatable negative claim, and it's corroborated mechanistically in mouse (see §15).

Molecular consequence classes:

[verbatim, PMID:24934643] "Most of the mutations identified in the genes encoding for the GP1BA (GPIbalpha), GP1BB (GPIbbeta), and GP9 (GPIX) subunits prevent expression of the complex at the platelet membrane or more rarely its interaction with VWF. As a consequence, platelets are unable to adhere to the vascular subendothelium and agglutinate in response to ristocetin."

So: mostly assembly/trafficking failure (the complex never reaches the surface), occasionally ligand-binding failure (the complex is there but deaf to VWF). That's a genuine two-branch mechanism worth modeling as separate pathophysiology nodes.

Genetic risk factors

Biallelic pathogenic variants in GP1BA / GP1BB / GP9 — causal, not "risk."
Consanguinity — the single biggest population-level risk multiplier. > [verbatim, PMID:24934643] "Consistent with the rarity of the disease, 85% of the probands carry homozygous mutations with evidence of founder effects in some geographical areas." And from a Moroccan series: > [verbatim, PMID:40703326] "Second-degree consanguinity was found in six cases." (of seven)
Founder variants — the best-characterized is the Bolzano allele: > [verbatim, PMID:21933849] "Analyses of the geographic origin of affected pedigrees and haplotypes indicated that this mutation originated in southern Italy." and "Our study indicates that monoallelic Bolzano mutation is the most frequent cause of inherited thrombocytopenia in Italy, affecting 20% of patients recruited at our institutions during the last 10 years."
22q11.2 deletion syndrome — a structural predisposing genotype. Because GP1BB sits inside the commonly deleted interval, every 22q11.2DS patient is a hemizygote: > [verbatim, PMID:38625506] "Patients with 22q11.2 deletion syndrome (22q11.2DS) are obligate carriers of BSS because GP1BB resides on chromosome 22q11.2." A second-hit variant on the retained allele produces full BSS.

Environmental risk factors

None that cause the disease. Factors that unmask or worsen the bleeding phenotype:

Antiplatelet and anti-inflammatory drugs (aspirin, other NSAIDs) — layering a second platelet hit on a platelet that already can't stick
Trauma, surgery, dental extraction, circumcision
Menarche and menstruation
Pregnancy and delivery
Anticoagulants; some antibiotics and antihistamines reported to impair platelet function
Iron-poor diet compounding chronic mucosal blood loss

An important acquired mimic: anti-GPIb/IX autoantibodies produce an acquired "pseudo-BSS" phenotype. A recent Moroccan series caught one: > [verbatim, PMID:40703326] "constitutional BSS was established in six patients, while one case was idiopathic acquired BSS." Do not curate acquired BSS as the same entity — it belongs as a differential, not a subtype.

Protective factors

Genetic: none identified. No modifier alleles have been established. Notably, a negative result — > [verbatim, PMID:21173099] "Regardless of mutations identified, the patients' bleeding diathesis did not correlate with thrombocytopenia, which was always moderate, and platelet GPIbalpha expression, which was always severely impaired." — which is exactly the shape you'd expect if unknown modifiers were doing the work.
Environmental/behavioral: NSAID avoidance, contact-sport avoidance, meticulous dental hygiene, hormonal menstrual suppression, iron repletion, planned peripartum prophylaxis (§12).

Gene-environment interactions

Essentially uncharacterized as a research topic. The clinically real one is gene-drug: a GPIb-deficient platelet exposed to aspirin, or to dual antiplatelet therapy after a coronary stent, is a genuinely hazardous combination. There is no PharmGKB/CPIC guideline for BSS.

3. Phenotypes

BSS phenotypes fall into three tidy buckets: laboratory abnormalities (obligate), mucocutaneous bleeding (near-universal but variable), and secondary consequences (iron deficiency).

3a. Laboratory abnormalities — the obligate core

Phenotype	HP term	Frequency	Notes
Macrothrombocytopenia	HP:0040185 [OLS-checked]	Obligate in biallelic BSS	The defining lab finding
Giant platelets	HP:0001902 [OLS-checked]	Very frequent / obligate	Platelets can approach lymphocyte size
Thrombocytopenia	HP:0001873 (verify)	Very frequent; typically moderate, ~20–100 × 10⁹/L	Savoia: "a moderate thrombocytopenia" in all 13 patients
Impaired ristocetin-induced platelet aggregation	HP:0011871 [OLS-checked]	Obligate in biallelic; variable in monoallelic	Not corrected by normal plasma — the discriminator vs VWD
Prolonged bleeding time	HP:0003010 [OLS-checked]	Very frequent	Historic test; largely superseded
Increased mean platelet volume	HP:0011877 (verify)	Very frequent	MPV >12.4 fL cited in secondary sources
Abnormal platelet function	HP:0011869 (verify)	Obligate	Parent term

Two under-cited lab findings worth curating because they are mechanistically informative:

[verbatim, PMID:17109744] "Prothrombin consumption is markedly reduced."

This one is a fingerprint of the procoagulant arm of GPIb function (thrombin/FXI/FXII binding), not just the adhesion arm — and it is the kind of thing that gets dropped from modern write-ups.

[verbatim, PMID:21173099] "Consistent with expression levels of GPIbalpha always lower than 10% of control values, platelet aggregation was absent or severely reduced."

3b. Bleeding phenotypes — clinical signs and symptoms

Phenotype	HP term	Frequency
Epistaxis	HP:0000421 (verify)	Very frequent — consistently the #1 symptom
Menorrhagia	HP:0000132 [OLS-checked]	All post-menarchal females in the Indian series
Gingival bleeding	HP:0000225 [OLS-checked]	Very frequent
Purpura / ecchymoses	HP:0000979 (verify); Bruising susceptibility HP:0000978 (verify)	Very frequent
Petechiae	HP:0000967 (verify)	Frequent
Gastrointestinal hemorrhage	HP:0002239 (verify)	Frequent
Prolonged bleeding after surgery / dental procedures	HP:0004846 [OLS-checked]	Frequent
Post-partum hemorrhage	HP:0011891 [OLS-checked]	~53% of reported deliveries (see below)
Intracranial hemorrhage	HP:0002170 (verify)	Occasional; the main mortality driver
Iron deficiency anemia	HP:0001891 (verify)	Frequent, esp. females

Frequency anchors from the literature:

[verbatim, PMID:17109744] "Clinical manifestations usually include purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding."

[verbatim, PMID:41100648] "Epistaxis, ecchymosis, gingival bleed, gastrointestinal bleed, and soft tissue bleed were the commonest clinical manifestations. Menorrhagia was seen in all females in the reproductive age group." — Natural history & QoL study, India, 76 participants (64 GT, 12 BSS). Indian J Med Res. 2025 Aug.

[verbatim, PMID:36889343] "In the literature review, postpartum hemorrhage (PPH) was found in 52.9% (27/51) of deliveries. Late PPH occurred more frequently than early PPH (35.3 and 31.4%, respectively). 49% (25/51) of pregnancies had severe thrombocytopenia, and antepartum hemorrhage was observed in 11.8% (6/51) of those."

Curation caution on frequency bands: per the dismech frequency-evidence SOP, most of these percentages come from literature reviews of published pregnancies, which is a heavily ascertainment-biased denominator. The 52.9% PPH figure supports a FREQUENT/VERY_FREQUENT band for PPH in reported BSS pregnancies, not in all BSS pregnancies. Quote the sentence, and say so in the explanation.

3c. Characteristics

Age of onset: Biallelic — infancy/early childhood, often neonatal. Monoallelic — later, frequently adulthood.

[verbatim, PMID:39191409] "Patients with biallelic form are usually diagnosed at a young age, typically with mucocutaneous bleeding, whereas monoallelic forms are generally identified later in life and are frequently misdiagnosed with immune thrombocytopenic purpura (ITP)." [verbatim, PMID:40703326] "Clinically, six patients had a history of hemorrhage since early childhood, while one patient presented with non-traumatic hemarthrosis at an advanced age compatible with acquired BSS."
Severity: highly variable, and — this is the striking finding — not predicted by genotype, platelet count, or receptor expression level.

[verbatim, PMID:21173099] "Patients all had a moderate thrombocytopenia with giant platelets and a bleeding tendency whose severity varied among individuals." and "Aware of the limitations of our cohort, we cannot define any correlations." This is a genuine KNOWLEDGE_GAP for the dismech entry, not a gap in the literature search.
Progression: Non-progressive. The underlying defect is static from birth. What changes is exposure — menarche, surgery, pregnancy, aging vasculature. The course is episodic against a stable baseline, lifelong.
Monoallelic Bolzano-type severity: > [verbatim, PMID:21933849] "Although the clinical expression was variable, patients with this mutation typically had a mild form of Bernard-Soulier syndrome with mild thrombocytopenia and bleeding tendency. The most indicative laboratory findings were enlarged platelets and reduced GPIb/IX/V platelet expression; in vitro platelet aggregation was normal in nearly all of the cases."

3d. Quality of life

The best available data — and it's a genuinely useful, recent, multi-instrument study:

[verbatim, PMID:41100648] "Health related quality of life (HRQoL) was captured using EuroQol five-dimensional questionnaire (EQ-5D), 36-Item short form health survey (SF-36) and functional assessment of chronic illness therapy (FACIT) scales. The severity of bleeding was assessed by annual bleed rate (ABR) and International Society on Thrombosis and Haemostasis - Bleeding assessment tool (ISTH-BAT) score."

[verbatim, PMID:41100648] "The relationship between quality of life scores and ISTH-BAT score was weak."

That decoupling is important: bleeding score does not equal lived burden. The burden drivers appear to be chronic anemia/fatigue, treatment access, and school/work disruption rather than event count.

4. Genetic / Molecular Information

Causal genes

Three, and only three. GP1BA, GP1BB, GP9 (HGNC IDs in §1). GP5 is the dog that didn't bark — see §15 for the mouse data explaining why.

Mutational spectrum

[verbatim, PMID:24934643] "There is a wide spectrum of mutations with 112 different variants, including 22 novel alterations."

Gene distribution across 211 families: GP9 44%, GP1BA 28%, GP1BB 28%.

Variant classes represented: missense, nonsense, frameshift (insertions and deletions), splice-site, and larger structural deletions. Concrete, recently published examples with proper HGVS from an Iranian cohort:

[verbatim, PMID:42229093] "Sequencing of the GP9 gene revealed two novel frameshift deletions: c.151_154delGCCC and c.357delT. Variants identified in the GP1BB gene consisted of one known missense mutation (c.47 T > C) and a single-nucleotide deletion (c.390delC). In the GP1BA gene, we identified three cases with a c.624_625insT mutation and one case with a novel missense substitution (c.522 C>A)." — Transfus Apher Sci. 2026 Aug.

And a structural/in-frame example tied to 22q11.2:

[verbatim, PMID:38625506] "Gene panel testing revealed a novel variant in GP1BB, p.(Val169_Leu172del)."

The named founder allele:

[verbatim, PMID:21933849] "However, some years ago it was shown that the monoallelic c.515C>T transition in the GP1BA gene (Bolzano mutation) was responsible for macrothrombocytopenia in a few Italian patients."

That's GP1BA c.515C>T, p.Ala156Val — southern Italian founder, autosomal dominant, mild. It matters far out of proportion to its severity because it is common: 20% of inherited thrombocytopenia referrals in the Pavia/Trieste catchment, across 42 families / 103 cases. And the authors flag its diaspora: > [verbatim, PMID:21933849] "Because many people from southern Italy have emigrated during the last century, this mutation may have spread to other countries."

Variant classification and allele frequency

ACMG/AMP classification: the recurrent BSS alleles are largely Pathogenic/Likely pathogenic in ClinVar; null variants in genes with established LOF mechanism get PVS1. Verify per-variant in ClinVar/VarSome before curating any specific classification.
Allele frequencies: biallelic BSS alleles are individually ultra-rare in gnomAD. I could not find a published gnomAD-based carrier-frequency analysis for BSS in this search — a PubMed query for exactly that returned zero hits. This is a real literature gap, and it matters, because the Bolzano data imply heterozygous BSS alleles are collectively much commoner than the biallelic disease prevalence would suggest. Flag as KNOWLEDGE_GAP.
Origin: germline in all inherited cases. No somatic BSS. (Acquired autoantibody pseudo-BSS is immunological, not somatic-genetic.)

Functional consequences

Predominant: loss of function via failure of complex assembly/surface expression. Because GPIbα, GPIbβ, and GPIX must assemble stoichiometrically in the ER to traffic, a null in any one subunit collapses surface expression of all of them. This is why flow cytometry shows loss of CD42a and CD42b together, regardless of which gene is hit — a genuinely elegant diagnostic consequence of an assembly-dependent receptor.
Rarer: expressed-but-nonfunctional receptor that cannot engage VWF (Savoia 2014, quoted above).
Structural rationale for missense variants: > [verbatim, PMID:21173099] "Homozygous mutations were identified in the GP1BA, GP1BB and GP9 genes; six were novel alterations expected to destabilize the conformation of the respective protein."
The mirror-image disease: gain-of-function GP1BA variants that increase VWF affinity cause platelet-type (pseudo-) von Willebrand disease, not BSS. Same gene, opposite functional direction, different disease. Curate as a differential with an explicit functional_impact_category contrast (LOSS_OF_FUNCTION vs GAIN_OF_FUNCTION).
Dominant-negative: the mechanism proposed for monoallelic BSS/Bolzano — a mutant subunit that incorporates into the complex and drags down its assembly/stability, giving ~50%+ reduction rather than the ~50% you'd get from simple haploinsufficiency.

Modifier genes

None established. But there is one delightful cis-genomic modifier — not a classical modifier gene, but a positional artifact:

[verbatim, PMID:15213102] "The SEPT5 gene resides approximately 250 nucleotides 5' to the GP Ibbeta gene and has been associated with modulating exocytosis from neurons and platelets as part of a presynaptic protein complex. Fusion mRNA transcripts present in megakaryocytes can contain both the SEPT5 and GP Ibbeta coding sequences as a result in an imperfect polyadenylation signal within the 3' end of both the human and mouse SEPT5 genes. We observed a 2- to 3-fold increase in SEPT5 protein levels in platelets from GP Ibbeta(Null) mice."

[verbatim, PMID:15213102] "These results implicate SEPT5 levels in the maintenance of normal alpha-granule size and may explain the variant granules associated with human GP Ibbeta mutations and the Bernard-Soulier syndrome."

Two genes 250 bp apart sharing a leaky polyadenylation signal, so knocking out one perturbs the other. That's a plumbing accident, and it predicts a GP1BB-specific α-granule phenotype not shared by GP1BA or GP9 forms. Worth a dedicated pathophysiology node on the GP1BB subtype.

Epigenetics

No BSS-specific DNA methylation, histone, or chromatin data located. Not applicable at current evidence level.

Chromosomal abnormalities

22q11.2 microdeletion (DiGeorge/velocardiofacial) removes one GP1BB copy → obligate monoallelic BSS carriage, with macrothrombocytopenia and reduced GPIbα by flow.

[verbatim, PMID:38625506] "A 15-month-old girl without bleeding symptoms had giant platelets and thrombocytopenia. Physical findings and macrothrombocytopenia suggested 22q11.2DS, which was confirmed by fluorescence in situ hybridization. Flow cytometry showed decreased GPIbalpha on the platelets." and the practice point: "This case suggests that any patient with 22q11.2DS and macrothrombocytopenia should be further tested for BSS."
Canine analogue: a 2,460-bp deletion spanning most of the single coding exon of GP9 (§14).

5. Environmental Information

Short section, honestly, and that's the finding.

Environmental factors: none causal. No toxin, radiation, pollutant, or occupational exposure is implicated in BSS pathogenesis. CTD/TOXNET have nothing disease-specific.
Lifestyle factors: modulate expression of bleeding, not risk of disease. Contact sports, NSAID/aspirin use, alcohol (adds platelet inhibition + variceal risk), and dietary iron adequacy are the practical levers.
Infectious agents: not applicable as cause. Relevant only as (a) transfusion-transmitted infection risk from repeated platelet exposure and (b) H. pylori/mucosal lesions amplifying GI bleeding.
Iatrogenic: repeated platelet transfusion → HLA and anti-GPIb alloimmunization → refractoriness, and in mothers → transplacental antibody causing fetal/neonatal alloimmune thrombocytopenia. This is the single most consequential "environmental" exposure in BSS care.

6. Mechanism / Pathophysiology

Here's the part where the metaphor earns its keep. GPIb-IX-V is doing two jobs that have nothing obvious to do with each other: it's the grappling hook the platelet throws at a damaged vessel wall, and it's a tent pole anchoring the membrane to the internal cytoskeleton while a megakaryocyte extrudes proplatelets. Delete it and both jobs fail — hence a bleeding disorder and a platelet-production disorder in the same patient. Model these as two parallel downstream branches from one shared upstream node.

The receptor

[verbatim, PMID:23336709] "The glycoprotein (GP)Ib-IX-V complex is the platelet receptor for von Willebrand factor and many other molecules that are critically involved in hemostasis and thrombosis. The lack of functional GPIb-IX-V complexes on the platelet surface is the cause of Bernard-Soulier syndrome, a rare hereditary bleeding disorder that is also associated with macrothrombocytopenia." — Li R, Emsley J. J Thromb Haemost. 2013 Apr. doi:10.1111/jth.12097

Stoichiometry: GPIbα : GPIbβ : GPIX : GPV in a 2 : 4 : 2 : 1 ratio. GPIbα is disulfide-linked to two GPIbβ chains; GPIX associates non-covalently; GPV associates loosely and is dispensable.

Ligands beyond VWF (the reason BSS is worse than a pure adhesion defect): thrombin, factor XI, factor XII, high-molecular-weight kininogen, P-selectin, and leukocyte integrin Mac-1 (αMβ2). Losing this hub also degrades platelet-leukocyte crosstalk and platelet-supported coagulation — which is exactly what "prothrombin consumption is markedly reduced" is reporting.

Causal chain — proposed dismech pathograph

[MOLECULAR] Biallelic LOF variant in GP1BA / GP1BB / GP9
│
▼
[MOLECULAR] Failure of GPIb-IX complex assembly in the megakaryocyte ER
│  (assembly is obligate-stoichiometric: one null subunit sinks all)
▼
[CELLULAR] Absent or severely reduced GPIb-IX-V at the platelet/MK surface
│
├──── BRANCH A: hemostatic failure ──────────────────────────────┐
│                                                                │
▼                                                                ▼
[CELLULAR] Loss of VWF-A1 capture under high shear          [MOLECULAR] Loss of GPIbα
│  → no tethering/rolling on subendothelium           thrombin/FXI/FXII/HK
▼                                                     binding sites
[CELLULAR] Failure of GPIb-IX outside-in signalling                      │
│  → no inside-out activation of αIIbβ3                          ▼
▼                                                    [ORGANISM] Reduced
[TISSUE] Failure of primary hemostatic plug formation         prothrombin consumption
│
▼
[ORGANISM] Mucocutaneous bleeding diathesis
│
▼
[ORGANISM] Chronic blood loss → iron deficiency anemia

└──── BRANCH B: thrombopoietic failure ─────────────┐
                                                     │
                                                     ▼
[CELLULAR] Loss of GPIbα cytoplasmic-tail linkage to filamin A / 14-3-3ζ
│  → membrane skeleton uncoupled from the cytoskeleton
▼
[CELLULAR] Abnormal demarcation membrane system development in MK
│
▼
[CELLULAR] Impaired proplatelet formation; deranged α-tubulin /
│  microtubule marginal-band assembly; enlarged proplatelet tips
▼
[CELLULAR] Release of fewer, abnormally large platelets
│
▼
[ORGANISM] Macrothrombocytopenia

Plus a modulating side-branch: shear-triggered receptor unfolding → platelet clearance (below), and, for GP1BB specifically, SEPT5 dysregulation → enlarged α-granules.

Branch A — adhesion and activation

Under arterial shear, VWF unfurls on exposed subendothelium and its A1 domain is the only thing fast enough to catch a platelet moving at that velocity. GPIbα is the catcher's mitt. Without it there is no capture step, so nothing downstream — αIIbβ3 activation, firm adhesion, spreading, aggregate growth — ever gets started. The clinical signature is a bleeding severity disproportionate to the platelet count:

[verbatim, PMID:10706630] "The bleeding in patients with the Bernard-Soulier syndrome is disproportionately more severe than suggested by the reduced platelet count and is explained by a defect in primary hemostasis owing to the absence of the platelet glycoprotein (GP) Ib-IX-V membrane receptor."

The functional readout of Branch A in the lab is the absent ristocetin response — ristocetin artificially promotes VWF-A1/GPIbα engagement, so a platelet with no GPIbα simply cannot agglutinate no matter how much normal plasma you add. That's the whole diagnostic logic in one sentence.

Branch B — thrombopoiesis (the part that took 50 years to work out)

[verbatim, PMID:10706630] "However, the molecular basis for the giant platelet phenotype and thrombocytopenia have remained unresolved but assumed to be linked to an absent receptor complex. We have disrupted the gene encoding the alpha-subunit of mouse GP Ib-IX-V (GP Ibalpha) and describe a murine model recapitulating the hallmark characteristics of the human Bernard-Soulier syndrome. The results demonstrate a direct link between expression of a GP Ib-IX-V complex and normal megakaryocytopoiesis and platelet morphogenesis." — Ware J, Russell S, Ruggeri ZM. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2803-8

The cell-biological detail, in mouse:

[verbatim, PMID:19377075] "The number of megakaryocyte progenitors, their differentiation and progressive maturation into distinct classes and their level of endoreplication were normal in GPIbbeta(-/-) bone marrow. However, the more mature cells exhibited ultrastructural anomalies with a thicker peripheral zone and a less well developed demarcation membrane system."

[verbatim, PMID:19377075] "GPIbbeta(-/-) megakaryocytes could be differentiated in culture from Lin(-) fetal liver cells in normal amounts but the proportion of cells able to extend proplatelets was decreased by 41%."

[verbatim, PMID:19377075] "The marginal microtubular ring contained twice as many tubulin fibers in GPIbbeta(-/-) proplatelet buds in cultured and circulating platelets."

[verbatim, PMID:19377075] "Altogether, these findings point to a role of the GPIb-V-IX complex intrinsic to megakaryocytes at the stage of proplatelet formation and suggest a functional link with the underlying microtubular cytoskeleton in platelet biogenesis." — Strassel C et al. Haematologica. 2009.

And — critically for translational validity — the same defect is demonstrable in human megakaryocytes, in monoallelic Bolzano patients:

[verbatim, PMID:19067792] "Megakaryocyte differentiation from both cord blood (one patient) and peripheral blood (five patients) was comparable to controls. However, proplatelet formation was reduced by about 50% with respect to controls."

[verbatim, PMID:19067792] "Morphological evaluation of proplatelet formation revealed an increased size of proplatelet tips, which was consistent with the increased diameters of patients' blood platelets. Moreover, alpha-tubulin distribution within proplatelets was severely deranged."

[verbatim, PMID:19067792] "These results suggest that a defect of platelet formation contributes to macrothrombocytopenia associated to the Bolzano mutation, and indicate a key role for GPIb alpha in proplatelet formation." — Balduini A et al. J Thromb Haemost. 2009 Mar;7(3):478-84

That human-plus-mouse convergence is unusually strong for a rare disease and should be curated as IN_VITRO (human MK culture) plus MODEL_ORGANISM evidence on the same node — not one standing in for the other.

Which part of GPIbα drives Branch B? An elegant chimera experiment separates the extracellular and cytoplasmic contributions:

[verbatim, PMID:12200373] "The characterization of these mice revealed a 2-fold increase in circulating platelet count and a 50% reduction in platelet size when compared with platelets from the mouse model of the Bernard-Soulier syndrome. Immunoprecipitation confirmed that the IL-4Ralpha/GP Ibalpha subunit interacts with filamin-1 and 14-3-3zeta, known binding proteins to the GP Ibalpha cytoplasmic tail. Mice expressing the chimeric receptor retain a severe bleeding phenotype, confirming a critical role for the GP Ibalpha extracytoplasmic domain in hemostasis." — Kanaji T et al. Blood. 2002 Sep 15

Read that carefully: replacing the outside of GPIbα with an unrelated domain fixes half the macrothrombocytopenia while leaving the bleeding phenotype intact. The cytoplasmic tail (filamin A / 14-3-3ζ) drives platelet size and count; the ectodomain drives hemostasis. Two jobs, two domains, cleanly dissociable. That's a beautiful piece of evidence for the two-branch model above.

Mechanosensing and platelet clearance

[verbatim, PMID:27670775] "Mechanisms by which blood cells sense shear stress are poorly characterized. In platelets, glycoprotein (GP)Ib-IX receptor complex has been long suggested to be a shear sensor and receptor. Recently, a relatively unstable and mechanosensitive domain in the GPIbalpha subunit of GPIb-IX was identified. Here we show that binding of its ligand, von Willebrand factor, under physiological shear stress induces unfolding of this mechanosensory domain (MSD) on the platelet surface. The unfolded MSD, particularly the juxtamembrane 'Trigger' sequence therein, leads to intracellular signalling and rapid platelet clearance." — Deng W et al. Nat Commun. 2016 Sep 27

This is the newest mechanistic layer and it's under-integrated into BSS thinking: GPIbα is a mechanoreceptor whose unfolding is a platelet-lifespan timer. Missense variants that destabilize the MSD could, in principle, shorten platelet survival independently of production — a plausible third contributor to thrombocytopenia. Curate as an EMERGING mechanistic hypothesis, not as canonical; the direct link from BSS-causing variants to accelerated clearance in patients has not, to my reading, been demonstrated.

GPIbβ has its own signalling role — with a surprise

[verbatim, PMID:27148783] "On the other hand, deletion of the C-flanking 159-170 segment allowed normal GPIb-IX expression, VWF-dependent responses and bleeding times, but resulted in enhanced arterial thrombosis." and "This pointed to a repressor role of GPIbbeta in thrombus formation in vivo that was not predicted in studies of heterologous cells." — Strassel C et al. J Thromb Haemost. 2016

So GPIbβ's cytoplasmic tail is partly a brake on thrombosis. Note the explicit heterologous-cell/in-vivo discordance — a textbook HUMAN_MODEL_MISMATCH-adjacent finding (here it's cell-line-vs-mouse rather than mouse-vs-human, but the epistemic shape is identical).

Suggested ontology terms

GO biological process: - GO:0030220 platelet formation [OLS-checked] — Branch B core, modifier: DECREASED - GO:0036344 platelet morphogenesis [OLS-checked] — Branch B, modifier: ABNORMAL/DECREASED - GO:0030168 platelet activation [OLS-checked] — Branch A, DECREASED - GO:0070527 platelet aggregation (verify) — Branch A, DECREASED - GO:0007596 blood coagulation (verify) — DECREASED - GO:0002576 platelet degranulation (verify) — relevant to the GP1BB/SEPT5 α-granule branch - GO:0007018 microtubule-based movement (verify) / microtubule cytoskeleton organization — proplatelet branch - GO:0051017 actin filament bundle assembly (verify) — filamin A linkage

GO cellular component: - GO:0005886 plasma membrane (verify) — where the complex should be and isn't - GO:0005783 endoplasmic reticulum (verify) — where assembly fails - GO:0031091 platelet alpha granule (verify) — GP1BB/SEPT5 branch

GO molecular function: the obvious one — von Willebrand factor binding — does not exist in GO (OLS query returned zero hits this session). Use GO:0005515 protein binding or a receptor-activity term, and note the ontology gap. This is a legitimate OBO gap to surface.

Cell Ontology: - CL:0000556 megakaryocyte [OLS-checked] - CL:0000233 platelet (verify) - CL:0000553 megakaryocyte progenitor cell [OLS-checked]

CHEBI: CHEBI:85129 ristocetin [OLS-checked] (note: CHEBI:201477 Ristocetin sulfate, CHEBI:201735 Ristocetin A sulfate also exist — pick the aglycone-free base for the reagent)

Molecular profiling

Transcriptomics: no BSS-specific published transcriptomic signature located. GP9-KO and patient-derived iPSC megakaryocyte systems now exist (PMID:37416759) and are the obvious substrate for one. Gap.
Proteomics: no BSS-specific proteomic dataset located. The SEPT5 finding (PMID:15213102) is a targeted immunoblot result, not discovery proteomics.
Metabolomics / lipidomics: none identified. Not applicable at present.
Single-cell / spatial: none BSS-specific identified. Bone-marrow megakaryocyte scRNA-seq atlases exist generally but no BSS cohort.
Functional genomics screens: no BSS-focused CRISPR/RNAi screen located; the gene-editing work in PMID:37416759 is targeted KO generation, not a screen.

For dismech datasets: — do not fabricate accessions. Run just discover-datasets Bernard-Soulier_Syndrome and triage relevance manually; note the short-gene-symbol NEC hazard applies hard here (GP5, GP9 will collide with unrelated titles constantly).

7. Anatomical Structures Affected

BSS is a blood and bone marrow disease whose symptoms appear at mucosal surfaces. Nothing is structurally diseased in the vessel wall, the liver, or anywhere else.

Organ level

Primary: - Bone marrow — UBERON:0002371 (verify) — site of the defective thrombopoiesis - Blood / circulating platelet pool — UBERON:0000178 blood (verify)

Secondary (bleeding sites, not diseased tissue): - Nasal cavity / nasal mucosa — epistaxis — UBERON:0001707 nasal cavity (verify) - Gingiva / oral mucosa — UBERON:0001828 gingiva (verify) - Gastrointestinal tract mucosa — UBERON:0001555 digestive tract (verify) - Endometrium / uterus — menorrhagia, PPH — UBERON:0001295 endometrium (verify) - Skin — purpura, ecchymoses, petechiae — UBERON:0002097 skin of body (verify) - Brain — intracranial hemorrhage (rare, high-lethality) — UBERON:0000955 brain (verify) - Joints — hemarthrosis is atypical for BSS (it's a coagulation-factor pattern), and its appearance should prompt a rethink — note the Moroccan acquired case presented that way

Body systems: hematologic/hematopoietic (primary); cardiovascular (as the compartment); integumentary, digestive, respiratory (upper), reproductive (as bleeding sites).

Tissue and cell level

Megakaryocyte (CL:0000556 [OLS-checked]) — the cell where the disease is actually made. Progenitor number, differentiation, and endoreplication are normal; the defect is at the terminal proplatelet-extrusion step (PMID:19377075). That's an important negative — don't model it as a proliferation defect.
Platelet (CL:0000233) — the cell that carries the defect out into circulation. Abnormally large but, notably, still discoid: > [verbatim, PMID:19377075] "GPIbbeta(-/-) released platelets were larger but retained a typical discoid shape."
Vascular endothelium / subendothelium — the partner tissue. Not diseased; it's the substrate the platelet fails to engage.
Blood vessel — UBERON:0001981 (verify)

Subcellular level

Plasma membrane (GO:0005886) — where the receptor is absent
Endoplasmic reticulum (GO:0005783) — where subunit assembly fails and misassembled subunits are retained/degraded
Demarcation membrane system — the megakaryocyte's internal membrane reservoir; poorly developed in GPIbβ-null MK. No clean GO term for DMS that I could confirm — another ontology gap worth flagging.
Marginal microtubule band / α-tubulin cytoskeleton — doubled fiber count in mutant proplatelet buds
α-granule (GO:0031091) — enlarged in the GP1BB/SEPT5 branch
Membrane skeleton — filamin A / 14-3-3ζ linkage

Localization and laterality

Systemic and bilateral by nature — this is a circulating-cell disorder, so there is no laterality. Bleeding sites are wherever mucosa meets mechanical stress. No focal or asymmetric anatomical pattern.

8. Temporal Development

Onset

Pattern: congenital genotype, insidious-to-early clinical onset. The receptor has been missing since fetal megakaryopoiesis; it just takes a hemostatic challenge to reveal it.
Biallelic BSS: neonatal to early childhood. Classic revealing events — bleeding at circumcision, prolonged umbilical-stump or venipuncture oozing, easy bruising as the child becomes mobile, epistaxis in the toddler years.
Monoallelic BSS: adolescence to adulthood, often incidentally on a CBC, or after a "refractory ITP" odyssey.
Diagnostic delay is the norm. Mean age at diagnosis around 16 years is cited in secondary sources (StatPearls, NBK557671 — secondary, verify against primary); the Moroccan series had a mean age of 21 years despite childhood-onset symptoms in 6/7.

Progression

Rate: non-progressive. The underlying lesion does not worsen.
Course pattern: episodic on a stable baseline. Bleeding events cluster around hemostatic challenges rather than accumulating.
Duration: chronic, lifelong.
Stages: BSS has no formal staging system. If you need an axis, use ISTH-BAT bleeding score and annual bleed rate (ABR) — both were applied to BSS in PMID:41100648 — rather than inventing stages.

Patterns

Remission: none spontaneous. Treatment-induced remission of bleeding (not of the disorder) is achievable — most durably in the eltrombopag long-term arm: > [verbatim, PMID:31273088] "Four patients with clinically significant spontaneous bleeding entered a program of long-term eltrombopag administration (16 additional weeks): all of them obtained remission of mucosal hemorrhages, with the remission persisting throughout the treatment period."
A false remission worth naming: splenectomy performed under a mistaken ITP diagnosis produces temporary improvement, which then reinforces the wrong diagnosis. > [verbatim, PMID:41853404] "She was misdiagnosed and treated for ITP, and due to refractory symptoms, she underwent splenectomy and experienced temporary symptom improvement. However, the symptoms returned, and further workup with ristocetin and flow cytometry confirmed her diagnosis of BSS." That's an iatrogenic-harm pathway worth curating explicitly.

Critical periods (windows of vulnerability / intervention)

Neonatal period — circumcision, heel-stick, and the ICH window; plus FNAIT risk if the mother is alloimmunized
Menarche — frequently the presenting crisis in females; a planned hormonal + antifibrinolytic strategy before menarche is the highest-yield preventive intervention in BSS
Any surgical or dental procedure — plan, don't react
Pregnancy and the peripartum window — including the late PPH window, which in BSS is more common than early PPH (35.3% vs 31.4%, PMID:36889343). Post-discharge is not safe territory.
First transfusion — the alloimmunization clock starts here; HLA-typing and leukoreduction decisions made at diagnosis determine options a decade later

9. Inheritance and Population

Epidemiology

Prevalence: <1 per 1,000,000 for classical biallelic BSS.

[verbatim, PMID:34878196] "Bernard-Soulier syndrome (BSS) is an inherited bleeding disorder characterized by macroplatelets and thrombocytopenia, prolonged bleeding time, and a prevalence of less than 1 in 1,000,000."

Orphanet-style class: BELOW_1_IN_1000000; rate_per_100000 ≈ 0.1 (upper bound). Note this figure is very likely an underestimate — every review says so, and the two independent reasons are (a) monoallelic BSS masquerading as ITP and (b) undiagnosis in low-resource settings.

Cumulative reported cases:

[verbatim, PMID:17109744] "This syndrome is extremely rare as only approximately 100 cases have been reported in the literature." (2006) [verbatim, PMID:40703326] "Bernard-Soulier syndrome (BSS) is a rare thrombopathy with only a few hundred cases reported in the medical literature." (2025)

Genotyped families: 211 (Savoia 2014 consortium).

Incidence: no published incidence rate located. Gap.

Regional variation

Consanguineous populations are markedly enriched. > [verbatim, PMID:40703326] "BSS is a thrombopathy that can be either constitutional or acquired, with a relatively high prevalence in Morocco, and should not be underestimated." Seven BSS-compatible profiles out of 268 platelet-aggregation tests over four years at one Rabat center.
Italy — the Bolzano allele makes monoallelic BSS the commonest inherited thrombocytopenia in the country (20% of referrals), with southern Italian origin and probable diaspora spread.
Founder effects generally: > [verbatim, PMID:24934643] "...85% of the probands carry homozygous mutations with evidence of founder effects in some geographical areas."
Iran, Turkey, North Africa, South Asia, Middle East — repeatedly represented in the case-series literature, consistent with consanguinity structure.

Inheritance

Autosomal recessive for classical biallelic BSS (types A1, B, C)
Autosomal dominant for monoallelic BSS (type A2; GP1BA and GP1BB only, never GP9 in the dominant form per Kaya 2025)
Penetrance: essentially complete for the laboratory phenotype (macrothrombocytopenia) in biallelic disease. Incomplete/variable for clinically significant bleeding — and even for detection in the monoallelic form, where a 15-month-old carried the full lab picture "without bleeding symptoms" (PMID:38625506).
Expressivity: highly variable, uncorrelated with genotype. This is the single most robustly replicated negative finding in BSS genetics (PMID:21173099).
Anticipation: not applicable — no repeat expansion mechanism.
Germline mosaicism: not reported.
Consanguinity: major driver (above).
Carrier frequency: heterozygous carriers of classical recessive alleles are generally asymptomatic with normal or near-normal platelets — with one important exception:

[verbatim, PMID:21173099] "Except for obligate carriers of a GP9 mutation with a reduced GPIb/IX/V expression and defective aggregation, all the other carriers had no obvious anomalies." and: "Obligate carriers had features similar to controls though their GPIb/IX/V expression showed discrepancies." So: some GP9 heterozygotes are not silent. Curate carrier status as variable, not unaffected. No gnomAD-based carrier-frequency estimate for BSS alleles was located. Gap.

Demographics

Sex ratio: ~1:1 expected (autosomal). Reported series deviate on small numbers — the Moroccan series reported a sex ratio of 2.5 (n=7), which is noise, not signal. Females carry disproportionate morbidity (menorrhagia, iron deficiency, pregnancy risk) even at equal prevalence — that's a burden asymmetry, not an incidence asymmetry, and the distinction matters for how you curate it.
Age distribution: all ages; biallelic patients are ascertained in childhood, monoallelic in adulthood. Median age 14 in the Indian GT/BSS cohort; mean 21 in the Moroccan BSS series.
Ethnic groups: no ethnicity is intrinsically predisposed; the enrichment tracks consanguinity rates and founder history, which is a different claim and should be curated as such.

10. Diagnostics

The diagnostic logic in one paragraph

Macrothrombocytopenia + mucocutaneous bleeding + absent ristocetin-induced aggregation that normal plasma does not fix + flow-cytometric loss of CD42a/CD42b = BSS. Genetics confirms and subtypes. Everything else is ruling out the mimics.

The definitive modern statement of the biallelic-vs-monoallelic diagnostic split

[verbatim, PMID:39191409] "In biallelic BSS, giant platelets in the peripheral blood smear, absence of ristocetin-induced platelet aggregation (RIPA) using light transmission aggregometry (LTA), and complete loss of GPIbIX complex in flow cytometry are observed, whereas in monoallelic forms, genetic diagnosis is recommended due to the presence of large platelets in the peripheral blood smear, decreased or normal RIPA response in LTA, and partial loss or normal GPIbIX complex in flow cytometry."

That single sentence should anchor the whole definitions block. Note the operational consequence: in monoallelic BSS the functional tests can be normal, so genetics is not confirmatory-optional, it's primary.

Laboratory tests

Test	Finding in BSS	Notes
CBC + MPV	Thrombocytopenia (typically 20–100 × 10⁹/L), MPV elevated (>12.4 fL cited)	Automated counters undercount giant platelets by sizing them as leukocytes — always confirm on smear
Peripheral blood smear	Giant platelets, reduced number	Cheap, fast, and the most under-used test in this disease
Light transmission aggregometry (LTA)	Absent/severely reduced RIPA; normal response to ADP, collagen, arachidonic acid, epinephrine; occasional thrombin hyporesponsiveness	The isolated ristocetin defect is the signature
RIPA + normal plasma mixing	No correction	Discriminates BSS (receptor absent) from VWD (ligand absent)
Flow cytometry	↓↓ CD42a (GPIX), ↓↓ CD42b (GPIbα); also CD42c (GPIbβ), CD42d (GPV)	Confirmatory; works in neonates and on tiny samples
Bleeding time	Markedly prolonged	Historic; largely abandoned
PFA-100 closure time	Prolonged (collagen/ADP and collagen/epinephrine)	Screening only
Prothrombin consumption	Markedly reduced (PMID:17109744)	Classic, informative, nearly forgotten
Iron studies / ferritin	Microcytic hypochromic anemia in 4/7 Moroccan cases	Monitor, don't just treat once
ISTH-BAT	Quantifies bleeding phenotype	Validated and used in BSS (PMID:41100648)

[verbatim, PMID:40703326] "Platelet aggregation showed a normal response to all inducers except ristocetin."

Biomarkers

There is no soluble biomarker for BSS. The "biomarker" is the receptor itself, measured on the cell — surface CD42b/CD42a density by flow, expressed as % of control. Savoia's cohort anchors the biallelic threshold: GPIbα <10% of control (PMID:21173099).

LOINC: platelet count, MPV, and platelet-aggregation panels have LOINC codes; CD42b flow does too. Look these up — I did not resolve specific LOINC IDs this session, and per the dismech reference_ranges guidance, an interval needs a citable source, not a guessed code.

Imaging, functional, electrophysiology, biopsy

Imaging: no diagnostic role. Used only to characterize a bleed (CT head for suspected ICH, ultrasound/CT for internal hemorrhage).
Functional / electrophysiology: not applicable.
Bone marrow biopsy: not required and not recommended for diagnosis. If done (usually during an ITP workup), megakaryocytes are present in normal-to-increased number with abnormal ultrastructure — which is the point: the marrow looks unhelpfully normal on light microscopy, and that reassures people toward the wrong diagnosis.
Electron microscopy: research-grade; shows the DMS and α-granule abnormalities.

Genetic testing

Recommended approach: targeted inherited-platelet-disorder / inherited-thrombocytopenia gene panel covering GP1BA, GP1BB, GP9 alongside MYH9, ACTN1, TUBB1, FLNA, ITGA2B, ITGB3, RUNX1, ANKRD26, ETV6, WAS, etc. Panel-first is right because the clinical differential is genetically broad and phenotypically overlapping.

Gene panel: first-line. Worked in PMID:38625506 ("Gene panel testing revealed a novel variant in GP1BB").
Single-gene / Sanger: appropriate when a founder allele is suspected (Bolzano c.515C>T in an Italian-ancestry patient; a known familial variant for cascade testing). PMID:42229093 used PCR + Sanger across all three genes successfully.
WES: reasonable when the panel is negative and the phenotype is syndromic.
WGS: catches the structural and deep-intronic variants panels miss — this is exactly how the canine 2,460-bp GP9 deletion was found (PMID:31484196), and the same logic applies in humans.
FISH / chromosomal microarray: mandatory if 22q11.2DS is suspected, and the reverse rule from PMID:38625506: any 22q11.2DS patient with macrothrombocytopenia should be tested for BSS.
Karyotype: low yield except for 22q11.2 context.
mtDNA testing / repeat expansion testing: not applicable.

Omics-based diagnostics

Not established for BSS. RNA-seq could in principle resolve splice variants of uncertain significance; no published BSS diagnostic RNA-seq protocol located. Proteomics, metabolomics, epigenomics, liquid biopsy: not applicable.

Clinical criteria

No formal consensus diagnostic criteria (no DSM/ICD-style checklist). The operative criteria are the ISTH SSC guidance on diagnosis of inherited platelet disorders plus the phenotype-test combination above. Kaya 2025 provides the most usable modern criteria set.

Differential diagnosis

Condition	Distinguishing feature
Immune thrombocytopenia (ITP)	Acquired, no family history, platelets normal-sized, responds to steroids/IVIG, normal RIPA and normal CD42b. The single most consequential misdiagnosis — leads to steroids, IVIG, and splenectomy
Type 2B VWD	Increased, not decreased, RIPA at low-dose ristocetin; VWF multimer abnormality
Platelet-type (pseudo-) VWD	Gain-of-function GP1BA; also enhanced low-dose RIPA; corrected by plasma-vs-platelet mixing studies
MYH9-related disease (May-Hegglin, Sebastian, Fechtner, Epstein)	Leukocyte Döhle-like inclusions; nephropathy, deafness, cataract; normal RIPA and CD42b
Gray platelet syndrome (NBEAL2)	Pale, agranular platelets; absent α-granules; myelofibrosis
Paris-Trousseau / Jacobsen (11q del, FLI1)	Giant α-granules; 11q deletion; dysmorphism
22q11.2DS / DiGeorge	Macrothrombocytopenia plus cardiac, palatal, immune, endocrine features — and the GP1BB mechanistic link
ACTN1, TUBB1, FLNA-related macrothrombocytopenia	Normal GPIb-IX-V by flow
ITGA2B/ITGB3-related macrothrombocytopenia	Reduced CD41/CD61, not CD42
Mediterranean macrothrombocytopenia	Often the mild monoallelic BSS end of the spectrum in disguise
Acquired / pseudo-BSS	Anti-GPIb autoantibody; adult onset without family history; may present atypically (the Moroccan hemarthrosis case)
Glanzmann thrombasthenia	Normal platelet count and size; absent aggregation to all agonists except ristocetin — the exact mirror image of BSS

That last row is the mnemonic that actually sticks: Glanzmann fails everything but ristocetin; Bernard-Soulier fails only ristocetin. Normal-sized platelets vs giant. Opposite in every way except that both bleed.

Screening

Newborn screening: not performed, not proposed.
Cascade screening: yes — first-degree relatives of a proband, especially in consanguineous kindreds and in dominant (Bolzano/type A2) families.
Carrier screening: targeted in founder populations; not population-wide.
Preconception/prenatal: available where the familial variant is known (§13).

11. Outcome / Prognosis

The headline

[verbatim, PMID:17109744] "The prognosis is usually good with adequate supportive care but severe bleeding episodes can occur with menses, trauma and surgical procedures."

That's the honest summary: BSS is compatible with a normal lifespan — conditional on access to care. Which is precisely where the recent data get uncomfortable.

Survival and mortality

Life expectancy: approaching normal with adequate management. No formal actuarial data exist.
Disease-specific mortality — the access-dependent reality:

[verbatim, PMID:41100648] "Between 2000 and 2025, 13 deaths were reported due to bleeding mainly due to inaccessibility to treatment or treatment products." In a 76-patient GT+BSS cohort. Read that again: the deaths were attributed principally to inaccessibility, not to intractable biology. That reframes prognosis from a property of the disease to a property of the health system.
A frequently cited figure of ~16% fatal bleeding appears in secondary sources (StatPearls NBK557671). I could not trace it to a primary source in this pass — do not curate it without finding the original.
5-/10-year survival: not applicable (not a malignancy; no staged survival data).

Morbidity and function

Chronic iron-deficiency anemia with fatigue and lost work/school time
Menorrhagia-driven disability in females of reproductive age
Transfusion dependence in severe cases, and the downstream alloimmunization spiral
Procedural and dental care restricted or deferred (PMID:34878196 documents how thin the evidence base for even routine oral surgery is — an integrative review found only five relevant articles: one letter and four case reports)
Quality of life: measured with EQ-5D, SF-36, and FACIT in PMID:41100648, with the key finding being weak correlation with ISTH-BAT — i.e. bleeding severity scores are a poor proxy for how people are actually doing.

Complications

Iron-deficiency anemia — the most common
Platelet alloimmunization → refractoriness — the most consequential; it converts the first-line therapy into a dead end
Anti-GPIb alloantibodies crossing the placenta → FNAIT in the neonate of a previously transfused mother; monitoring is advised for weeks postpartum
Transfusion-transmitted infection — low but non-zero
Postpartum hemorrhage, disproportionately late PPH
Iatrogenic harm from ITP misdiagnosis — steroids, IVIG, and unnecessary splenectomy (PMID:41853404)
Antithrombotic dilemma — patients who develop coronary disease and need stents face an unresolvable risk trade-off
Intracranial hemorrhage — rare, and the dominant cause of catastrophic outcome

Prognostic factors

Access to platelet products and rFVIIa — the strongest determinant in the only cohort that measured mortality
Biallelic vs monoallelic genotype — monoallelic is milder (PMID:21933849)
Alloimmunization status — the key branch point in the treatment tree
Female reproductive-age status — higher cumulative morbidity
Early correct diagnosis — avoids the splenectomy detour
NOT prognostic: platelet count and GPIbα expression level. This deserves emphasis because it's counterintuitive: > [verbatim, PMID:21173099] "...the patients' bleeding diathesis did not correlate with thrombocytopenia, which was always moderate, and platelet GPIbalpha expression, which was always severely impaired."

There are no validated prognostic biomarkers in BSS. Flag as a gap.

12. Treatment

12a. Overall strategy

[verbatim, PMID:39191409] "Platelet transfusion is the main therapy but recombinant factor VIIa is advised in alloimmunized patients, and allogeneic stem cell transplantation is suggested in refractory cases. Antifibrinolytics and oral contraceptives are utilized as supplementary treatments."

That's the whole algorithm in one sentence, and it's the best single citation for a treatments: block. The escalation ladder:

Local measures + antifibrinolytics
↓ (inadequate)
Platelet transfusion (HLA-matched, leukoreduced, apheresis-preferred)
↓ (alloimmunized / refractory / access-limited)
Recombinant activated factor VIIa
↓ (severe, refractory, transfusion-dependent)
Allogeneic HSCT
↓ (experimental)
Autologous lentiviral gene therapy

12b. Pharmacotherapy

Antifibrinolytics — tranexamic acid, ε-aminocaproic acid - First-line for mucocutaneous bleeding and menorrhagia; oral, topical (mouthwash), or IV - Contraindicated in upper urinary tract bleeding (clot obstruction) and generally avoided in pulmonary hemorrhage - Used peripartum in the obstetric case: "Single donor platelet transfusions and oral tranexamic acid were administered as prophylaxis at the peripartum period" [verbatim, PMID:36889343] - Suggested annotation: treatment_term NCIT:C15986 Pharmacotherapy + therapeutic_agent CHEBI:48669 tranexamic acid (verify CHEBI ID); therapeutic_modality: SMALL_MOLECULE

Hormonal control of menorrhagia - Combined oral contraceptives, levonorgestrel-releasing IUD, progestins, GnRH agonists - Named explicitly by Kaya 2025 as supplementary therapy - therapeutic_modality: SMALL_MOLECULE

Recombinant activated factor VIIa (rFVIIa, NovoSeven) - Licensed for Glanzmann thrombasthenia, not BSS. Use in BSS is off-label but guideline-endorsed (UKHCDO/BSH) for severe bleeding, especially in alloimmunized/refractory patients. - Mechanism: bypasses the GPIb-dependent adhesion step by driving thrombin generation on the platelet surface directly - Newest evidence — prophylactic, not just on-demand:

[verbatim, PMID:41259294] "Both were initiated on prophylactic rFVIIa (4.5 mg IV and 4 mg IV, respectively) on a weekly basis. Following initiation of prophylaxis, both patients experienced a marked reduction in the frequency and severity of bleeding episodes." and: "Prophylactic administration of rFVIIa was effective in reducing bleeding episodes in both siblings with severe BSS. This case highlights the potential role of rFVIIa as a viable alternative to platelet transfusions in patients with recurrent bleeding. Further studies are needed to establish standardized protocols for prophylactic rFVIIa use in BSS." — n=2, so supports: PARTIAL at best, and say "case report" in the explanation. - A parallel access story from Japan: > [verbatim, PMID:42419992] "rFVIIa has conventionally been used in GT patients refractory to platelet transfusion due to alloantibody production, but is now available in Japan regardless of alloantibody status or platelet transfusion refractoriness. rFVIIa should be considered especially in patients at risk of alloantibody production due to platelet transfusion." - Real-world access gap: > [verbatim, PMID:41100648] "Platelet transfusion was the main mode of treatment; none of the patients in the present series were on activated recombinant factor VII (rFVIIa) therapy." - therapeutic_modality: PROTEIN_REPLACEMENT (or OTHER — it's a recombinant zymogen-activated factor; PROTEIN_REPLACEMENT is the closest honest fit)

Desmopressin (DDAVP) - Largely ineffective in BSS — it works by mobilizing VWF, and BSS platelets have no receptor to receive it. Support is anecdotal only. Risks: hyponatremia, seizures with repeat dosing. - Worth curating as a negative/limited-efficacy treatment with treatment_effect reflecting that. Negative treatment claims are as useful as positive ones here.

Eltrombopag (thrombopoietin-receptor agonist) — the most interesting off-label option

[verbatim, PMID:31273088] "We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia." [verbatim, PMID:31273088] "Of 23 patients evaluable for response, 11 (47.8%) achieved a major response (platelet count >100 x10(9)/L), ten (43.5%) had a minor response (platelet count at least twice the baseline value), and two patients (8.7%) did not respond. The average increase of platelet count compared to baseline was 64.5 x10(9)/L (P<0.001)." [verbatim, PMID:31273088] "Despite these encouraging results, caution is recommended when using thrombopoietinmimetics in inherited thrombocytopenias predisposing to leukemia." - NCT02422394 — Phase II, Zaninetti/Pecci, Haematologica 2020 - Critical scope caveat for curation: the trial included monoallelic BSS, and only as part of a mixed cohort. Do not curate this as evidence for eltrombopag efficacy in biallelic BSS. Also note the mechanistic asymmetry — raising the count of platelets that still can't bind VWF addresses only half the disease. - therapeutic_modality: SMALL_MOLECULE; therapeutic_agent CHEBI/NCIT eltrombopag (verify ID)

Iron supplementation — routine, and under-prescribed. therapeutic_modality: SMALL_MOLECULE.

Drugs to avoid: aspirin, other NSAIDs, and (per secondary sources) certain antihistamines and antibiotics with antiplatelet effects. Curate as a contraindication note.

12c. Pharmacogenomics

None established. No PharmGKB or CPIC guideline for BSS. Gap. The relevant "pharmacogenomic" fact is structural rather than metabolic: a GP1BA/GP1BB/GP9-null genotype makes DDAVP mechanistically futile and antiplatelet drugs disproportionately dangerous.

12d. Advanced therapeutics

Gene therapy — the most active research front, and it now spans all three genes

Type A1 / GP1BA, mouse, proof of concept:

[verbatim, PMID:22044935] "GPIbalpha(null) hematopoietic stem cells (HSC) transduced with 2bIbalpha LV were transplanted into lethally irradiated GPIbalpha(null) littermates. Therapeutic levels of hGPIbalpha expression were achieved that corrected the tail bleeding time and improved the macrothrombocytopenia." and: "These results demonstrate that lentivirus-mediated gene transfer can provide sustained phenotypic correction of murine BSS, indicating that this approach may be a promising strategy for gene therapy of BSS patients." — Kanaji S et al. Mol Ther. 2012 Mar;20(3):625-32

Note the vector design: human GP1BA under the platelet-specific integrin αIIb promoter — lineage-restricted expression, which is the right architecture for a megakaryocyte-autonomous disease.

Making the conditioning clinically tolerable:

[verbatim, PMID:25066812] "Transplantation of 10-20% hGPIbalpha(tg+/+) BM HSCs mixed with GPIbalpha(null) BM HSCs into irradiated GPIbalpha(null) mice was sufficient to correct bleeding time (n = 5)." and: "A combination of busulfan plus ATG conditioning successfully prevented antibody development and significantly increased therapeutic engraftment." and: "A conditioning regimen of busulfan in combination with ATG could potentially be used in non-myeloablative autologous gene therapy in human BSS." — Kanaji S et al. J Thromb Haemost. 2014 Oct

That 10–20% corrected-HSC threshold is a genuinely important translational number: you don't need full chimerism, which is what makes non-myeloablative conditioning viable.

Type B / GP1BB, and a structure-function bonus:

[verbatim, PMID:27148783] "hGPIbbeta transplanted into the bone marrow of GPIbbeta(null) mice rescued GPIb-IX expression in 97% of circulating platelets. These platelets efficiently bound von Willebrand factor (VWF) and extended filopodia on a VWF matrix, demonstrating the restoration of GPIb-dependent adhesive and signaling properties. These mice exhibited less severe macrothrombocytopenia and had normal tail bleeding times as compared with GPIbbeta(null) mice." — Strassel C et al. J Thromb Haemost. 2016

Type C / GP9 — and this one reaches patient cells:

[verbatim, PMID:37416759] "Using gene-editing tools, we generated knockout (KO) human cellular models that helped us to better understand GPIb-V-IX complex assembly. Furthermore, we developed novel lentiviral vectors capable of correcting GPIX expression, localization, and functionality in human GP9-KO megakaryoblastic cell lines. Generated GP9-KO induced pluripotent stem cells produced platelets that recapitulated the BSS phenotype: absence of GPIX on the membrane surface and large size. Importantly, gene therapy tools reverted both characteristics. Finally, hematopoietic stem cells from two unrelated BSS type C patients were transduced with the gene therapy vectors and differentiated to produce GPIX-expressing megakaryocytes and platelets with a reduced size. These results demonstrate the potential of lentiviral-based gene therapy to rescue BSS type C." — Mol Ther Nucleic Acids. 2023 Sep 12;33:75-92 (a corrigendum/companion record exists at PMID:37621411, same title, Mol Ther Nucleic Acids 33:749)

This is the most advanced human-cell evidence in BSS and belongs on the entry as IN_VITRO evidence for a GENE_THERAPY treatment with target_mechanisms pointing at the receptor-assembly node. Still preclinical — no BSS gene therapy has entered a clinical trial, and the entry should say so plainly.

Cell therapy — allogeneic HSCT - The only curative therapy currently available to actual patients - Reserved for severe, refractory, transfusion-dependent, alloimmunized disease - Evidence base is case reports/small series; endorsed by Kaya 2025 for refractory cases - treatment_term NCIT:C15431 hematopoietic cell transplantation (verify); therapeutic_modality: CELL_THERAPY

RNA-based therapies, targeted therapies, immunotherapies: none applicable to BSS.

12e. Surgical and interventional

Splenectomy: not indicated. It is a marker of misdiagnosis. (PMID:41853404)
Surgery of any kind requires pre-procedural planning: HLA-matched platelets on standby, antifibrinolytic cover, and hematology co-management.
Dental/oral surgery is disproportionately represented in BSS bleeding events and disproportionately under-evidenced: > [verbatim, PMID:34878196] "As a result, only five articles with the main theme were included: one letter to the editor and four case reports" and "We conclude with this review the need for adequate knowledge of surgeons regarding coagulation disorders and the need to discuss and plan procedures with the hematology team."

12f. Obstetric management

[verbatim, PMID:36889343] "64.7% (33/51) of the patients were delivered via cesarean section. PPH and late PPH were found to be more common in those who delivered vaginally compared to those who delivered by caesarean section. It was observed that PPH was less common in women who were given prophylaxis in the peripartum period."

[verbatim, PMID:36889343] "BSS is an inherited macro-thrombocytopathy that may cause adverse maternal and neonatal outcomes. The optimal mode and timing of delivery remain unclear. A multidisciplinary approach with prophylaxis at the peripartum period should be applied."

Practical points: neuraxial anesthesia is contraindicated; uterotonics, HLA-matched platelets, and tranexamic acid are the toolkit; monitor the neonate for FNAIT for weeks postpartum if the mother has been transfused. Note the observational-design caveat before curating the cesarean/vaginal comparison — the mode of delivery was not randomized and confounding by indication is severe.

12g. Supportive care and prevention-of-harm

Patient education, medical alert bracelet/card, registration with a 24-hour hemophilia treatment center, contact-sport avoidance, meticulous dental hygiene, HLA typing at diagnosis (so matched products are obtainable later), iron repletion, and hepatitis B vaccination before transfusion exposure.

12h. Suggested NCIT annotations

I did not resolve NCIT IDs against OAK in this session, so treat these as candidates to verify, not as verified terms: - NCIT:C15986 Pharmacotherapy — antifibrinolytics, hormonal therapy, eltrombopag, rFVIIa - NCIT:C15431 Hematopoietic Cell Transplantation — allogeneic HSCT - NCIT:C15238 Gene Therapy — experimental LV gene therapy - NCIT:C15747 Supportive Care — the education/avoidance bundle - NCIT:C15240 Genetic Counseling - NCIT:C15329 Surgical Procedure — procedural planning context - Platelet transfusion — NCIT has a term; look it up with uv run runoak -i sqlite:obo:ncit info "l^Platelet Transfusion" rather than guessing the ID

Remember the dismech gotcha: NCIT drug terms frequently fail therapeutic_agent validation — prefer CHEBI for the small molecules (tranexamic acid, eltrombopag) and reserve NCIT for classes and for biologics with no CHEBI entry.

13. Prevention

Primary prevention

You cannot prevent the genotype. What you can prevent is its transmission and its complications.

Genetic counseling — the core intervention. For AR families: 25% recurrence risk per pregnancy, carrier testing for relatives. For AD/Bolzano families: 50% transmission, but with the honest caveat that clinical expression is mild and variable.
Carrier and cascade screening — targeted at families and at consanguineous communities with founder alleles. Not population-wide screening; the prevalence doesn't justify it.
Preimplantation genetic testing (PGT-M) and prenatal diagnosis (CVS/amniocentesis) — technically available whenever the familial variant is known. Lanza 2006 and Orphanet both note antenatal diagnosis is feasible.
Consanguinity counseling — the single highest-yield population-level lever in the regions where BSS actually clusters, and also the most socially delicate. Frame it as informed choice and carrier testing, not as prohibition.
Immunization: no vaccine prevents BSS. But hepatitis B vaccination before first transfusion exposure is genuine primary prevention of a transfusion-associated harm and belongs here.

Secondary prevention (early detection)

No newborn screening program exists or is proposed.
The real secondary-prevention target is diagnostic delay. Two rules with published support:
Any patient with "refractory ITP" + macrothrombocytopenia + family history → run ristocetin aggregometry and CD42 flow before considering splenectomy. > [verbatim, PMID:39191409] "Thus, BSS should be kept in mind in the presence of individuals with chronic persistent thrombocytopenia, positive family history, unresponsive ITP treatment, macrothrombocytopenia, and absence of RIPA response."
Any 22q11.2DS patient with macrothrombocytopenia → test for BSS (PMID:38625506).
Risk stratification: ISTH-BAT score + genotype (biallelic vs monoallelic) + alloimmunization status.

Tertiary prevention (preventing complications in diagnosed patients)

This is where nearly all the achievable benefit sits:

Prevent alloimmunization — leukoreduced, HLA-matched, apheresis-derived (single-donor) platelets; minimize transfusion episodes by using antifibrinolytics and rFVIIa where they'll do the job; HLA-type at diagnosis
Prevent iron deficiency — proactive ferritin monitoring and repletion, not reactive
Prevent menstrual morbidity — a hormonal + tranexamic acid plan established before menarche in known-affected girls
Prevent procedural bleeding — pre-procedure hematology consultation for every dental extraction and surgery; the oral-surgery review (PMID:34878196) exists precisely because this keeps failing
Prevent peripartum hemorrhage — planned multidisciplinary delivery with peripartum prophylaxis; prophylaxis was associated with less PPH (PMID:36889343)
Prevent FNAIT — identify maternal anti-GPIb antibodies; monitor the neonate's platelet count for weeks after delivery
Prevent iatrogenic harm — no splenectomy, no steroids, no IVIG for what is not ITP; no NSAIDs; no IM injections; no neuraxial anesthesia in labor
Prevent trauma — activity counseling, helmets, contact-sport avoidance, medical alert identification

Behavioral interventions and public health

Patient/family education is repeatedly identified as the highest-value single intervention
Public health / systems intervention: the Indian mortality data make the case bluntly — 13 bleeding deaths attributed mainly to inaccessibility of treatment products. Supply-chain and access policy is a prevention intervention for this disease, on par with anything clinical. > [verbatim, PMID:41100648] "The need for optimal treatment strategies to improve QoL and providing timely access to specific treatment products to prevent mortality is underscored."
Environmental interventions: not applicable.

Prophylaxis

Peripartum: platelet transfusion + tranexamic acid (PMID:36889343)
Pre-procedural: HLA-matched platelets + antifibrinolytic
Long-term regular prophylaxis — this is genuinely new and worth flagging as an emerging practice rather than a standard: weekly rFVIIa in two severely affected brothers (PMID:41259294), and 16-week continuous eltrombopag maintaining mucosal-hemorrhage remission (PMID:31273088)

14. Other Species / Natural Disease

Taxonomy

Dog — Canis lupus familiaris, NCBITaxon:9615 (verify) — the only species with a well-characterized naturally occurring BSS
Mouse — Mus musculus, NCBITaxon:10090 (verify) — engineered only, no natural BSS (§15)
Human — Homo sapiens, NCBITaxon:9606

Breed

Cocker Spaniel — VBO term exists for the breed; I did not resolve the VBO ID this session — look it up before curating.

Orthologous genes

Canine GP9, located on dog chromosome 20, single coding exon (as in human). NCBI Gene IDs for canine GP1BA/GP1BB/GP9 exist — not resolved this session.

Natural disease in dogs — the flagship finding

[verbatim, PMID:31484196] "Four cases of a mild to severe bleeding disorder in Cocker Spaniel dogs are herein presented. The affected dogs showed a platelet adhesion defect characterized by macrothrombocytopenia with variable platelet counts resembling human Bernard-Soulier syndrome (BSS). Furthermore, the lack of functional GPIb-IX-V was demonstrated by immunocytochemistry."

[verbatim, PMID:31484196] "Whole genome sequencing of one affected dog and visual inspection of the candidate genes identified a deletion in the glycoprotein IX platelet (GP9) gene."

[verbatim, PMID:31484196] "The deletion spanned 2460 bp, and included a significant part of the single coding exon of the canine GP9 gene on dog chromosome 20. The variant results in a frameshift and premature stop codon which is predicted to truncate almost two-thirds of the encoded protein. PCR-based genotyping confirmed recessive inheritance. The homozygous variant genotype seen in affected dogs did not occur in 98 control Cocker Spaniels."

[verbatim, PMID:31484196] "Thus, it was concluded that the structural variant identified in the GP9 gene was most likely causative for the BSS-phenotype in the dogs examined. These findings provide the first large animal GP9 model for this group of inherited platelet disorders and greatly facilitate the diagnosis and identification of affected and/or normal carriers in Cocker Spaniels." — PLoS One. 2019

Beautiful parallelism: same gene, same recessive mode, same macrothrombocytopenia + adhesion defect, same "variable platelet counts," and a structural variant that a gene panel would have missed. MONDO already carries it as MONDO:1010672 "Bernard-Soulier syndrome, GP9-related, dog" [OLS-checked].

Veterinary relevance

[verbatim, PMID:31484196] "Inherited bleeding disorders including abnormalities of platelet number and function rarely occur in a variety of dog breeds, but are probably underdiagnosed. Genetically characterized canine forms of platelet disorders provide valuable large animal models for understanding similar platelet disorders in people. Breed-specific disease associated genetic variants in only eight different genes are known to cause intrinsic platelet disorders in dogs."

Practical veterinary value: a PCR genotyping assay now exists for Cocker Spaniel breeding programs. OMIA carries the entry — look up the OMIA ID rather than guessing it.

Comparative biology

Conservation: the GPIb-IX-V complex and its VWF-binding function are conserved across mammals. The dog and mouse both reproduce the core macrothrombocytopenia + adhesion-defect phenotype from orthologous lesions — strong evidence that the mechanism is not human-specific.
The GPV exception is the most informative comparative finding. In mouse, deleting GPV changes essentially nothing about megakaryocyte biology:

[verbatim, PMID:10959706] "Our study extends previous results and reports that electron microscopy of bone marrow from the GPV knockout mice revealed a normal MK ultrastructure and development of the demarcation membrane system (DMS)." and: "Thus GPV is not crucial to MK development and platelet production, consistent with the fact that no mutation in the GPV gene has as yet been described in BSS." — Poujol C et al. Thromb Haemost. 2000 Aug;84(2):312-8

A mouse knockout independently predicting the absence of a human disease gene, and being right for twenty-six years running. That's about as good as cross-species validation gets, and it's the strongest available evidence for curating "GP5 is not a BSS gene" as a positive claim rather than a null result.

Transmission

Zoonotic potential: none. Genetic, non-transmissible.
Cross-species susceptibility: not applicable.

15. Model Organisms

15a. Mouse models — the workhorse

Model	Genotype	Key phenotype	PMID
GPIbα-null	Gp1ba targeted disruption	Full BSS phenocopy: macrothrombocytopenia + severe bleeding; the founding model	10706630
GPIbβ-null	Gp1bb targeted disruption	Macrothrombocytopenia + severe bleeding + enlarged α-granules (SEPT5 effect)	15213102
GPIbβ-null, MK biology	same	Normal progenitor number/endoreplication; DMS underdeveloped; proplatelet formation ↓41%; doubled tubulin fibers	19377075
GPV-null	Gp5 targeted disruption	Normal MK ultrastructure, DMS, GPIb-IX expression, adhesion — fails to phenocopy BSS, and correctly so	10959706
hGPIbα transgenic rescue	GPIbα-null + human GP1BA transgene	Phenotype rescued — the in vivo humanized platform	10706630
IL-4Rα/GPIbα chimera	GPIbα-null + chimeric receptor transgene	Dissociates the two branches: 2× platelet count, 50% smaller platelets, bleeding unchanged	12200373
LV gene-therapy recipients	GPIbα-null + 2bIbα lentivirus in HSC	Corrected bleeding time, improved macrothrombocytopenia, sustained through serial BMT	22044935
Non-myeloablative conditioning	GPIbα-null + busulfan ± ATG	10–20% corrected HSC sufficient; ATG prevents anti-hGPIbα antibody	25066812
GPIbβ LV rescue + tail deletions	GPIbβ-null + hGPIbβ variants	97% platelet rescue; Δ150-160 ↓ expression 43% and ↑ bleeding; Δ159-170 ↑ thrombosis	27148783

Foundational quote for the model-organism block:

[verbatim, PMID:10706630] "Thus, an in vivo model is defined for analysis of the human GP Ib-IX-V receptor and its role in the processes performed exclusively by megakaryocytes and platelets."

For the dismech animal_models: block with modeled_mechanisms: - GPIbα-null mouse → RECAPITULATES "Macrothrombocytopenia" and "Failure of primary hemostasis", fidelity: HIGH - GPIbβ-null mouse → RECAPITULATES "Impaired proplatelet formation", fidelity: HIGH; readouts: proplatelet-forming MK fraction (DECREASED), marginal-band tubulin fiber count (INCREASED), platelet diameter (INCREASED) - GPV-null mouse → FAILS_TO_RECAPITULATE the BSS phenotype — and this is the textbook case for that relationship value, because the failure is informative, not a limitation. Requires limitations + evidence, both of which PMID:10959706 supplies. - IL-4Rα/GPIbα chimera → PARTIALLY_RECAPITULATES / RESCUES — partial rescue of the size/count branch with the bleeding branch untouched

Limitations to record honestly: - Baseline mouse platelets are smaller and far more numerous than human platelets, so "macrothrombocytopenia" is scaled differently - Tail-bleeding time is a crude, high-variance surrogate for human mucocutaneous bleeding - Mouse models are homozygous nulls; they say little about the monoallelic/dominant-negative human forms, which is where the Bolzano human-megakaryocyte work (PMID:19067792) is irreplaceable - Transgenic rescue expresses human GPIbα in a mouse complex — an interspecies chimera by construction

15b. Human cellular and in vitro models (NAMs)

These belong in experimental_models:, not animal_models:.

Patient-derived megakaryocyte cultures from CD34+ cord blood and CD45+ peripheral blood — the Bolzano proplatelet study (PMID:19067792). Directly human, directly on the mechanism, six patients. Highest translational fidelity available.
GP9-KO human megakaryoblastic cell lines — gene-edited, used to dissect complex assembly (PMID:37416759)
GP9-KO iPSC → megakaryocyte → platelet — > [verbatim, PMID:37416759] "Generated GP9-KO induced pluripotent stem cells produced platelets that recapitulated the BSS phenotype: absence of GPIX on the membrane surface and large size. Importantly, gene therapy tools reverted both characteristics."
Patient HSC-derived megakaryocytes from two unrelated BSS type C patients, transduced and differentiated (PMID:37416759) — the closest thing to a human-in-a-dish trial
CHO heterologous expression — used for complex-assembly stoichiometry (PMID:12200373). Caveat with teeth: heterologous cells mispredicted GPIbβ's in vivo role (PMID:27148783 explicitly: "a repressor role of GPIbbeta in thrombus formation in vivo that was not predicted in studies of heterologous cells"). Record as a limitations field, and consider a HUMAN_MODEL_MISMATCH-style discussion.

15c. Large-animal model

Cocker Spaniel GP9-deletion dog (PMID:31484196) — "the first large animal GP9 model for this group of inherited platelet disorders." Naturally occurring, outbred, human-scale physiology, spontaneous bleeding phenotype. Ideal for testing transfusion alternatives and, eventually, gene-therapy dosing at realistic body size.

15d. What does not exist

No zebrafish, Drosophila, or C. elegans BSS model located. Invertebrates lack platelets entirely; zebrafish thrombocytes are nucleated and the GPIb-IX-V orthology is imperfect.
No BSS organoid or organ-chip model. A bone-marrow-on-chip with BSS iPSC-derived megakaryocytes under physiological shear is the obvious missing NAM — it would let you interrogate both branches (proplatelet extrusion and shear-dependent adhesion) in one human system. Flag as a proposed_experiment.
No functional genomics screen (CRISPR/RNAi) targeting the BSS pathway.

15e. Resources

MGI (mouse alleles for Gp1ba, Gp1bb, Gp5, Gp9), IMPC, Alliance of Genome Resources, IMSR (strain availability), OMIA (canine BSS), Cellosaurus (the GP9-KO megakaryoblastic lines and iPSC lines from PMID:37416759 — request accessions from the authors if not deposited).

Synthesis: what to build first in the KB entry

If I were laying out the pathograph, I'd anchor on the two-branch structure, because that's the thing about BSS that nothing else in the inherited-platelet-disorder space does as cleanly. One receptor, two jobs, and a chimera experiment (PMID:12200373) that surgically separates them. That's the spine.

Then: - conforms_to candidates: none of the existing dismech modules fit well. thrombogenesis is the inverse (failure to form a thrombus, not formation of one) — do not wire BSS to it as a conformer; the module models pathological thrombus formation, and BSS is its mirror. If anything, BSS is a candidate trigger for a future "primary hemostatic failure" module, which does not yet exist. - differentials: ITP, Glanzmann thrombasthenia, type 2B VWD, platelet-type VWD, MYH9-RD, gray platelet syndrome, 22q11.2DS. Grep the sibling entries for their MONDO IDs — do not guess them. - Grouping candidate: BSS belongs in an "Inherited macrothrombocytopenias" or "Inherited platelet function disorders" grouping alongside Glanzmann thrombasthenia and MYH9-RD, with grouping_basis: SHARED_MECHANISM + SHARED_PHENOTYPE. Check whether one already exists before creating. - discussions / KNOWLEDGE_GAP items worth curating explicitly: 1. No genotype-phenotype correlation for bleeding severity (PMID:21173099) — replicated, mechanistically unexplained 2. No gnomAD-derived carrier-frequency estimate; monoallelic BSS prevalence is unknown and probably substantially underestimated 3. Whether GPIbα mechanosensor-domain destabilization shortens platelet survival in patients (PMID:27670775) — EMERGING, not canonical 4. No prognostic biomarker; no validated severity model 5. The ~16% fatal-bleeding figure circulating in secondary sources has no traceable primary citation 6. No BSS gene-therapy clinical trial despite strong preclinical data across all three genes

Before writing YAML: run just preflight-dr if you generate any DR report for this disease. BSS is moderate NEC risk — the eponym is shared with nothing obvious, but the subtype letters (A1/A2/B/C) are exactly the numbered-series pattern that trips DR tools, and "Bernard" collides with several unrelated eponyms. Also verify every OMIM number, every NCIT ID, and the ICD-11 code, all of which I could not confirm in this pass.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	34
Resolved	34
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	1
Quoted claims found in source	1

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Prevalence

Clinical Burden

Differential Diagnoses

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Bernard-Soulier Syndrome — Comprehensive Research Report

1. Disease Information

Overview

Key identifiers

Genes (HGNC) — [OLS-checked, all four]

Synonyms / alternative names

Data provenance

2. Etiology

Primary cause: genetic, monogenic, no environmental trigger required

Genetic risk factors

Environmental risk factors

Protective factors

Gene-environment interactions

3. Phenotypes

3a. Laboratory abnormalities — the obligate core

3b. Bleeding phenotypes — clinical signs and symptoms

3c. Characteristics

3d. Quality of life

4. Genetic / Molecular Information

Causal genes

Mutational spectrum

Variant classification and allele frequency

Functional consequences

Modifier genes

Epigenetics

Chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

The receptor

Causal chain — proposed dismech pathograph

Branch A — adhesion and activation

Branch B — thrombopoiesis (the part that took 50 years to work out)

Mechanosensing and platelet clearance

GPIbβ has its own signalling role — with a surprise

Suggested ontology terms

Molecular profiling

7. Anatomical Structures Affected

Organ level

Tissue and cell level

Subcellular level

Localization and laterality

8. Temporal Development

Onset

Progression

Patterns

Critical periods (windows of vulnerability / intervention)

9. Inheritance and Population

Epidemiology

Regional variation

Inheritance

Demographics

10. Diagnostics

The diagnostic logic in one paragraph

The definitive modern statement of the biallelic-vs-monoallelic diagnostic split

Laboratory tests

Biomarkers

Imaging, functional, electrophysiology, biopsy